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Rheumatoid arthritis
Rheumatoid arthritis (RA) is an auto-immune disease marked by chronic inflammation 
in the joints, resulting in pain and loss of function. Approximately 1% of the population 
worldwide is affected by RA. Although the exact etiology of the disease is still unknown, 
the current understanding is that RA is caused by a combination of genetic predisposition 
and environmental factors. Different genetic loci are associated with the susceptibility 
of developing RA. Polymorphisms in the human leukocyte antigen (HLA) gene clusters, 
involved in antigen presentation, appear to be the most significant genetic risk factor1,2. 
A strong association for a polymorphism and the risk of developing RA has also been 
made for the STAT4 gene, a transcription factor important in type I interferon signaling3. 
Environmental risk factors which have been shown to influence the development of RA 
are, amongst others, smoking4,5 and periodontitis6,7. 
Figure 1 | Schematic overview of a healthy and an arthritic joint
A healthy joint (left) and arthritic joint (right). The latter is characterized by synovial thickening 
and influx of inflammatory cells. These cells promote cartilage degradation and bone erosion. 
Figure was extracted from20.
 
At diagnosis, 50-70% of RA patients are positive for antibodies directed against citrullinated 
proteins (anti-citrullinated protein antibodies or ACPAs) and/or IgG (rheumatoid factor 
or RF)8. Numerous proteins in the joint can be citrullinated, which can form immune 
complexes containing these citrullinated antigens and ACPAs. Immune complexes can be 
pathogenic by activating both macrophages and osteoclasts8, or by inflicting complement 
activation9. This results in an influx and activation of various inflammatory cells into 
the joint cavity, including neutrophils10-12. These short-living cells can directly cause 
connective tissue damage but also drive inflammation10. Upon programmed cell death, or 
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apoptosis, neutrophils need to be cleared swiftly in order to prevent secondary necrosis 
and concomitant inflammation13. Not only neutrophils, but also other innate, as well as 
adaptive immune cells, infiltrate the synovium14,15 (Figure 1). All these cells produce various 
cytokines and chemokines which fuel the migration of inflammatory cells into the joint. 
Migration of monocytes and differentiation into macrophages, together with proliferation 
of tissue-resident fibroblasts, leads to hyperplasia of the synovial lining16,17. This eventually 
results in pannus tissue formation at the articular cartilage and bone interface, that, by 
the production of several matrix-degrading enzymes, results in damage and loss of the 
articular cartilage matrix and bone tissue18,19. 
Experimental models of RA
To study pathological processes, therapeutic strategies and drug testing related to 
RA, in vitro models with human primary cells are frequently applied. Most research is 
performed in monolayer culture with patient-derived synovial fibroblasts. The lack of 
extracellular matrix and other cell types results in alterations of cell functioning and 
loss of phenotype21. One way to maintain the cell composition and matrix interactions 
of the cells is by using synovial explants instead of monolayer cells. Although synovial 
explants better represent the original joint environment for the cells, important disease 
processes including hyperplasia and fibrosis have already occurred and thus cannot be 
studied using explants. Moreover, there is considerable variability between biopsies from 
different patients and even within a single joint of one patient22-24. The arthritis field would 
greatly benefit from new, technical advances in in vitro assays like three-dimensional 
cultures and organ-on-a-chip systems. 
In addition to in vitro models, a diverse set of animal arthritis models is available, which 
have contributed to the understanding of inflammatory joint disease. In addition to the 
mouse models which develop spontanesouly due to genetic manipulation, such as the 
Il1rn-/- (also called IL-1Ra knockout) and Tumor Necrosis Factor (TNF) transgenic mice 25-27, 
there are various models which oblige induction. A couple of these models necessitate 
further attention for this thesis: the collagen-induced arthritis (CIA) model and the KRN 
serum transfer arthritis (KRN STA) model. In both models, as in RA, autoimmunity plays 
a role and they are both poly-arthritic and destructive. The biggest distinction between 
the models is the dependency on the adaptive immune system. CIA is one of the most 
widely used models for RA28. Susceptibility to CIA is strongly associated with Major 
Histocompatibility Complex (MHC) class II genes29. This model is both T and B cell-
dependent30,31. The main pathological features of CIA include a proliferative synovitis 
with infiltration of polymorphonuclear and mononuclear cells32. Cytokines such as TNF-α 
and IL-1β play a major role33. In contrast to the adaptive-immunity driven CIA model, the 
KRN STA model is T and B cell-independent and is driven by macrophages34,35. Like the 
CIA model, one of the main pathological features of the KRN STA model is an influx of 
polymorphonuclear and mononuclear cells into the joint36,37. 
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Treatment options for RA
Currently, there is no curative therapy available for RA. In general, patients are treated 
with analgesics, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs) and 
disease-modifying anti-rheumatic drugs (DMARDs). The approach of treating RA is by 
either stopping the autoimmune reaction by targeting T and B cells, their interaction 
or by restoring the cytokine imbalance by targeting pro-inflammatory cytokines. For 
this, biological protein-based drugs, often humanized antibodies, are developed that 
inhibit the inflammatory cytokines TNF-α, which is the gold standard in RA treatment, 
or Interleukin (IL) 1, target the IL-6 receptor, deplete B cells by targeting Cluster of 
Differentiation (CD) 20 or by inhibiting the co-stimulation of T cells by antigen-presenting 
cells (APCs). Although biologicals have increased the treatment options for RA patients, 
a substantial percentage of RA patients do not respond adequately to current treatment 
or relapse within months after treatment termination8. Furthermore, the side effects 
are significant and include increased risk of infections and the development of other 
autoimmune diseases38,39. 
Numerous biologicals used to treat RA patients derive from knowledge the scientific 
community has gained on anti-inflammatory mechanisms and mimic these mechanisms 
to control the inflammatory process and restore homeostasis. For example, anakinra is an 
IL-1 receptor antagonist (IL-1RA)40, and mimics the natural IL-1RA to inhibit IL-1 signaling. 
In addition to physiological antagonists, various receptors can be cleaved from the cell 
surface to produce soluble decoy receptors that inhibit signaling. Moreover, a number 
of anti-inflammatory cytokines and proteins exist, such as IL-10. Various studies have 
shown the therapeutic efficacy of IL-10 by using gene therapy in models of RA41,42. One of 
the proteins that is induced by IL-10, and is responsible for its anti-inflammatory property, 
is Suppressor of Cytokine Signaling (SOCS) 341,43. Viral overexpression of SOCS3 in APCs 
potently ameliorated CIA44,45. In addition to IL-10, another system that can potently 
induce SOCS3 is the TYRO3 – AXL – MER (TAM) receptor family46. Viral overexpression 
of genes encoding the TAM receptor agonists Gas6 and Pros1 effectively attenuated the 
clinical and histological characteristics of CIA47. These animal studies have shown that 
enhancing a natural feedback mechanism is very effective by interfering with several 
targets in a more pleiotropic fashion to modify disease, rather than by targeting one 
single cytokine. 
As mentioned before, another family of proteins involved in a natural feedback 
mechanism are the TAM receptors and their ligands. One of the first indications that these 
proteins play a role in inflammation is by the fact that mice deficient for all three TAM 
receptors develop broad-spectrum autoimmunity, due to hyper-proliferation of T and B 
cells. Remarkably, this process is not cell-intrinsic to T and B cells. It is, however, initiated 
by hyper-activated APCs, which produce high levels of type I interferons and have an 
increased Major Histocompatibility Complex (MHC) II expression48. 
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There is a general understanding what drives chronic inflammation in RA but less is known 
about the natural feedback mechanisms, and whether they are effective or impaired in RA 
patients. In the latter situation, activation of the natural negative feedback mechanisms 
could be an interesting alternative therapy approach to disrupt the progression of the 
inflammatory process. Below, the TAM receptor tyrosine kinases (RTKs) and their ligands 
are described, which are essential for controlling the immune response. 
TAM receptors
The receptors TYRO3, AXL and MER (gene name Mertk) are members of a family of RTKs 
which have been named TAM receptors according to their first letters. This RTK subfamily 
was first clustered as a structurally distinct group, based on their sequence49, and its 
members were cloned subsequently: TYRO350-55, AXL56-58, and MER59-61. All three TAM 
receptors are composed of three different regions: at the N-terminal extracellular site 
they consist of two immunoglobulin (Ig)-related regions which have an important function 
in ligand binding62,63. These domains are followed by two fibronectin type III repeats50,56,59 
which are connected via a trans-membrane domain to a cytoplasmic protein tyrosine 
kinase domain, the catalytically active domain of the receptors64 (Figure 2). The receptors 
are described to signal as dimers63. TAM receptors are expressed in various cell types 
and tissues with partly overlapping and partially unique expression patterns. More than 
one TAM receptor can be expressed on a given cell type and some cell types even co-
express all three receptors65. Within the hematopoietic linage, the TAM receptors are 
mainly expressed on APCs like monocytes, macrophages and dendritic cells (reviewed 
in66). The TAM receptors can be cleaved in the extracellular domain leading to the release 
of soluble ectodomains (soluble TYRO3, AXL, and MER). 
TAM receptor ligands
At the time the TAM receptors were cloned, they were orphan receptors and their ligands 
were unknown. Approximately half a decade after the cloning of the TAM receptors, 
Growth Arrest Specific 6 (GAS6) and Protein S (PROS1), two structurally related 
proteins, were identified as TAM receptor ligands67. PROS1 and GAS6 have different 
properties in TAM receptor activation: GAS6 is able to activate all three TAM receptors 
with different affinities (Axl > Tyro3 > Mer)68, whereas PROS1 only activates MER and 
TYRO3, but not AXL67,69-71. PROS1 also has a TAM-independent function in the coagulation 
cascade72,73. Structurally, the TAM receptor ligands GAS6 and PROS1 consist of a 
C-terminal Sex Hormone Binding Globuline (SHGB) domain and four Epidermal Growth 
Factor (EGF)-like domains. The C-terminal part of the ligands binds to the lg-domain of the 
TAM receptors63,74. Furthermore, they consist of a N-terminal gamma-carboxyglutamic 
acid-rich (Gla) domain, which is a structural motive containing several glutamic acid 
residues that can be γ-carboxylated in a vitamin K-dependent manner75. Via the Gla-
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domain, GAS6 and PROS1 can bind to the phospholipid phosphatidylserine (PtdSer) on 
the surface of apoptotic cells in a calcium-dependent manner, and induce TAM receptor-
mediated uptake. During this process, the ligands function as a bridging molecule 
between the apoptotic cell and the phagocyte70 (Figure 2).
 
Figure 2 | Schematic overview of the signaling module of the TAM receptors
Shown is the binding of a TAM receptor (in black) present on cell 1, with a TAM receptor ligand (in 
blue) bound to cell 2 via PtdSer (in purple). EGF = Epidermal Growth Factor; FN = fibronectin type 
III; Gla = Gla domain; Ig = Immunoglobulin;  PtdSer  = phosphatidylserine; SHGB = Sex Hormone 
Binding Globulin; TAM = TYRO3, AXL, MER; TK = tyrosine kinase; TM = trans-membrane domain. 
Figure was extracted from76.
 
TAM receptor signaling and function
Activation of the TAM receptors can induce multiple cellular functions including cell 
survival and proliferation, immune regulation and efferocytosis. Which pathway will 
be induced is dependent on the cell type, the ligand-receptor combination and the 
microenvironment (reviewed in77). Binding of the ligands to the extracellular Ig-related 
domain of the TAM receptors induces phosphorylation of their cytoplasmic protein 
tyrosine kinase domain. When associated with the type I interferon receptor (IFNAR), 
in a Signal Transducer and Activator of Transcription (STAT) 1-dependent manner, TAM 
receptor activation by GAS6 and PROS1 leads to induction of the Janus Kinase (JAK)/
STAT pathway. This activation induces transcription of Suppressor of Cytokine Signaling 
(SOCS) 1 and 3 and subsequently blocks production of Toll-Like Receptor (TLR)- and 
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cytokine receptor-induced pro-inflammatory cytokines46, 78-81 (Figure 3). An additional TAM 
receptor-mediated inhibition of inflammation is by the up-regulation of the transcription 
factor TWIST, which results in the reduction of TNF-α82. 
The TAM receptors also play a pivotal role in clearance of apoptotic cells, a process 
called efferocytosis83 (Figure 3). This process is critical for maintaining homeostasis in 
immune-privileged sites, in which the retinal pigment epithelium, mammary epithelium 
cells and Sertoli cells employ MER for the clearance of apoptotic debris65,69,84. In the 
sentinel cells of the immune system, the TAM receptors, amongst others, perform the 
role of efferocytosis. All three receptors can mediate efferocytosis and which receptor is 
employed for this functions appears to be cell- and environment-specific85-87. In addition 
to the clearance of debris, efferocytosis induces the production of the anti-inflammatory 
cytokines IL-10 and Transforming Growth Factor Beta 1 (TGF-β1) and reduces a whole 
array of pro-inflammatory cytokines, including IL-1β and TNF-α88-93.
 
Figure 3 | Schematic overview of TAM receptor intra-cellular signaling
Binding of GAS6 or Protein S to an apoptotic cell on one hand, and to one of the TAM receptors 
on the other hand, can induce phagocytosis of the apoptotic cell (efferocytosis) and negative 
regulation of the innate immune response via STAT1 and SOCS1/3. GAS6 = Growth Arrest 
Specific 6; GR = Glucocorticoid Receptor; IFN = Interferon; IFNAR = Interferon Alpha/Beta 
Receptor; LXR = Liver X Receptor; PPAR = Peroxisome Proliferator-Activated Receptor; PtdSer 
= Phosphatidylserine; SOCS = Suppressor of Cytokine Signaling; STAT = Signal Transducer 
and Activator of Transcription; TAM = TYRO3, AXL, MER; TLR = Toll-Like Receptor. Figure was 
extracted from94.
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TAM receptors in rheumatic diseases
Based on the role of the TAM receptors to maintain immune homeostasis and that 
deficiencies in TAM receptors lead to aberrant immunity and inflammation, it can be 
envisioned that in systemic autoimmune diseases, the TAM modulatory system could be 
impaired.
Over the years, an abundant number of studies have been published on the TAM receptors 
in rheumatic diseases. Systemic lupus erythematosus (SLE) is an heterogeneous 
autoimmune disease marked by anti-nuclear antibodies and inflammation of the kidneys, 
lungs and joints (reviewed in95). Mice deficient for Mertk phenotypically had a lupus-like 
phenotype and an accumulation of apoptotic cells in their lymph nodes96-98. The latter 
phenomenon was also found in SLE patients, and is rarely found in healthy people99,100. 
Numerous studies have found that the systemic levels of either total or free PROS1 were 
decreased in (a subgroup of) patients with SLE and correlated with disease activity101-104. 
One study showed that GAS6 levels were higher in patients with SLE102, whereas another 
study claimed the opposite105. Soluble TYRO3, AXL and MER levels were significantly 
higher in SLE patients and, for soluble TYRO3 and MER, correlated with disease 
activity102,105,106. In juvenile onset SLE, the soluble forms of all three TAM receptors were 
also significantly enhanced107. 
In Sjögren’s syndrome (SS), another rheumatic disease characterized by exocrinopathy 
and joint pain (reviewed in108), TYRO3 and AXL expression were reduced in peripheral 
blood mononuclear cells. Moreover, soluble MER levels were enhanced and positively 
correlated with disease activity109. Plasma GAS6 levels in patients with primary SS were 
significantly reduced110. 
In Behçet’s disease (BD), characterized by ulcers and skin lesions (reviewed in111), an 
association study showed two single-nucleotide polymorphisms (SNPs) in the genes of 
GAS6 and PROS1 which were significantly increased in BD patients. One of these SNPs 
correlated with decreased gene expression of GAS6 and enhanced protein expression 
of IL-6 and IFN-γ 112. Moreover, GAS6 levels were significantly lower whereas soluble AXL 
levels were enhanced in patients with BD105. 
The TAM receptors also received much interest in the field of RA during the last years. Mice 
lacking all three TAM receptors developed a lymphoproliferative disorder accompanied 
by broad-spectrum autoimmunity and have been described to spontaneously develop 
clinical characteristics of RA including swollen footpads48. TYRO3 played an enhancing 
role in bone degradation and synovial hyperplasia in experimental arthritis113. Both 
systemic and intra-articular adenoviral overexpression of Gas6 and Pros1 in CIA reduced 
inflammation and bone and cartilage erosion in murine knee joints47. In the human 
situation, AXL and GAS6 were expressed in synovial tissue of RA patients114. In addition, a 
synovial fluid proteome study identified soluble AXL in RA synovial fluid115. Plasma levels 
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of GAS6 were significantly reduced in RA patients. Moreover, GAS6 levels were lower in 
erosive compared to non-erosive RA116. Furthermore, AXL expression was significantly 
reduced in a subset of dendritic cells of RA patients117. One study showed that soluble 
MER levels were enhanced in plasma of RA patients106, whereas another study showed 
that soluble MER levels were reduced118. Similar contrasting results were found for 
soluble AXL116,118. Moreover, soluble TYRO3 levels were higher in RA patients106,118.
With regards to all the above-mentioned findings of the TAM receptors and their ligands in 
rheumatic diseases, it remains to be established if any of these deficiencies or excesses 
contribute to the onset or progression of disease and whether supplementing the 
reduced levels of the TAM receptor ligands, or whether inhibiting the soluble ectodomain 
formation of the TAM receptors to basal levels, can restore homeostasis. 
Outline of this thesis
RA is an auto-immune disease of the synovial joints, hallmarked by chronic inflammation 
and subsequent progressive connective tissue destruction. Despite the development 
of numerous biological agents targeting a whole array of biological pathways, 
approximately 30% of patients still fail to respond adequately to currently available 
treatments. Moreover, numerous side effects of these treatments have been described. 
Therefore, the identification of new therapeutic targets remains necessary. Activation of 
the natural negative feedback mechanism mediated by the TAM receptors could be an 
interesting alternative therapeutic approach to treat RA. However, little is known about 
the endogenous role of the TAM regulatory system in arthritis. In this thesis, the role of 
the TAM receptor family in experimental models of RA is described. 
In Chapter 2, mice deficient for all three TAM receptors (Tyro3/Axl/Mertk knock-out or TAM 
TKO), known to spontaneously develop macroscopic signs of arthritis, were histologically 
examined. Surprisingly, TAM TKO mice did not develop synovial inflammation nor any signs 
of damage to the cartilage or bone. However, bone marrow edema was observed in TAM 
TKO mice, a pathological manifestation observed in humans at a pre-clinical phase of RA.
After finding that TAM TKO did not (any longer) spontaneously develop arthritis, the aim 
was to unravel the relative contribution of AXL and MER in experimental arthritis and 
RA (Chapter 3-5). In Chapter 3, the role of AXL in arthritis was investigated. During KRN 
STA, ankle joints of Axl-/- mice showed exacerbated arthritis pathology whereas no effect 
of Axl deletion was observed on gonarthritis pathology. These data coincided with the 
observation that ankle synovial cells of mice prominently expressed AXL, in contrast to the 
knee. Next, it was investigated which factor could cause this spatial difference. In murine 
and human synovium, TGFB1 and AXL expression correlated. In human macrophages and 
synovial micromasses, and in naïve murine knee joints, TGF-β1 induced AXL expression. It 
appears that the local differences in AXL expression could be due to TGF-β1.
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In Chapter 4, the contribution of the MER tyrosine kinase to gonarthritis was investigated. 
Mertk-/- mice showed exacerbated arthritis pathology during KRN STA whereas Pros1 
overexpression diminished joint pathology in experimental arthritis. Human synovial 
micromasses challenged with MER-specific antibodies enhanced the secretion of 
inflammatory cytokines whereas stimulating MER with PROS1 reduced the secretion 
of these cytokines. All these effects were associated with modulation of efferocytosis 
and inhibiting secondary necrosis of apoptotic cells. Moreover, treatment of CIA 
with MER receptor agonistic antibodies was deleterious due to its counterproductive 
effect of blocking efferocytosis. These data show that MER can play a protective role in 
gonarthritis. 
In Chapter 5, a switch to the human situation was made and the role of soluble MER 
in RA was described in a first attempt. RA synovium contained an abundant number of 
MER+ macrophages. In line with the increased levels of serum soluble MER during KRN 
STA, enhanced soluble MER levels were observed in RA synovial conditioned-medium 
compared to OA controls. Soluble MER levels in RA synovial conditioned-medium 
positively correlated with secreted GAS6 levels. Moreover, in synovial fluid of RA patients, 
soluble MER and GAS6 also correlated positively. 
In Chapter 6, a human three-dimensional synovial membrane model made of primary 
fibroblast-like synoviocytes and CD14+ mononuclear cells was further developed 
and examined. The outer surface of these mature micromasses formed a lining layer 
consisting out of fibroblast-like and macrophage-like cells, reflecting the in vivo naïve 
synovial membrane. To recreate the affected synovial membrane in RA, the micromasses 
were exposed to TNF-α. This led to increased pro-inflammatory cytokine expression, 
modulation of the macrophage phenotype and hyperplasia of the membrane. This shows 
the human model mimics several characteristics of RA synovium in vitro. Therefore, it 
could be a suitable model to study the pathology of RA in vitro and test whether activation 
of the TAM receptor feedback system reduces the inflammatory process in the presence 
or absence of neutrophils to confirm the mouse data described in this thesis. 
In Chapter 7, the major findings of this thesis are summarized and discussed in the light 
of recent literature, and directions for future studies on the TAM receptors as therapeutic 
targets in RA are provided.
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Abstract
 
Rheumatoid arthritis is an auto-immune disease of the synovial joints, hallmarked by 
chronic inflammation and subsequent progressive tissue destruction. TYRO3, AXL and 
MER (gene name Mertk) (TAM) receptors are part of a negative feedback signaling system 
in the immune reaction and mediate efferocytosis thereby tempering the inflammatory 
process.  We have shown that Axl-/- and Mertk-/- mice develop more severe arthritis whereas 
activating these receptors by overexpressing their ligands Pros1 and Gas6 ameliorates 
arthritis. Mice genetically ablated for the three genes of the TAM receptor family Tyro3/
Axl/Mertk (TAM triple knock-out or TKO) have been described to spontaneously develop 
macroscopic signs of arthritis. In this study we aimed to analyze arthritis development 
in TAM TKO mice histologically to determine the extent and sequence of pathological 
changes in the joint. Ankle joints of three different age groups, adolescence (14 weeks), 
mature adult (34 weeks) and middle-age (52 weeks), of TAM TKO or wild-type mice were 
examined macroscopically, histologically and immunohistochemically. Surprisingly, until 
the age of 52 weeks, none of the mice examined developed spontaneous macroscopic 
signs of arthritis. There was no synovial inflammation nor any signs of damage to the 
cartilage or bone. However, bone marrow edema was observed in TAM TKO mice in 
the two latter age groups. The infiltrate in the bone marrow was characterized by both 
myeloid cells and lymphocytes. This study showed that TAM TKO mice developed a pre-
stage (pre-clinical phase) of arthritis marked by bone marrow edema. 
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Introduction
Rheumatoid arthritis (RA) is an auto-immune disease marked by chronic and unrestrained 
inflammation, often in multiple synovial joints in the same patient. In the arthritic joint, the 
synovium is infiltrated by both innate and adaptive immune cells which, together with the 
proliferation of the tissue-resident fibroblasts, leads to pannus tissue formation at the 
articular cartilage and bone interface. Overall, this eventually leads to damage and loss of 
the articular cartilage matrix and bone tissue1,2. 
One family of receptors that has been linked to RA and experimental models of RA are 
the TAM receptors3-10. The TAM receptors – TYRO3, AXL and MER (gene name Mertk) – are 
a family of tyrosine kinases essential for immune homeostasis by negatively regulating 
the innate immune response. Together with their ligands Growth Arrest Specific 6 (GAS6) 
and Protein S (PROS1), they also mediate the resolution of inflammation by facilitating 
efferocytosis11. We have found that both AXL and MER play a suppressive role by 
alleviating joint inflammation and others have found that TYRO3 plays an enhancing role 
in bone degradation and synovial hyperplasia in experimental arthritis5,7,10.
More than a decade ago, it was reported that mice lacking all three TAM receptors (triple 
knock-out or TKO) develop a lymphoproliferative disorder accompanied by broad-
spectrum autoimmunity including splenomegaly12. In this paper, they showed TAM TKO 
mice spontaneously developed clinical characteristics of RA including swollen footpads 
in a 6-month-old mouse. Furthermore, deficiency of all three receptors led to enhanced 
proliferation of both B cells and T cells. Moreover, auto-antibodies were detectable in 
serum of these mice. 
In this study, we aimed to analyze arthritis development in TAM TKO mice histologically 
to determine the extent and sequence of pathological changes in the disease-prone 
ankle joints. Surprisingly, until the age of 52 weeks, none of the TAM TKO mice examined 
developed any macroscopic signs of arthritis. Histologically, neither tissue destruction 
nor synovial inflammation was observed. However, bone marrow edema (BME), which was 
characterized by an infiltrate of myeloid cells and lymphocytes, was present at the age of 
34 weeks which had persisted to the age of 52 weeks. 
Materials and methods
Mice
Tyro3/Axl/Mertk-deficient mice were generated as described previously13. Mice were 
bred and housed in the Salk Institute Animal Facility under a 12-hour light/dark cycle in 
individually-ventilated cages, with freely available food and water. Mice were on a mixed 
C57BL/6 × 129/Sv background. Both male and female mice were used, and wild-type (WT) 
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and Tyro3/Axl/Mertk-deficient mice were sex-matched. At the ages of 14 weeks (n=6), 34 
weeks (n=6) and 52 weeks (n=12) (adolescent, mature adult and middle-age, respectively), 
mice were sacrificed by an overdose of isoflurane. As the mice were not visibly affected 
and suffering by the genotype, no analgesics were used to alleviate suffering. All 
procedures were approved by and conducted according to guidelines established by the 
Salk Institutional Animal Care and Use Committee (IACUC).
Histology
Whole ankle joints were dissected, fixed in 4% phosphate-buffered formalin, followed 
by decalcification with 5% formic acid for 7 days. Tissues were dehydrated with 
an automated tissue processing apparatus (Leica ASP 300, Leica Biosystems) and 
embedded in paraffin. Semi-serial tissue sections (7 μm) were stained with hematoxylin 
and eosin (H&E) (both Merck), safranin O and fast green (both Brunschwig Chemie) or 
were used for immunohistochemical staining. 
Quantification of synovial cellularity and BME
Histological slides of ankle joints stained with H&E were blinded and randomized. For 
randomization, each joint was given a random number. Pictures of the indicated region 
of the ankle joint were taken with the Leica DMR microscope (Leica Microsystems) at 
50x magnification. To measure the synovial cellularity, the surface area of the synovium 
was selected as the region of interest. The surface area staining positive for H&E was 
measured and corrected for the total area that was measured. To measure BME, the 
surface area of the bone marrow cavity was selected as the region of interest. The 
surface area staining positive for H&E was measured and corrected for the total area 
(bone marrow cavity) that was measured. Two to three tissue sections were examined per 
ankle joint per region (tibia, os talus or os naviculare), the average of two to three sections 
per region was calculated and is depicted. For all measurements, Leica Application Suite 
software (Leica Microsystems) was used. WT controls were set at 1 in Figure 1 and 3. WT 
controls of different ages were compared in Supplementary Figure 1 and area over total 
area, calculated as percentage, is depicted.
Quantification of articular cartilage depletion
Histological slides of ankle joints stained with safranin O and fast green were blinded 
and randomized. For randomization, each joint was given a random number. Pictures of 
the indicated region of the ankle joint were taken with the Leica DMR microscope (Leica 
Microsystems) at 100x magnification. Two to three tissue sections were examined per 
ankle joint per region, the average per joint was calculated and is depicted. To determine 
cartilage depletion, mean blue was measured using Leica Application Suite software 
(Leica Microsystems). The surface area of the cartilage was selected and the amount 
of blue light passing through the region of interest was measured by the software. WT 
controls were set at 1.  
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Immunohistochemistry 
Protein expression was evaluated on 7 μm tissue sections of ankle joints. Sections 
were deparaffinized and rehydrated. Endogenous peroxidase was blocked by 3% (v/v) 
hydrogen peroxide in methanol for 20 minutes at room temperature (RT). Sections were 
washed in between incubation steps with phosphate-buffered saline (PBS) 3 times for 
5 minutes. For all sections, a biotin-streptavidin horseradish peroxidase detection 
system was used according to manufacturer’s protocol (Vector Laboratories; PK6101). 
Bound complexes were visualized with diaminobenzidine (DAB) (Merck) for 10 minutes 
at RT. Sections were counterstained with hematoxylin for 30 seconds. Sections were 
dehydrated and enclosed with Permount. 
F4/80
For F4/80 detection, antigen-retrieval was performed in citrate buffer (pH 6.0) heated 
to 37ºC for 2 hours and subsequent trypsin treatment (Sigma; T-9201; 0.075% in PBS) 
at 37°C for 7 minutes. Sections were blocked by 10% (v/v) rabbit serum in PBS for 20 
minutes at RT. Tissue sections were incubated with rat anti-mouse F4/80 (eBioscience; 
14-4801-81; monoclonal (BM8); 1 µg/mL) or rat IgG2a (BD Pharmingen; 553927; 1 µg/mL) 
overnight at 4°C. Subsequently, sections were incubated with biotinylated rabbit anti-rat 
2% (v/v) rabbit serum in PBS. 
CD3
For CD3 detection, antigen retrieval was performed in citrate buffer (pH 6.0) heated to 
60ºC for 10 minutes. Sections were blocked by 5% (w/v) skimmed milk (ELK) 3% (v/v) 
fetal calf serum (FCS) 2% (w/v) bovine serum albumin (BSA) in PBS for 1 hour at RT. Tissue 
sections were incubated with rabbit anti-mouse CD3 (DAKO; A0452; polyclonal; 3 µg/mL) 
or rabbit IgG control (DAKO; X0936; 3 µg/mL) overnight at 4°C. Subsequently, sections 
were incubated with biotinylated goat anti-rabbit IgG (PK6101; 1:400) for 30 minutes at RT. 
Antibodies were diluted in 5% ELK 3% FCS 2% BSA in PBS.
CD19
For CD19 detection, antigen retrieval was performed in citrate buffer heated (pH 6.0) to 
60ºC for 10 minutes. Sections were blocked by 5% ELK 3% FCS 2% BSA in PBS for 1 hour 
at RT. Tissue sections were incubated with rabbit anti-mouse CD19 (Abcam; ab203615; 
polyclonal; 0.4 µg/mL) or rabbit IgG control (DAKO; X0936; 0.4 µg/mL) overnight at 4°C. 
Subsequently, sections were incubated with biotinylated goat anti-rabbit IgG (PK6101; 
1:400) for 30 minutes at RT. Antibodies were diluted in 5% ELK 3% FCS 2% BSA in PBS.
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Statistical analysis
Data were analyzed with GraphPad Prism software (version 5.03). Data are shown as dot-
plots with mean. Analysis of significance was performed using a two-tailed Mann Whitney 
test. p-Values lower than 0.05 were considered to be significantly different. 
Results
Synovial cellularity and connective tissue integrity is unaltered in the 
ankle joints of mice genetically ablated for Tyro3/Axl/Mertk 
We examined the ankle joints of mice deficient for Tyro3/Axl/Mertk at three different 
ages, namely adolescence (14 weeks), mature adult (34 weeks) and middle-age (52 
weeks). Surprisingly, we found that TAM TKO mice up to 1 year of age did not develop any 
macroscopic arthritis-like symptoms, such as swollen toes or footpads, spontaneously. 
The ankle joint is the privileged site of disease in spontaneous arthritis models14, but 
histological examination showed that the ankle joints in the TAM TKO mice appeared 
to be indistinguishable from their WT controls. The synovial cellularity was comparable 
between TAM TKO and WT mice at all three ages (Figure 1). Next, we examined the tissue 
destruction. No bone erosion was observed in any of the mice. In addition, no cartilage 
erosion was observed nor were there any prominent and significant differences on the 
upper-layer depletion of cartilage proteoglycan (loss of safranin O staining of the non-
calcified upper cartilage layer) (Figure 2). 
TAM TKO mice develop BME in the ankle joint region
No tissue destruction nor synovial inflammation was present in any of the joints examined 
in TAM TKO mice (Figure 1-2). Therefore, we focused on BME, a phenomenon which has 
been described to be present in the preclinical phase of RA15,16. It appeared that TAM 
TKO mice developed an inflammatory infiltrate in the bone marrow replacing the fat-rich 
marrow, termed BME. Indeed, BME was enhanced in TAM TKO mice compared to WT in 
all three regions investigated in mature and middle-age mice (Figure 3). During aging, the 
fat-rich bone marrow composition in the WT mice was not changed (see Supplementary 
Figure 1). These data show that the TAM TKO mice examined developed early signs of 
arthritis without signs of joint pathology characteristic for full-blown arthritis. 
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Figure 1 | Effect of genetic deletion of Tyro3/Axl/Mertk on synovial cellularity in ankle joints
(A) Ankle joints of naïve wild-type (WT) and Tyro3/Axl/Mertk triple knock-out (TAM TKO) mice of 
14, 34 and 52 weeks old were processed for histology. Sections were stained with hematoxylin 
and eosin. Shown are representative pictures in 50x magnification. Staining is representative 
for 6 mice (14 and 34 weeks old mice) or 12 mice (52 weeks old mice). (B) Synovial cellularity was 
quantified in all joints in a random and blinded manner using Leica Application Suite software. 
Data are presented as dot-plots with mean. Data were statistically analyzed with a Mann 
Whitney test. n=6 at 14 and 34 weeks old, n=12 at 52 weeks old. BM = bone marrow, ON = os 
naviculare, OT = os talus, S = synovium, T = tibia. Black scale bars represent 100 µm.
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Figure 2 | Effect of genetic deletion of Tyro3/Axl/Mertk on cartilage destruction in ankle joints 
(A) Ankle joints of naïve wild-type (WT) and Tyro3/Axl/Mertk triple knock-out (TAM TKO) mice of 
14, 34 and 52 weeks old were processed for histology. Sections were stained with safranin O 
and fast green. Shown are representative pictures of the tibia – os talus region and os talus – os 
naviculare region in 50x magnification. Staining is representative for 6 mice (14 and 34 weeks 
old mice) or 12 mice (52 weeks old mice). (B) Cartilage proteoglycan depletion was quantified 
in both regions in all joints in a random and blinded manner using Leica Application Suite 
software. Data are presented as dot-plots with mean. Data were statistically analyzed with a 
Mann Whitney test. n=6 at 14 and 34 weeks old, n=12 at 52 weeks old. ON = os naviculare, OT = 
os talus, T = tibia. Black scale bars represent 100 µm.
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Figure 3 | Effect of genetic deletion of Tyro3/Axl/Mertk on bone marrow edema
Ankle joints of naïve wild-type (WT) and Tyro3/Axl/Mertk triple knock-out (TAM TKO) mice of 14, 
34 and 52 weeks old were processed for histology. (A) Sections were stained with hematoxylin 
and eosin. Shown are representative pictures in 100x magnification of the os naviculare, os 
talus and tibia of 52 weeks old mice. Staining is representative for 12 mice. (B) Bone marrow 
edema was quantified in all joints in a random and blinded manner using Leica Application 
Suite software. Data are presented as dot-plots with mean. Data were statistically analyzed 
with a Mann Whitney test. *=p<0.05, **=p<0.01. n=6 at 14 and 34 weeks old, n=12 at 52 weeks 
old. Black scale bars represent 100 µm. See Supplementary Figure 1 for comparison of bone 
marrow edema quantification in WT mice among different ages. 
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Figure 4 | Characterization of bone marrow cells in mice lacking Tyro3/Axl/Mertk 
Ankle joints of naïve wild-type (WT) and Tyro3/Axl/Mertk triple knock-out (TAM TKO) mice of 52 
weeks old were processed for histology. Sections were immunohistochemically stained for the 
cell surface marker of interest, or IgG negative control, and counterstained with hematoxylin. 
Shown are representative pictures in 200x magnification of the os naviculare, os talus and tibia. 
Staining is representative for 12 mice. (A) F4/80, (B) CD3, (C) CD19. Black scale bars represent 
100 µm.
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BME in TAM TKO mice is characterized by cells of myeloid and 
lymphocyte lineage 
To further characterize the type of cells of the BME, cells were examined morphologically 
and cell surface markers were examined by immunohistochemistry. Although to a lesser 
extent than in WT mice, adipocytes were still present in the bone marrow of TAM TKO 
mice (Figure 3A, Figure 4). The infiltrate in the bone marrow of TAM TKO mice consisted of 
a significant amount of F4/80+ macrophages (Figure 4A). Moreover, cells of the lymphoid 
lineage were also abundantly present. CD19+ B cells, and to a lesser extent, CD3+ T cells 
were scattered between the F4/80+ cells (Figure 4B-C).
Discussion
In this manuscript, we describe that mice deficient for Tyro3/Axl/Mertk do not develop 
clinical characteristics of arthritis until the age of 52 weeks. Nonetheless, they do develop 
an early phenomenon observed in RA, but which is not specific for RA, namely BME. 
However, in contrast to the publication in 200112, they do not (any longer) develop any 
aberrant macroscopic signs of arthritis at mature adulthood. Moreover, histologically, 
joints are not characterized by synovial inflammation and lymphocyte invasion. This 
is remarkable as the source of the mice was from the same laboratory where they 
were initially described. Nevertheless, we cannot exclude that TAM TKO mice develop 
macroscopic signs of arthritis, synovial inflammation or connective tissue destruction at 
ages over 52 weeks. 
In RA, the fat-rich tissue in the bone marrow, also called the yellow marrow, can be 
replaced by a cell-rich inflammatory environment. This phenomenon, called BME, 
strongly associates with development of bone erosions and poor functional outcome 
in patients with RA17-21. Very early in the disease process, BME is present and prognostic 
for the development from undifferentiated arthritis to RA15,16,22. Moreover, BME is the 
strongest predictor for bone erosions in RA patients using magnetic resonance imaging 
(MRI)17-21. Histological and immunohistochemical analysis showed that BME observed by 
MRI is characterized by an infiltrate of inflammatory cells into the bone marrow normally 
replaced by adipocytes upon ageing. The infiltrate mainly consists of lymphocytes, 
CD3+, CD4+, or CD8+ T cells and CD20+ B cells, but also CD68+ macrophages have been 
described23-28. One study in TNF-transgenic mice showed that the BME observed in these 
mice consisted mainly of myeloid cells29. We show that the BME observed in TAM TKO 
mice is also characterized by the presence of both lymphocytes and macrophages, the 
latter being abundantly present as quantified by the presence of the macrophage marker 
F4/80. This may confirm the lymphoproliferative disorder in the TAM TKO mice, caused by 
constitutively active cells of the myeloid lineage, as elegantly demonstrated by adoptive 
cell transfers12. It is unknown whether the lymphocytes in these mice were targeting any 
joint-specific antigens that could cause joint-specific disease. 
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It is tempting to speculate that the absence of spontaneous arthritis development we 
observed compared to the publication of Lu and Lemke12, is a result of an interaction 
between genetic and environmental factors. Phenotypic differences in mice with similar 
genotypes, although from a different breeding generation, have been described before30. 
Moreover, long-term breeding of mouse lines results in marked changes in intestinal 
microbiota composition and microbiota can account for genotype-specific phenotypes31. 
This is in line with overall better hygiene and housing facilities of mice compared to a 
decade ago. Numerous studies implicate mucosal surfaces as sites of disease initiation 
in RA32. The simultaneous occurrence of periodontitis, a bacterial-induced inflammation 
of the gums, and RA suggests that oral pathogens may initiate the production of disease-
specific antibodies against citrullinated proteins (ACPA)33. This coincides with the fact 
that periodontitis is characterized by the presence of similar citrullinated auto-antigens 
in neutrophils, caused by the bacteria Aggregatibacter actinomycetemcomitans, as found in 
the arthritic joint34. Interestingly, the TAM receptor ligand GAS6 has been shown to be an 
immunological regulator in oral mucosal homeostasis35.
Currently, it remains to be elucidated what causes BME development in TAM TKO 
mice. We have shown that MER mediates efferocytosis in the arthritic joint10.  Moreover, 
AXL plays a protective role in experimental arthritis, possibly by regulating the post-
translational activation of IL-1β (manuscript accepted for publication). However, none of 
the joints examined in the single knock-out mice for Axl and Mertk showed any signs of 
BME, nor did the Axl/Mertk double knock-out (own observations). Therefore, it appears 
that all 3 receptors need to be knocked-out in order to develop this phenotype. As we 
found BME in mature TAM TKO mice, and this is a phenomenon present in preclinical 
RA, it is interesting to investigate whether it would be effective to treat these patients 
with GAS6 in a preclinical stage to stop the progression of BME and subsequent bone 
erosions. To conclude, TAM TKO mice develop and early stage of RA, namely BME, without 
spontaneously developing clinical and histopathological signs of arthritis. 
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Supplementary figure
 
 
Supplementary Figure 1 | Effect of aging on bone marrow edema 
Ankle joints of naïve wild-type mice of 14, 34 and 52 weeks old were processed for histology. 
Sections were stained with hematoxylin and eosin. Bone marrow edema was quantified in the 
os naviculare, os talus and tibia in a random and blinded manner using Leica Application Suite 
software. Data are presented as dot-plots with mean. n=6 at 14 and 34 weeks old, n=12 at 52 
weeks old. See Figure 3 for comparison of bone marrow edema quantification between wild-
type and Tyro3/Axl/Mertk triple knock-out mice. These data are the same data as in Figure 3 
for the wild-type mice, but presented in a different manner, to show the effect of aging on bone 
marrow edema. 
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Abstract
Objective: To investigate the role of AXL, a member of the anti-inflammatory TYRO3, AXL, 
MER (TAM) receptor family, in arthritis.
Methods: KRN serum transfer arthritis was induced in Axl-/- and wild-type mice. Knee 
and ankle joints were scored macro- and microscopically. Synovial gene and protein 
expression of Axl was determined in naïve and TGF-β1-overexpressing joints. AXL 
expression was determined in M1-like or M2-like macrophages and RA synovium. Human 
macrophages, fibroblasts and synovial micromasses were stimulated with TGF-β1 or the 
AXL inhibitor R428. 
Results: Ankle joints of Axl-/- mice showed exacerbated arthritis pathology whereas no 
effect of Axl gene deletion was observed on gonarthritis pathology. To explain this spatial 
difference, we examined the synovium of naïve mice. In contrast to the knee, the ankle 
synovial cells prominently expressed AXL. Moreover, the M2-like macrophage phenotype 
was the dominant cell type in the naïve ankle joint. Human M2-like macrophages 
expressed higher levels of AXL and blocking AXL increased their inflammatory response. 
In the murine ankle synovium, gene expression of Tgfb1 was increased and Tgfb1 
correlated with Axl. Moreover, TGFB1 and AXL expression also correlated in human RA 
synovium. In human macrophages and synovial micromasses, TGF-β1 enhanced AXL 
expression. Moreover, TGF-β1 overexpression in naïve murine knee joints induced 
synovial AXL expression 
Conclusion: Differences in synovial AXL expression are in accordance with the 
observation that AXL dampens arthritis in ankle, but not in knee joints. We provide 
evidence that the local differences in AXL expression could be due to TGF-β1, and suggest 
similar pathways operate in RA synovium.   
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Introduction
Rheumatoid arthritis (RA) is a progressive and degenerative joint disease where chronic 
synovial inflammation and cartilage and bone destruction in multiple joints are the main 
hallmarks. Although often considered a disease of the adaptive immune system, innate 
immunity plays an important role in RA. This is highlighted by the fact that the number of 
synovial macrophages correlates with joint destruction in RA1. In addition, the efficacy of 
many biologicals are targeting cytokines mainly produced by macrophages2. 
One family of tyrosine kinase receptors expressed by macrophages and other sentinel 
cells, cells in the body’s first line of defense, are the TAM receptors. The TAM receptors 
– TYRO3, AXL and MER (gene name MERTK) – play a critical role in innate immune 
homeostasis3-7. The two principal TAM receptor ligands are Growth Arrest Specific 
6 (GAS6) and Protein S (PROS1)8-12. Notably, GAS6 is a ligand for all three receptors but 
with the highest affinity for AXL. In contrast, PROS1 can only activate TYRO3 and MER 
but not AXL10. These ligands display divalent binding: they bridge TAM receptors and 
phosphatidylserine expressed on the surface of apoptotic cells10,11. Activation of the 
TAM receptors reduces numerous inflammatory cytokines4,7,13,14. Moreover, activation of 
AXL inhibits Nucleotide-binding domain Leucine-rich Repeat (NLR) family pyrin domain 
containing 3 (NLPR3) inflammasome activation, thereby inhibiting the maturation of 
Interleukin (IL) 1β15, 16.
We have previously shown that targeted delivery of TAM receptor ligand genes Pros1 or 
Gas6 diminishes the arthritis pathology effectively13. Because all three receptors can 
be activated by GAS610,11, the endogenous role of AXL in arthritis is not fully understood. 
AXL and GAS6 are expressed in synovial tissue of RA patients17. In addition, a synovial 
fluid proteome study identified the soluble form of AXL in RA synovial fluid18. In contrast, 
the plasma levels of soluble AXL and GAS6 are significantly reduced in RA patients. 
Moreover, GAS6 levels are lower in erosive compared to non-erosive RA19. Furthermore, 
AXL expression was significantly reduced in CD1c+ dendritic cells of RA patients14. To 
understand the role of AXL in RA, mechanistic studies are needed. Therefore, we studied 
the effect of Axl deficiency in the KRN serum transfer model of arthritis (KRN STA), an 
inflammatory polyarthritis model driven by macrophages20. 
Materials and methods
Patient material
RA synovial tissue was obtained during surgery from the Radboud University Medical 
Center or the Sint Maartenskliniek (both Nijmegen, the Netherlands). This material was 
considered surgery surplus material. For the Radboud University Medical Center, patients 
gave informed consent for the surgery, were informed and were able to decline the use of 
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their material for research. According to Dutch law, informed consent was not necessary. 
In addition, patient material was anonymized and no patient data is available. For the Sint 
Maartenskliniek, patients gave written informed consent for the use of their material for 
research. The patient material was pseudonymized and patient demographic information 
is listed in Table 1 of the Supplementary Materials and Methods. There was no need for 
the approval by an ethical committee. Procedures were performed in accordance to the 
code of conduct for responsible use of human tissue in medical research (https://www.
federa.org/code-goed-gebruik). Tissue samples were fixed in formalin for histological 
analysis, digested for the production of synovial micromasses or 3 mm biopsies were 
snap-frozen.
Human RA fibroblast-like synoviocytes (RAFLS)
Synovial samples were digested using Liberase TM (50 μg/mL; Roche) for 2 hours at 37°C 
in Roswell Park Memorial Institute (RPMI) medium. Subsequently, red blood cells were 
lysed. Cells were put in culture with RPMI supplemented with 10% heat-inactivated foetal 
calf serum (FCS), 1 mM pyruvate and penicillin/streptomycin (P/S). Medium was refreshed 
weekly. RAFLS were used between passage 2 and 4.
Human CD14+ monocytes
Whole blood was mixed with phosphate-buffered saline (PBS) 1.5% acid citrate-
dextrose solution A 1:1. Peripheral blood mononuclear cells (PBMCs) were isolated by 
density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare). CD14+ cells 
were isolated with the MagniSort Human CD14 Positive Selection Kit according to 
manufacturer’s protocol (Invitrogen) (purity >90%). CD14+ cells were used to generate 
macrophages or synovial micromasses. Healthy donors gave informed consent for the 
use of the blood (Sanquin Blood Bank, Nijmegen, the Netherlands).
Human synovial three-dimensional micromasses
For the generation of micromasses, RAFLS and CD14+ cells were mixed with a ratio of 
1:5 (200.000 RAFLS and 1x106 monocytes per micromass). Cells were dissolved in ice-
cold Matrigel (Corning) and droplets were placed in culture plates coated with poly-(2-
hydroxyethyl methacrylate) (Sigma-Aldrich). After 30 minutes gelation at 37°C, RPMI, 
supplemented with 10% FCS, 1 mM pyruvate and P/S, was added. After 7 days of culture, 
the formation of a synovial-like lining and the presence of CD68+ macrophages was 
confirmed on histology. Subsequently, micromasses were cultured in the absence or 
presence of 10 ng/mL recombinant human Transforming Growth Factor Beta 1 (TGF-β1) 
(Biolegend) for 3 weeks. Medium was refreshed twice weekly. After 3 weeks, micromasses 
were lysed in TRIzol (Sigma Aldrich) or put on ice for 60 minutes to reliquify Matrigel and 
use cells for flow cytometry analysis.
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TGF-β1 stimulation of RAFLS
RAFLS were plated in 24 wells-plates with 0.5x106 cells/well in RPMI supplemented with 
10% FCS, 1 mM pyruvate and P/S. After 1 day, cells were serum-starved for 24 hours by 
culturing in RPMI supplemented with 2% FCS, 1 mM pyruvate and P/S before stimulation 
with 10 ng/mL human TGF-β1. After 6 hours, medium was removed and TRIzol was added. 
For each donor, each condition was performed in triplicate and the average is depicted.
Human monocyte-derived macrophages (Mφs)
CD14+ cells were plated in 24 wells-plates with 0.5x106 cells/well, RPMI supplemented 
with 10% FCS, 1 mM pyruvate, P/S and 50 ng mL GM-CSF (Prospec) or 20 ng/mL hM-CSF 
(R&D), termed M1-like GM-CSF Mφs and M2-like M-CSF Mφs, respectively. Medium was 
refreshed at day 3, and cells were ready for further experiments at day 6/7 or lysed in 
TRIzol. For each donor, each condition was performed in triplicate and the average is 
depicted.
TGF-β1 stimulation of Mφs
M2-like M-CSF Mφs were serum-starved for 24 hours by culturing in RPMI supplemented 
with 2% FCS, 1 mM pyruvate, P/S and 20 ng/mL hM-CSF before stimulation with 10 ng/
mL human TGF-β1. After 6 hours, medium was removed and TRIzol was added. After 24 
hours, cells were harvested for flow cytometry analysis. For each donor, each condition 
was performed in triplicate and the average is depicted.
AXL inhibition of M-CSF Mφs 
M2-like M-CSF Mφs were treated with 1 µM R428 dihydrochloride (Axon Medchem) 
for 2 hours before stimulation with 100 ng/mL E. coli lipopolysaccharide (LPS), CpG 
oligodeoxynucleotide 2006 (CpG) or Pam3CSK4 (P3C). After 24 hours, supernatants were 
stored in -20°C for further analysis. For each donor, each condition was performed in 
triplicate and the average is depicted.
Flow cytometry
Cells were incubated with human Fc block (BD Pharmingen), diluted in FACS buffer (PBS 
5% FCS 2mM ethylenediaminetetraacetic acid (EDTA)). Subsequently, surface marker 
expression was evaluated using the following antibodies: CD14-FITC (325603; Biolegend), 
CD68-PE (12-0689; eBioscience), AXL (#8661; Cell Signaling) and Anti-Rabbit IgG F(ab’)2 
Fragment-Alexa Fluor 647 Conjugate (#4414; Cell Signaling). Samples were measured on 
BD FACSCalibur (BD Biosciences) and analyzed with FlowJo software (Tree Star). 
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Measurement of IL-1β and TNF-α
IL-1β and Tumour Necrosis Factor Alpha (TNF-α) in supernatants was measured on a Bio-
Plex 200 system using a magnetic bead-based multiplex immunoassay. Data analysis 
was performed with Bio-Plex Manager software (both Bio-Rad). 
Human GAS6 ELISA
Supernatants were examined for GAS6 using the human GAS6 DuoSet ELISA (R&D) 
according to manufacturer’s instructions. 
Mice
The Axl-/- strain was generated as described previously21. All lines were backcrossed 
for >9 generations to a C57BL/6 background. For the KRN STA model, and histological 
and immunohistochemical analysis of AXL before the induction of this model, Axl-/- and 
their wild-type (WT) littermates of this strain were used. Naïve C57BL/6 mice were used 
for adenoviral overexpression study and for gene expression analysis of ankle and 
knee synovium. All mice were fed a standard diet with freely available food and water. 
Histological and immunohistochemical analysis were performed in a randomized and 
blinded manner. Clinical signs of arthritis were monitored macroscopically as described 
in the ‘Induction of KRN STA’ section. In vivo studies performed in the Netherlands 
complied with Dutch legislation and were approved by local authorities. In vivo studies 
executed in The United States of America were conducted according to guidelines 
established by the Salk Institutional Animal Care and Use Committee. For details, see 
Table 2 of the Supplementary Materials and Methods.
Induction of KRN STA
Arthritis was induced by two intraperitoneal injections, at day 0 and 2, of 150 µL arthritic 
K/BxN serum. Clinical signs of arthritis were monitored and macroscopically scored until 
the end of the experiment at day 7. Cumulative scoring was based on redness, swelling, 
and ankylosis: 0=no changes; 0.25=1-2 toes red or swollen; 0.5=3-5 toes red or swollen; 
0.5=swollen ankle; 0.5=swollen footpad; 0.5=severe swelling and ankylosis, with a 
maximal score of 2 per paw. Clinical signs of arthritis in knee joints were macroscopically 
scored at day 7 as determined by swelling and blood vessel formation, with a maximal 
score of 2 per knee joint.
Adenoviral overexpression 
First generation adenoviruses encoding for luciferase (Ad Luc) and active porcine TGFB1 
(Ad TGF-β1) (gift from Dr. C.D. Richards, McMaster University, Canada) were produced as 
described before13. The overexpression of luciferase or TGFB1 was accomplished by an 
intra-articular injection into the knee joint of 1x107 plaque-forming units.
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Histological analysis
Human synovial biopsies were embedded in paraffin. Whole ankle and knee joints of 
mice were dissected, fixed in formalin, decalcified with 5% formic acid and embedded 
in paraffin. Tissue sections (7 μm) were stained with hematoxylin and eosin (both Merck) 
(HE) or with safranin O and fast green (both BHD Chemicals) (SAGO/FG). Three semi-serial 
sections per joint were scored for histopathologic changes on a scale from 0–3, by two 
independent observers in a blinded manner as described previously22. The average of 
this score was calculated, the average of two joints per mouse was calculated and is 
depicted. In knee joints, inflammation was determined by the presence of synovial cell 
infiltrates and inflammatory cell exudates. In ankle joints, this distinction could not be 
made because the joint space was too narrow and the infiltrate and exudate appear 
to merge into one another. Therefore, total inflammatory cell content was scored. 
Connective tissue damage was determined by the depletion of cartilage proteoglycan 
and by cartilage and bone erosion.
Immunohistochemistry 
Protein expression of murine AXL, F4/80 and CD206 was evaluated on sections of ankle 
and knee joints. Sections were deparaffinized and rehydrated. Endogenous peroxidase 
was blocked by 3% hydrogen peroxide in methanol. For AXL and CD206, antigen 
retrieval was performed in citrate buffer heated to 60ºC. For F4/80, antigen-retrieval was 
performed in citrate buffer heated to 37ºC and subsequent trypsin treatment. For AXL, 
tissue sections were incubated with goat anti-AXL (AF854; R&D) or goat IgG (AB-108-C; 
R&D) followed by incubation with biotinylated anti-goat (BA-5000; Vector Laboratories). 
For F4/80, tissue sections were incubated with rat anti-F4/80 (14-4801-81; Thermo Fisher) 
or rat IgG2a (553927; BD Pharmingen) followed by incubation with biotinylated anti-rat 
(BA-4001; Vector Laboratories). For CD206, tissue sections were incubated with goat anti-
CD206 (AF2535; R&D;) or goat IgG (AB-108-C) followed by incubation with biotinylated 
anti-goat (BA-5000). A biotin-streptavidin detection system was used according to 
manufacturer’s protocol (PK-6101; Vector Laboratories) and bound complexes were 
visualized with diaminobenzidine (DAB) (Sigma Aldrich). Protein expression of human 
CD68 and CD163 was evaluated on synovial micromasses. Sections were deparaffinized 
and rehydrated. Endogenous peroxidase was blocked by 3% hydrogen peroxide and 
antigen-retrieval was performed in citrate buffer. For CD68, tissue sections were 
incubated with mouse anti-CD68 (M0814, DAKO) or mouse IgG (X0931, DAKO) followed by 
incubation with HRP-conjugated rabbit-anti-mouse Ig (P0260, DAKO). For CD163, tissue 
sections were incubated with mouse anti-human CD163 (MA5-11458; Thermo Fisher) 
or mouse IgG (X0931) followed by incubation with biotinylated anti-mouse IgG (BA-
2001, Vector Laboratories). A biotin-streptavidin detection system was used according 
to manufacturer’s protocol (PK-6101). Bound complexes were visualized with DAB. All 
sections were counterstained with hematoxylin.  
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RNA isolation and quantitative polymerase chain reaction (PCR)
All tissues were disrupted using the MagNA Lyser (Roche) and lysed with TRIzol. Total 
RNA was extracted using TRIzol/Chloroform and treated with DNAse followed by reverse 
transcription into cDNA using oligo(dT) primers. Quantitative PCR was performed with 
SYBR green PCR master mix using the StepOnePlus Real-Time PCR System (Applied 
Biosystems). The threshold cycle of the gene of interest was corrected for the reference 
gene Gapdh or GAPDH to obtain the –delta CT. The CT value was set to a threshold of 40 in 
samples in which no CT value was detected. The primer sequences are listed in Table 3 of 
the Supplementary Materials and Methods. 
Statistics
Data were analyzed with GraphPad Prism software (version 5.03). Data were checked 
for normality with the D’Agostino-Pearson omnibus test. Analysis of significance was 
performed using an unpaired t-test when data were normally distributed or a Mann 
Whitney test if data were not normally distributed. Analysis of significance was performed 
using a paired t test when data were paired. For correlations, the Pearson’s correlation 
coefficient was calculated. For evaluation of the macroscopic arthritis severity over 
time, analysis of significance was tested using a repeated measures two-way ANOVA 
with Bonferroni post test. p-Values lower than 0.05 were considered to be significantly 
different.
Results
Arthritic Axl-/- mice show enhanced joint pathology in ankle joints but 
not in knee joints
To study the role of AXL in arthritis, KRN STA was induced in mice deficient for Axl and their 
WT littermates. At day 4 until the end of the experiment, Axl-/- mice showed a significantly 
higher macroscopic arthritis score in their hind paws relative to WT mice (Figure 1A). 
Histological analysis showed that ankle joints in Axl-/- mice had exacerbated arthritis 
pathology (Figure 1B-C). Knee joints of Axl-deficient mice showed, however, comparable 
clinical and histological arthritis scores to WT (Supplementary Figure 1). To rule out that 
Axl deficiency lead to aberrant ankle joints, we examined naïve ankle joints of WT and 
Axl-/- mice. Histological analyses showed that Axl-/- mice neither spontaneously developed 
arthritis nor developed anomalous joints (Supplementary Figure 2). 
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Figure 1 | Effect of genetic deletion of Axl on ankle joints arthritic conditions
Wild-type (WT) and Axl-/- mice with KRN serum transfer arthritis. Data are represented as mean + 
S.E.M. (A) Arthritis severity of hind paws determined macroscopically. n=14-15 mice per group. 
***=p<0.001 with Two-way ANOVA with Bonferroni post test. Percentage of total variation 
values: subjects: 16.82, time: 58.44, interaction: 3.83. (B) Histological analysis of ankle joints at 
day 7. n=14-15 mice per group. *=p<0.05, ***=p<0.001 with unpaired t test. (C) Representative 
pictures of sections of ankle joints at day 7 in 50x magnification. S=synovium, T=talus, Ti=tibia. 
Effects of genetic deletion of Axl on knee joints are shown in Supplementary Figure 1. Histology 
of naïve WT and Axl-/- ankle joints is shown Supplementary Figure 2. 
AXL is expressed by the synovial lining layer in ankle joints but not in 
knee joints
Due to the prominent differences between ankles and knees regarding Axl involvement 
in arthritis, we determined the synovial AXL expression in both joints in naïve mice. The 
cells of the synovial lining layer of ankle joints were positive for the AXL tyrosine kinase 
receptor (Figure 2A-B), whereas the synovial cells of the knee joints were completely 
devoid of AXL (Figure 2C-D). The specificity of the staining was confirmed by joints from 
Axl-/- mice (Figure 2A-D). 
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Figure 2 | AXL protein expression in naïve ankle and knee joints
(A) Ankle joints of naïve wild-type (WT) and Axl-/- mice were processed for histology and 
sections were examined for AXL protein expression. Shown are representative pictures 
of immunohistochemical staining of AXL or IgG control in 50x (B) and 100x magnification. 
Staining is representative for 6 mice. (C) Knee joints of the same mice depicted in (A-B) were 
processed for histology and sections were examined for AXL protein expression. Shown are 
representative pictures of immunohistochemical staining of AXL or IgG control in 50x (D) and 
100x magnification. Staining is representative for6 mice. F=femur, P=patella, S=synovium, 
T=talus, Ti=tibia.
 
M2-like Mφs express enhanced levels of AXL which controls their 
activation
As TAM receptors are expressed by sentinel cells, we further characterized the 
phenotype of the synovial macrophages in naïve mice. Classically M1 and alternatively 
M2 activated macrophages are, amongst others, characterized by their expression of 
Nos2 and Arg1, respectively23. As shown in Figure 3A, cells in the ankle appeared to have 
a more prominent M2-like phenotype as the ratio Arg1/Nos2 was significantly enhanced. 
Moreover, the synovial lining of the ankle joints were also markedly positive for F4/80, 
a macrophage marker, and CD206 (mannose receptor), another M2 marker (Figure 3B). 
When we differentiated human blood monocytes to either M1-like GM-CSF or M2-like 
M-CSF Mφs, the latter cell type also expressed significantly higher levels of AXL and GAS6 
whereas MERTK was unaltered (Figure 3C). Furthermore, addition of the AXL inhibitor 
R428 led to a significant increase of IL-1β upon Toll-like receptor (TLR) ligation (Figure 
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3D). In contrast, TNF-α and GAS6 levels were unaltered by AXL inhibition (Supplementary 
Figure 3). The mouse in vivo and human in vitro data strongly suggest that AXL is expressed 
by M2-like macrophages in the murine ankle joint. 
Figure 3 | AXL expression by macrophage subsets and the effect of AXL inhibition on 
macrophage activation
(A) Ankle and knee synovial biopsies were obtained from naïve wild-type mice and gene 
expression was determined. Data are represented as dot-plots with mean. n=5 synovial 
biopsies per group. *=p<0.05 with Mann Whitney test. (B) Ankle joints and knee joints of naïve 
wild-type (WT) mice were processed for histology and sections were examined for F4/80 
and CD206 protein expression. Shown are representative pictures of immunohistochemical 
staining in 100x magnification. Staining is representative for 6 mice. (C) Gene expression 
was determined in M-CSF human monocyte-derived macrophages (Mφ) and GM-CSF Mφ. n=7 
donors. *=p<0.05, **=p<0.01 with paired t test. (D) M-CSF Mφ were treated with 1 µM R428 and 
100 ng/mL of lipopolysaccharide (LPS), CpG oligodeoxynucleotide 2006 (CpG) or Pam3CSK4 
(P3C). Supernatants were examined for IL-1β. n=4 donors. *=p<0.05, **=p<0.01 with paired t 
test. GAS6 and TNF-α levels are shown in Supplementary Figure 3.
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Synovial AXL expression correlates with TGFB1 expression
TGF-β1 potently stimulates M2-like macrophage differentiation24,25 and enhances 
AXL expression in Langerhans cells26 and cancer cells27. Therefore, we examined the 
synovial expression of several TGF-β genes in ankle and knee joints. Tgfb1, and also 
Tgfb2 expression, were significantly higher in naïve murine ankle joints compared to 
knee joints, whereas Tgfb3 expression was unaltered. In addition, the expression of the 
TGF-β receptor Acvrl1, also known as activin receptor-like kinase (ALK) 1, was significantly 
enhanced in ankle joint synovium whereas Tgfbr1, also known as ALK5, expression was 
similar between the two joints. Moreover, Axl and Gas6 expression were also significantly 
enhanced in ankle joint synovium (Figure 4A). The expression of Tgfb1 and Axl in murine 
synovium significantly correlated (Figure 4B). In human synovial RA biopsies, AXL and 
TGFB1 also showed a strong correlation, corroborating the murine data (Figure 4C, 
Supplementary Figure 4).
 
Figure 4 | Gene expression analysis of human and murine synovium
(A) Ankle and knee synovial biopsies were obtained from naïve wild-type (WT) mice and gene 
expression was determined. Data are represented as dot-plots with mean. n=5 synovial 
biopsies per group. *=p<0.05, **=p<0.01 with Mann Whitney test. (B) Ankle and knee synovial 
biopsies were obtained from naïve WT mice and gene expression was determined. n=10 
synovial biopsies, n=5 mice. ■ = synovial biopsy derived from knee joint, ● = synovial biopsy 
derived from ankle joint. **=p<0.01 with Pearson r’s correlation analysis. (C) Synovial biopsies 
were obtained from RA patients and gene expression was determined. n=14 synovial biopsies. 
■ = synovial biopsy derived from knee joint; ○ = synovial biopsy derived from hip joint, □ = 
synovial biopsy derived from shoulder joint **=p<0.01 with Pearson r’s correlation analysis. 
Hematoxylin and eosin staining of synovium is shown in Supplementary Figure 4.
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Figure 5 | Effect of TGF-β1 on AXL expression in human macrophages and synovial micromasses
(A) M-CSF human monocyte-derived macrophages (Mφ) were stimulated with 10 ng/mL TGF-β1 
and gene expression was determined. n=7 donors. **=p<0.01, ***=p<0.001 with paired t test. 
(B) M-CSF Mφs were stimulated with 10 ng/mL TGF-β1 and cells were analyzed for median 
fluorescence intensity (MFI). n=8 donors. **=p<0.01 with paired t test. (C) Synovial micromasses 
were cultured with 10 ng/mL TGF-β1 for 3 weeks and gene expression was determined. Data are 
presented as dot-plots with mean. n=5-6 micromasses per group. *=p<0.05 with Mann Whitney 
test. RAFLS stimulated with TGF-β1 are shown in Supplementary Figure 5. Immunohistochemical 
and flow cytometry analyses of micromasses are shown in Supplementary Figure 6. 
 
TGF-β1 potently induces AXL in human Mφs, human synovial 
micromasses and murine knee joints
To further explore the effect of TGF-β1 on AXL in macrophages, M2-like M-CSF Mφs 
were stimulated with TGF-β1. The expression of AXL and PLOD2, a gene regulated by 
TGF-β128, were significantly enhanced by TGF-β1 (Figure 5A). The TGF-β1-induced AXL 
expression on M2-like M-CSF Mφs was confirmed on protein level by flow cytometry 
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(Figure 5B). In contrast, RAFLS did respond to TGF-β1 but did not enhance AXL expression 
(Supplementary Figure 5). Synovial micromasses, a model for the human synovial 
membrane containing synovial-like fibroblasts and CD68+ and CD163+ macrophages, 
which express AXL, (Supplementary Figure 6), when stimulated with TGF-β1, also 
expressed higher levels of AXL and PLOD2 (Figure 5C). In M2-like M-CSF Mφs, TGF-β1 
reduced MERTK and GAS6 expression whereas in synovial micromasses, TGF-β1 did 
not alter their expression (Figure 5A-C). Next, we adenovirally overexpressed active 
TGF-β1 in murine knee joints, a tissue devoid of AXL during homeostasis (Figure 2). Ad-
TGF-β1 injected intra-articularly into the knee joint of naïve mice resulted in a significant 
increase of pTGFB1 expression (Figure 6A and 6C). As found in human Mφs and synovial 
micromasses, Axl was significantly upregulated at day 3 and day 7 after Ad-TGF-β1. In 
contrast, Gas6 expression was significantly upregulated at day 7 whereas Mertk gene 
expression was not differently expressed at either time point (Figure 6A and 6C). The 
enhanced expression of Axl by Ad-TGF-β1 was confirmed on protein level (Figure 6B and 
6D). Knee joints overexpressing TGF-β1 had more F4/80+ macrophages compared to the 
control virus. Moreover, some of these cells were also positive for the M2-like marker 
CD206. This shows that the murine knee joint was not intrinsically impaired in expressing 
AXL but does not express AXL under naïve conditions. 
Figure 6 | Effect of adenoviral TGF-β1 overexpression on AXL expression in murine knee 
synovium
Wild-type mice were injected intra-articularly into the knee joint with Adenovirus (Ad) Luciferase 
(Luc) or Ad TGF-β1. (A-C) At day 3 and day 7, knee synovial biopsies were obtained. Messenger 
RNA was extracted and gene expression was determined. Data are represented as dot-plots 
with mean. n=5 mice per group. *=p<0.05 with Mann Whitney test. (B-D) At day 3 and day 7, knee 
joints were processed for histology and sections were examined for AXL, F4/80 and CD206 
protein expression. Shown are representative pictures of immunohistochemical synovial 
staining of AXL in 200x magnification. Staining is representative for 6 mice. ND = not detected. 
B=bone, BM=bone marrow, S=synovium.
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Discussion
This study shows that AXL plays a protective role in inflammatory arthritis in a spatial 
manner whereby it protects ankle joints but not knee joints. The distinct anatomical 
location of AXL expression appears to be regulated by TGF-β1. We show that TGF-β1-
induced AXL expression is preserved in human sentinel cells and that AXL dampens their 
activation by controlling IL-1β secretion. 
The symmetry and distinct anatomical locations of affected joints are clinically significant 
signs of RA29. However, the foundation for such selective positional manifestation of RA is 
an unsolved scientific knowledge gap. Our data show that the ratio of M2-like over M1-
like macrophages is increased in ankle versus knee synovium. These findings are in line 
with the fact that ankle synovial CD64hi macrophages express lower levels of MHC II+ 
compared to the knee synovial macrophages30. In addition, we show a robust difference 
in the expression of the anti-inflammatory tyrosine kinase receptor AXL between ankle 
and knee synovium. Raghu and colleagues elegantly showed that plasminogen can be 
either deleterious or ameliorating in TNF-α-driven experimental arthritis, dependent on 
the anatomic location31. These data all corroborate the differences between spatially 
distinct joints. 
We cannot exclude that there were no, or hardly any macrophages, in the synovium of the 
murine knee joints based on this study. However, it appears that the cells in the murine 
knee joints were not strongly positive for F4/80, a macrophage marker. However, there 
are also F4/80low macrophages32,33. Moreover, some CD206+ cells, a marker for M2-like 
macrophages, appeared to be present in the murine knee joint synovium. Furthermore, 
we also cannot rule out that the correlation we find between TGFB1 and AXL expression in 
synovial tissue is (also) due to other cells than macrophages. However, we can eliminate 
the fact that TGF-β1 can enhance AXL expression in synovial fibroblasts. The role of AXL is 
cell-type specific34. It has been described that endothelial cells and smooth muscle cells 
in synovial tissue can express AXL17. The endothelium also contains CD68+ macrophages 
that express AXL35. As O’Donnell and colleagues did not show co-localization of AXL with 
any other markers, we cannot exclude that these cells were macrophages, Moreover, a 
recent publication showed that the CD68+ synovial lining macrophages predominantly 
express AXL36.
The articular cartilage in the ankle joint experiences the highest contact force of all the 
major joints37-39. Loading articular cartilage leads to the activation of TGF-β1 which in turn 
induces TGF-β1 in a positive feedback loop40. Therefore, the enhanced force experienced 
in the ankle, compared to the knee, could explain the increased levels of Tgfb1 we 
observed in the ankle compared to the knee joint synovium. As TGF-β1 is a strong inducer 
of M2-like macrophage differentiation24,25, this could explain the dominance of these cells. 
Knee joints overexpressing TGF-β1 had more macrophages compared to the control virus. 
Moreover, these cells were also positive for CD206. As TGF-β1 can act as a chemokine for 
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monocytes41, and TGF-β1 is involved in the differentiation of M2-like macrophages24,25, it 
is plausible that monocytes were recruited to the knee joint, differentiated into M2-like 
macrophages that expressed high levels of AXL. The intracellular mechanism through 
which TGF-β1 induced AXL remains to be elucidated. Previously described, miR-34c is 
significantly higher expressed in knee synovial fibroblasts compared to ankle synovial 
fibroblasts of naïve mice42. Interestingly, TGF-β1 suppresses the expression of this miR, in 
addition to suppressing miR-34a43,44. In turn, miR-34a and miR-34c are known to suppress 
AXL14,45,46. This leads to the hypothesis that AXL protein expression in ankle synovium is 
de-repressed by the loss of these miRs, mediated by TGF-β1. 
Recently, it has been described that AXL knock-down leads to enhanced levels of TNF-α 
secretion by monocyte-derived dendritic cells14. The mechanism by which AXL exerts 
its protective effects in inflammatory arthritis remains to be elucidated. We show that 
inhibiting AXL activation on human macrophages leads to enhanced IL-1β levels. Recent 
studies show that AXL inhibits NLPR3 inflammasome activation thereby preventing the 
maturation of IL-1β15,16. As the KRN STA is IL-1-dependent47, a loss of inflammasome 
inhibition by AXL could lead to increased IL-1β levels and exacerbation of ankle arthritis. 
Previous studies examining AXL and GAS6 in RA focused on systemic effects. The 
significant reduction of soluble AXL and GAS6 in RA patients were measured in plasma19. 
Furthermore, AXL expression was significantly reduced in CD1c+ dendritic cells from 
blood of RA patients14. We show that the expression of AXL is joint-specific. For this, the 
plasma levels of GAS6 or AXL might not be indicative for the local role of synovial AXL in 
anatomically distinct joints in RA patients.
To conclude, TGFB1 and AXL expression significantly correlate in human and murine 
synovium. Local differences in AXL expression in mice lead to joint-specific differences 
in arthritis severity and the evidence provided suggest that these local differences in AXL 
might be due to TGF-β1. The TGF-β1-induced AXL expression and its anti-inflammatory 
properties are conserved in human macrophages and human synovial micromasses. 
These data suggest that AXL is a potential therapeutic target in RA, dependent on the 
joint(s) affected. 
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Supplementary materials and methods
Table 1 | Details of RA patients of Sint Maartenskliniek
Gender Age (y) Disease duration (y) Treatment Joint of synovium
Female 47 23 Prednisone
Methotrexate
Abatacept
Shoulder
Female 76 20 Acetylsalicylic acid
Calcichew
Colchicine
Celecoxib
Persantin retard
Fentanyl patch
Omeprazol
Oxycodone
Panadol
Rosuvastatin
Telmisartan
Shoulder
Male 70 25 Desloratadine
Diclofenac
Esomeprazol
Levothyroxine
Levocabastine
Mometasone
Olopatadine
Prednisone
Tocilizumab 
Sotalol
Knee
y: years
Table 2 | Details of experimental mice
Experiment Strain Sex Age 
(weeks)
Genetic 
modification
Housing Number 
of 
animals
Euthanized
(day in 
experiment)
Origin
KRN STA C57BL/6J Male 10 WT littermates IVC 15 7 Breeding at SI
KRN STA C57BL/6J Male 10 Axl-/- IVC 14 7 Breeding at SI
Naïve C57BL/6J Male 10-12 WT littermates IVC 6 N/A Breeding at SI
Naïve C57BL/6J Male 10-12 Axl-/- IVC 6 N/A Breeding at SI
Ankle and knee 
synovium
C57BL/6J Male 12-16 N/A SPF 5 N/A Janvier, France
Adenoviral 
overexpression 
of luciferase
C57BL/6J Male 12 N/A IVC 5 3 Janvier, France
Adenoviral 
overexpression
of luciferase
C57BL/6J Male 12 N/A IVC 6 7 Janvier, France
Adenoviral 
overexpression 
of TGF-β1
C57BL/6J Male 12 N/A IVC 5 3 Janvier, France
Adenoviral 
overexpression 
of TGF-β1
C57BL/6J Male 12 N/A IVC 6 7 Janvier, France
IVC: individually-ventilated cage  ;  KRN STA: KRN serum transfer arthritis  ;  N/A: not applicable
SI: Salk Institute for Biological Studies, La Jolla, CA, USA  ;  SPF: specific pathogen free; filter-top cage ;  WT: wild-type
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Table 3 | List of oligonucleotide primer sequences (in alphabetical order) 
Species Oligo description Sequence (5’ → 3’)
Human AXL_FW CAGCTCAGAATCACCTCCC
Human AXL_RV ACACGAAGGTCTGATGTCC
Human GAPDH_FW ATCTTCTTTTGCGTCGCCAG
Human GAPDH_RV TTCCCCATGGTGTCTGAGC
Human GAS6_FW ACTTCTTCTGCCTGTGTAAAGC
Human GAS6_RV TCCTGGCTGCATTCGTTGAC
Human MERTK_FW TCTGGGTGAAGGAGAGTTTGG
Human MERTK_RV TCCCGCTGTGAAGAGTTGTC
Human PLOD2_FW AAGACTCCCCTACTCCGGAAA
Human PLOD2_RV AGCAGTGGATAATAGCCTTCCAA
Human TGFB1_FW GAGGTCACCCGCGTGCTA
Human TGFB1_RV TGCTTGAACTTGTCATAGATTTCGTT
Mouse Acvrl1_FW CCATCGTGAATGGCATCGT
Mouse Acvrl1_RV GGTCATTGGGCACCACATC
Mouse Arg1_FW GAAAGTTCCCAGATGTACCAGGAT
Mouse Arg1_RV CGATGTCTTTGGCAGATATGCA
Mouse Axl_FW GGCTCATTGGCGTCTGTTTT
Mouse Axl_RV AACTGTGTAGGTCTCCGTGTTTCAT
Mouse Gapdh_FW GGCAAATTCAACGGCACA
Mouse Gapdh_RV GTTAGTGGGGTCTCGCTCCTG
Mouse Gas6_FW CCTGCCAGAAGTATCGGTGATT
Mouse Gas6_RV GTCCAGGATTTTCCCGTTTACC
Mouse Ifna_FW ACCTCCACCAGCAGCTCAAT
Mouse Ifna_RV CCCCACCTGCTGCATCAG
Mouse Ifnb1_FW CCCTATGGAGATGACGGAGAAG
Mouse Ifnb1_RV ATGGCAAAGGCAGTGTAACTCTT
Mouse Il6_FW CAAGTCGGAGGCTTAATTACACATG
Mouse Il6_RV ATTGCCATTGCACAACTCTTTTCT
Mouse Mertk_FW GCTGGCATTTCATGGTGGAA
Mouse Mertk_RV GCACACTGGCTATGCTGAAC
Mouse Nos2_FW CGTTTCGGGATCTGAATGTGA
Mouse Nos2_RV GGGCAGCCTGTGAGACCTT
Mouse Nr1h2_FW CGGCTGAGAAGATGTTGATG
Mouse Nr1h2_RV AACAGCCAGACGCTACAACC
Mouse Nr1h3_FW AGAAGGAGCGCCTGTTACAC
Mouse Nr1h3_RV ACGGAGGAGTGTGTGCTGTC
Mouse Socs1_FW CCGTGGGTCGCGAGAAC
Mouse Socs1_RV AAGGAACTCAGGTAGTCACGGAGTA
Mouse Socs3_FW TAGACTTCACGGCTGCCAAC
Mouse Socs3_RV CGGGGAGCTAGTCCCGAA
Mouse Tgfb1_FW GCAGTGGCTGAACCAAGGA
Mouse Tgfb1_RV AAGAGCAGTGAGCGCTGAATC
Mouse Tgfb2_FW AGAGCTCGAGGCGAGATTTG
Mouse Tgfb2_RV TTCTGATCACCACTGGCATATGT
Mouse Tgfb3_FW GCAGAGAATTGAGCTCTTCCAGAT
Mouse Tgfb3_RV GCACAGTGTCAGTGACATCGAA
Mouse Tgfbr1_FW CGACGGCGTTACAGTGTTTCT 
Mouse Tgfbr1_RV CCCATCTGTCACACAAGTAAA 
Mouse Tnf_FW CAGACCCTCACACTCAGATCATCT
Mouse Tnf_RV CCTCCACTTGGTGGTTTGCTA
Pig TGFB1_FW TGACCTGGCCACCATTCAT
Pig TGFB1_RV TCCGTGGAGCTGAAGCAATA
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Supplementary figures
Supplementary Figure 1 | Effect of genetic deletion of Axl on knee joints under homeostatic 
and arthritic conditions
(A) Sections of knee joints of naïve wild-type (WT) and Axl-/- mice in 50x magnification, 
representative for 6 mice per group. For (B-E), WT and Axl-/- mice with KRN serum transfer 
arthritis at day 7. Data are represented as mean + S.E.M. (B) Macroscopic scoring of gonarthritis 
severity. n=14-15 mice per group. (C) Histological analysis of knee joints. n=14-15 mice per 
group. (D) Representative sections of knee joints in 50x magnification. (E) Gene expression 
of knee synovial biopsies. n=12-14 knee synovial biopsies per group. HE=hematoxylin/eosin, 
SAFO/FG=safranin O/fast green, F=femur, P=patella, S=synovium. Data on ankle joints are 
shown in Supplementary Figure 2 and Figure 1.
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Supplementary Figure 2 | Effect of genetic deletion of Axl on ankle joints under homeostatic 
conditions
Ankle joints of naïve wild-type (WT) and Axl-/- mice were processed for histology. Shown 
are representative pictures of sections of ankle joints in 50x magnification. Staining is 
representative for 6 mice per group. HE=hematoxylin/eosin, SAFO/FG=safranin O/fast green, 
T=talus, T=tibia, S=synovium. Data on ankle joints under arthritic conditions are shown in 
Figure 1.
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Supplementary Figure 3 | TNF-α and GAS6 secretion by human macrophages
M-CSF human monocyte-derived macrophages were stimulated with 10 ng/mL TGF-β1 
for 24 hours. Cells were treated with 1 µM R428 for 2 hours and stimulated with 100 ng/mL 
lipopolysaccharide (LPS), 100 ng/mL CpG oligodeoxynucleotide 2006 (CpG) or 100 ng/mL 
Pam3CSK4 (P3C) for 24 hours. Supernatants were examined for (A) GAS6 and (B) TNF-α. For 
each donor, each condition was performed in triplicate and the average is depicted. n=4 
donors. Data on the presence of IL-1β in supernatants are shown in Figure 3.
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Supplementary Figure 4 | Histological and immunohistochemical analysis of RA synovium
Synovial tissue of each RA patient was stained with hematoxylin and eosin. Shown are 
representative pictures for each patient’s synovium. Indicated is the joint of which the 
synovium derived. Remainder of synovium was used to punch synovial biopsies for gene 
expression analysis as shown in Figure 4C.
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Supplementary Figure 5 | Effect of TGF-β1 on AXL expression in human RAFLS
Rheumatoid arthritis fibroblast-like synoviocytes (RAFLS) were stimulated with 10 ng/mL 
TGF-β1 and gene expression was determined. For each donor, each condition was performed in 
triplicate and the average is depicted. n=3 donors. **=p<0.01 with paired t test.
3Supplementary Figure 6 | Immunohistochemical and flow cytometry analysis of synovial 
micromasses
Micromasses were generated from primary FLS and CD14+ PBMCs. Micromasses were 
processed for histology and sections were examined for (A) CD68 or (B) CD163 protein 
expression, or IgG controls. Shown are representative pictures of immunohistochemical 
staining in 100x magnification. (C) Micromasses were reliquified and cells were analyzed by flow 
cytometry for the protein expression of CD68 and AXL, or their respective IgG controls. Shown 
are a representative contourplot for CD68 expression and histogram for AXL expression. 
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Abstract
Objective: Rheumatoid arthritis is a chronic and progressive joint disease. It appears 
that anti-inflammatory feedback mechanisms that could restrain joint inflammation and 
restore homeostasis are insufficient to perform this control. In this study, we investigated 
the contribution of the MER tyrosine kinase-mediated anti-inflammatory response on 
arthritis and whether targeting MER could be a valid approach to treat RA. 
Methods: KRN serum transfer arthritis (KRN STA) was induced in either Mertk-deficient 
mice, or in mice that adenovirally overexpressed Pros1. Human synovial micromasses 
were treated with MER-specific antibodies or PROS1. Collagen-induced arthritis (CIA) 
mice were treated with MER-specific agonistic antibodies or by viral overexpression of 
Pros1. 
Results: Mertk-/- mice showed exacerbated arthritis pathology whereas Pros1 over-
expression diminished joint pathology in KRN STA. Human synovial micromasses 
challenged with MER-specific antibodies enhanced the secretion of inflammatory 
cytokines whereas stimulating MER with PROS1 reduced the secretion of these cytokines, 
confirming the protective role of MER. Next, we treated CIA mice with MER-specific 
agonistic antibodies and this unexpectedly resulted in exacerbated arthritis pathology. 
This was associated with increased numbers of apoptotic cells in their knee joints and 
higher serum levels of IL-16C, a cytokine released by secondary necrotic neutrophils. 
Apoptotic cell numbers and IL-16C levels were enhanced during arthritis in Mertk-/- mice 
and reduced in Pros1-overexpressing mice.  
Conclusion: MER plays a protective role during joint inflammation and activating MER by 
its ligand PROS1 ameliorates disease. Treatment of mice with MER receptor agonistic 
antibodies is deleterious due to its counterproductive effect of blocking efferocytosis in 
the arthritic joint.
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Introduction
Rheumatoid arthritis (RA) is a chronic disease that is characterized by synovitis and 
damage of both cartilage and bone in synovial joints, leading to functional disabilities 
that affect up to 1% of the population worldwide1,2. The current generation of biological 
drugs are inhibiting inflammatory cytokines such as Tumor Necrosis Factor Alpha (TNF-α), 
Interleukin (IL) 6, and IL-1, depleting B cells by targeting Cluster of Differentiation (CD) 
20 or by inhibiting the co-stimulation of T cells by antigen-presenting cells3. Although 
biologicals have increased the treatment efficacy of RA patients, a substantial percentage 
of RA patients do not respond or are refractory to current treatment. Furthermore, side 
effects of biologicals are increased risk of infections and the development of other 
autoimmune diseases4. Restoring homeostasis by for example the administration of the 
anti-inflammatory cytokine IL-10 has shown little efficacy in clinical trials either due to 
counteractive effects or poor pharmacokinetics of this protein5,6. Activation of natural 
negative feedback mechanisms as a potential therapy for RA have not been fully explored.
The TAM receptors – TYRO3, AXL and MER (gene name MERTK) – are receptor tyrosine 
kinases that play a critical role in natural anti-inflammatory feedback mechanisms. The 
two principal TAM receptor protein ligands are Growth Arrest-Specific 6 (GAS6) and 
Protein S (PROS1). Notably, GAS6 is a ligand for all three receptors but with the highest 
affinity for AXL. In contrast, PROS1 can only activate TYRO3 and MER but not AXL7. These 
ligands display divalent binding activities: they bind to TAM receptors through a carboxy-
terminal domain, and also, via an amino-terminal domain, to phosphatidylserine (PS) that 
is expressed as an ‘eat-me signal’ on the surface of apoptotic cells7. PROS1/GAS6 binding 
to PS effectively opsonizes apoptotic cells for TAM receptor-mediated phagocytic 
uptake, a process called efferocytosis8,9. Additionally, the TAM receptors negatively 
regulate inflammation, amongst others by inducing Suppressor of Cytokine Signaling 
(SOCS) proteins 1 and 310-16. SOCS1 and 3 inhibit TLR- and cytokine receptor signaling, 
resulting in reduced production of pro-inflammatory cytokines10,16,17. The TAM receptors 
can also be shed from the cell surface thereby creating a soluble ectodomain. For MER, 
the enzyme responsible for this shedding is A Disintegrin And Metallopeptidase Domain 
17 (ADAM17)18. By competing for the ligands with the membrane-bound MER, soluble MER 
has been shown to inhibit efferocytosis19-21.
TAM receptors have been associated with numerous inflammatory diseases such 
multiple sclerosis, atherosclerosis, and various rheumatic diseases22-26. These studies 
focused mainly on the association of the soluble ectodomains of the TAM receptors 
with disease activity parameters. We have previously shown that both systemic and 
intra-articular adenoviral overexpression of Gas6 and Pros1 in collagen-induced arthritis 
(CIA) reduces inflammation and bone and cartilage erosion in murine knee joints16. The 
objective of this study was to illuminate the endogenous role of the MER tyrosine kinase, 
and its role upon PROS1 stimulation, in two different experimental models of arthritis and 
a three-dimensional model of the human synovium. 
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Materials and methods
Antibodies
Table 1 |  List of antibodies, origin, and function
Antibody Reactivity Company Catalog 
number
Monoclonal/
polyclonal
Function Figure (F) / 
Supplementary 
Figure (SF)
MER Human Abcam ab52968 Monoclonal
[Y323]
Immunohisto-
chemistry
F3A
IgG for MER - DAKO X0936 - Immunohisto-
chemistry
F3A
CD68 Human DAKO M0814 Monoclonal 
[KP1]
Immunohisto-
chemistry
F3A
IgG for CD68 - DAKO X0931 - Immunohisto-
chemistry
F3A
Secondary 
antibody
Mouse DAKO P0260 Polyclonal Immunohisto-
chemistry
F3A
MER Human Abcam ab176887 Monoclonal
[Y323]
Neutralization F3B
SF3A,B,C
IgG for MER - Abcam ab176094 - Neutralization F3B
SF3A,B,C
MER Mouse R&D
systems
AF591 Polyclonal Activation F4
F5A,B
F6A,B,C,D
SF4, SF5
IgG for MER - R&D
systems
AB-
108-C
- Activation F4
F5A,B
F6A,B,C,D
SF4, SF5
MER Mouse R&D
systems
AF591 Polyclonal Immunoprecipi-
tation
F4A
MER Mouse R&D
systems
AF591 Polyclonal Immunoblotting F4A
Phosphoryla-
tion
Mouse Millipore 05-321 Monoclonal
[4G10]
Immunoblotting F4A
Cleaved 
Caspase-3
Mouse BD Pharmin-
gen
559565 Monoclonal
[C92-605]
Immunohisto-
chemistry
F5
IgG for Cleaved 
Caspase-3
- DAKO X0936 - Immunohisto-
chemistry
F5
MER Mouse eBioscience 12-5751 Monoclonal
[DS5MMER]
Flow cytometry SF1A
F4/80 Mouse BioRad MCA497 Monoclonal
[Cl:A3-1]
Immunofluores-
cence 
F6A
SF5A
Secondary 
antibody
Rat Molecular
Probes
A11006 Polyclonal Immunofluores-
cence
F6A
SF5A
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In vivo
Mice 
Male DBA/1 mice (Janvier) were used for the CIA model and housed in filter top cages. 
Male C57BL/6 mice (Janvier) were used for KRN serum transfer arthritis (STA) experiments 
using viral overexpression in knee joints. Mice were housed in individually-ventilated 
cages. Both mouse strains were used at an age range of 10-12 weeks. The Mertk-/- strain 
was generated as described previously27. All lines were backcrossed for >9 generations 
to a C57BL/6 background. Male Mertk-/- mice and wild-type (WT) littermates at 10 
weeks of age were used for CIA and KRN STA experiments and housed in individually-
ventilated cages. Male and female mice on a C57BL/6 background were used for bone 
marrow isolations. All mice were fed a standard diet with freely available food and water. 
Mice which received a treatment (adenovirus or antibody) were randomly allocated to 
experimental groups. Histological and immunohistochemical analyses were performed 
in a randomized and blinded manner. Clinical signs of arthritis in paws and ankle joints 
were monitored macroscopically 3 times per week. Cumulative scoring was based on 
redness, swelling, and, in later stages, ankylosis, with a maximal score of 2 per paw. 
Humane endpoint was defined as reaching an individual score higher than 6 (on a scale 
of 0-8), followed by euthanization of the mouse. All in vivo studies performed in the 
Netherlands complied with Dutch legislation and were approved by local authorities for 
the care and use of animals with related codes of practice. The in vivo studies executed 
in The United States of America were conducted according to guidelines established by 
the Salk Institutional Animal Care and Use Committee. Group sizes were determined by 
power calculation on basis of incidence, mean and standard deviation, and are indicated 
per experiment.
KRN STA
KRN STA was induced by 2 intraperitoneal injections, at day 0 and 2, of 150 µL arthritic 
K/BxN serum in either wild-type (WT) or Mertk-/- mice or in WT C57BL/6J mice that 
virally overexpressed luciferase (Ad Luc) or Pros1 (Ad Pros1) in their knee joints. The 
overexpression of luciferase or Pros1 was accomplished by an intra-articular injection into 
the knee joint of 1x107 plaque-forming units (PFU) of adenovirus, 24 hours prior to the first 
serum injection. Mice were euthanized at day 7 or 14, respectively.
CIA 
For induction of CIA in DBA/1 mice, bovine type II collagen was dissolved in 0.05 M 
acetic acid at a concentration of 2 mg/mL and emulsified in an equal volume of Freund’s 
complete adjuvant (2 mg/mL of Mycobacterium tuberculosis strain H37Ra; Difco). Mice 
were immunized with 100 μL of this emulsion intradermally at the base of the tail. At day 
21, mice were given an intraperitoneal booster injection of 100 μg of type II collagen 
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dissolved in PBS. One day after the booster injection, mice were injected intravenously 
with 10 µg of anti-MER (AF591) or IgG (AB-108-C) or 3x108 PFU of Ad Luc or Ad Pros1. Mice 
were euthanized at day 30 or day 36, respectively. 
In vitro – human
Patient material
Synovial samples of RA patients were obtained during surgery from the Radboud 
University Medical Center or the Sint Maartenskliniek (both the Netherlands). This 
material was considered surgery surplus material. Patients were informed and were 
able to decline the use of their material for research. According to Dutch law, informed 
consent was not necessary. In addition, the material was anonymized. Therefore, there 
was no need for the approval by an ethical committee. Synovial samples were digested 
using Liberase TM (50 μg/mL; Roche) for 2 hours at 37°C in Roswell Park Memorial 
Institute (RPMI) medium (Gibco). Subsequently, red blood cells were lysed. Cells were 
put in culture with RPMI medium supplemented with 10% heat-inactivated fetal calf 
serum (FCS), 1 mM pyruvate and penicillin/streptomycin (P/S). Medium was refreshed 
weekly. Cells were kept at 37°C with 5% CO2.
Human monocytes
Whole blood from healthy donors was mixed with phosphate-buffered saline (PBS) 1.5% 
acid citrate-dextrose solution A 1:1. Peripheral blood mononuclear cells were isolated by 
a density gradient centrifugation method using Ficoll-Paque PLUS (GE Healthcare). CD14+ 
cells were isolated with the MagniSort Human CD14 Positive Selection Kit according to 
manufacturer’s protocol (Invitrogen) (purity >90%). 
Human synovial three-dimensional micromasses
For the construction of micromasses, rheumatoid arthritis fibroblast-like synoviocytes 
(RAFLS) obtained from synovial samples (see ‘Patient material’) and monocytes were 
mixed with a ratio of 1:5 (200.000 RAFLS and 1x106 monocytes per micromass). The 
cell suspension was centrifuged and cell pellets were dissolved in ice-cold Matrigel 
(Corning). Using cooled pipette tips, 25 μL droplets were placed in 24-well culture plates 
which were coated with poly-(2-hydroxyethyl methacrylate) (Sigma-Aldrich). After 30 
minutes gelation at 37°C, RPMI medium supplemented with 10% FCS, 1 mM pyruvate and 
P/S was added. Micromasses were kept at 37°C with 5% CO2. After 7 days of culture, the 
formation of a synovial-like lining was confirmed on histology (not shown). Subsequently, 
experiments were set in. In one set of experiments, micromasses were pre-incubated 
with 50 nM PROS1 (Haematologic Technologies) for 24 hours before stimulation with 100 
ng/mL E. coli lipopolysaccharide (LPS) (Invivogen), 100 ng/mL Pam3Cys-Ser(Lys)4 (P3C) 
(Invivogen) or 10 ng/mL recombinant human TNF-α (Abcam). After 6 hours, cells were lysed 
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in TRIzol (Sigma Aldrich) and processed for quantitative PCR analysis. Supernatants were 
collected after 24 hours for further analysis. In another set of experiments, micromasses 
were treated with human anti-MER (Abcam; as previously described28). Supernatants 
were collected after 24 hours for further analysis.
In vitro - murine
In vitro Pros1 overexpression 
Bone marrow cells were isolated by flushing murine femur and tibia bones followed by red 
blood cell lysis. Cells were differentiated into bone marrow-derived macrophages (BMMs) 
by culturing them in the presence of 15 ng/mL M-CSF (R&D). Medium was refreshed at day 
4. At day 7, BMMs were transduced with adenoviruses encoding for luciferase or Pros1 with 
a multiplicity of infection of 200. Viruses were removed after 2 hours. After 48 hours, cells 
were stimulated with 100 ng/mL LPS or 100 ng/mL P3C. After 6 hours, cells were lysed in 
TRIzol and processed for quantitative PCR analysis. Supernatants were collected after 
24 hours for further analysis.
Cell lines
J774A.1 macrophages were maintained in Dulbecco’s modified eagle medium (Life 
Technologies). EL-4 T cells were cultured in RPMI medium. Both media were supplemented 
with 10% FCS, 1 mM pyruvate and P/S. Cells were kept at 37°C with 5% CO2.
Apoptosis induction 
EL-4 cells were serum-starved for 16 hours and incubated with 2 µM Staurosporine for 
4 hours. This resulted in 70% apoptotic cells verified by Annexin V and 7-AAD staining and 
flow cytometry, measured on FACSCalibur (BD Biosciences). 
In vitro efferocytosis assay
J774A.1 cells were cultured on 8-well chamber slides, serum-starved for 16 hours and 
pre-incubated with anti-MER or IgG for 30 minutes. Apoptotic cells were labeled with 
pHrodo (Life Technologies) as described previously29. J774A.1 cells were co-incubated 
with a tenfold excess of apoptotic cells in presence of anti-MER or IgG for 2 hours. Excess 
of apoptotic cells was removed and J774A.1 cells were fixed with 4% paraformaldehyde 
(PFA). Slides were incubated with rat anti-mouse F4/80 (Bio-Rad) followed by AF488-
labeled goat anti-rat IgG (Invitrogen). Nuclei were stained with DAPI. Pictures were taken 
and the ratio of phagocytic macrophages compared to total number of macrophages was 
determined per well. Cells were counted as phagocytic if there was at least one pHrodo-
labeled apoptotic cell within the F4/80-labeled membrane. The quantification was 
performed in a randomized and blinded manner by 2 independent observers. 
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In vitro secondary necrosis assay
J774A.1 cells were cultured on 8-well chamber slides. Bone marrow neutrophils were 
isolated using Anti-Ly-6B.2 (7/4) MicroBeads (Miltenyi Biotec) according to manufacturer’s 
protocol after flushing tibia and femur bones and red blood cell lysis. Neutrophils were 
co-cultured with J774A.1 cells at a ratio 2:1 in the presence of 5 µg/mL anti-MER or IgG for 
24 or 48 hours. For microscopy, cells were stained with F4/80 and DAPI as described for 
‘in vitro efferocytosis assay’ and representative pictures were taken. Supernatants after 
48 hours co-culture were collected for further analysis. 
Other
Adenoviruses
First generation adenoviruses encoding for luciferase (Ad Luc) and Pros1 (Ad Pros1) were 
produced as previously described16. 
Flow cytometry MER
BMMs were incubated with mouse Fc Block (BD Pharmingen) to block Fcγ receptors, 
diluted in FACS buffer (PBS, 5% FCS, 2mM EDTA). Subsequently, surface marker expression 
was evaluated using rat anti-mouse MER PE (eBioscience). Samples were measured on BD 
FACSCalibur (BD Biosciences) and analyzed with FlowJo software (Tree Star). 
Histological and immunohistochemical analysis
Micromasses at day 7 of culture were fixed for 2 hours in 2% PFA in PBS/1 mM CaCl2, 
dehydrated and embedded in paraffin. Sections were deparaffinized, rehydrated and 
stained with hematoxylin and eosin to confirm synovial-like lining formation, or were 
further processes for immunohistochemistry. Knee joints were fixed in formalin, 
decalcified with formic acid and embedded in paraffin. Tissue sections were stained 
with safranin O and fast green (both BHD Chemicals), or were further processes 
for immunohistochemistry. Three semi-serial sections per joint were scored for 
histopathologic changes on an arbitrary scale from 0–3, by 2 independent observers 
in a blinded manner as described previously30. The average of the three semi-serial 
sections is depicted per joint. Joint inflammation was determined by the presence of 
synovial cell infiltrates and inflammatory cell exudates. Connective tissue destruction 
was determined by the depletion of proteoglycans and by cartilage and bone erosion. 
Cluster of differentiation (CD) 68 and MER were evaluated on paraffin section of 
micromasses. Cleaved Caspase-3 was evaluated on paraffin sections of murine knee 
joints. Sections were deparaffinized and rehydrated. Antigen-retrieval was performed 
in Tris/ethylenediaminetetraacetic acid (EDTA) buffer at 60°C for MER and citrate buffer 
at 60°C for CD68 and cleaved Caspase-3. Endogenous peroxidase was blocked by 3% 
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hydrogen peroxide. Tissue sections were incubated with 0.2 µg/mL rabbit anti-human 
MER (Abcam) or control rabbit IgG followed by incubation with biotinylated goat anti-
rabbit (Vector Laboratories), 41 µg/mL mouse anti-human CD68 (DAKO) or control 
mouse IgG, followed by rabbit anti-mouse horseradish peroxidase-labeled antibody 
(DAKO), or 0.5 µg/mL rabbit anti-cleaved Caspase-3 (BD Bioscience) or control rabbit IgG 
followed by incubation with biotinylated goat anti-rabbit (Vector Laboratories). A biotin-
streptavidin detection system was used according to manufacturer’s protocol for MER 
and cleaved Caspase-3 (Vector Laboratories). Bound complexes were visualized via 
reaction with diaminobenzidine (Sigma Aldrich). All sections were counterstained with 
haematoxylin. For cleaved Caspase-3, 2 to 6 pictures were taken of different areas of each 
joint section in a standardized and blinded manner. Three semi-serial tissues sections 
per joint were analyzed. The average of the three semi-serial sections was depicted per 
joint. Quantification of the staining was performed using the LAS V4.3 software (Leica). 
The inflamed area was selected and the area of cleaved Caspase-3 positive cells was 
expressed as percentage. 
RNA isolation and quantitative PCR analysis
Three mm synovial biopsies were disrupted using the MagNA Lyser (Roche). Biopsies, 
BMMs and micromasses were lysed with TRIzol. Total RNA was extracted using TRIzol/
Chloroform extraction and treated with DNAse followed by reverse transcription 
into cDNA using oligo(dT) primers. Quantitative PCR was performed with SYBR green 
PCR master mix using the StepOnePlus Real-Time PCR System (Applied Biosystems). 
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh or GAPDH) was used as reference 
gene. The primer sequences are listed in Supplementary Table 1. The CT value was set to 
a threshold of 40 in the samples in which no CT value was detected. 
Measurement of cytokines and chemokines
Cytokines and chemokines in sera and supernatants were measured on a Bio-Plex 
200 system using a magnetic bead-based multiplex immunoassay. Data analysis was 
performed with Bio-Plex Manager software (all Bio-Rad). IL-16C in sera and supernatants 
was examined using the mouse IL-16 DuoSet ELISA (DY1727; R&D systems). Murine 
soluble MER in sera and supernatants was examined using the mouse MER DuoSet ELISA 
(DY591; R&D systems). Human soluble MER in supernatants was examined using the 
total human MER DuoSet ELISA (DYC891; R&D systems). All ELISAs of R&D systems were 
used according to manufacturer’s instructions using the DuoSet Ancillary Reagent kit 2 
(DY008; R&D systems).
Immunoprecipitation and immunoblotting
Tissues were snap frozen in liquid nitrogen and processed for immunoprecipitation 
and immunoblotting as described previously31. Tissues lysed on ice in lysis buffer. Cell 
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lysates were incubated overnight at 4°C with protein-G/A Sepharose to pre-clear lysates. 
For immunoprecipitation (IP), cell lysates were incubated for 2.5 hours at 4°C with anti-
Mer. Protein G-Sepharose (Invitrogen) was added for 2 hours and immunoprecipitates 
(IPs) were washed twice with lysis buffer containing 0.5 M NaCl and once with 50 mM 
Tris/HCl pH 7.5. IPs were eluted in SDS sample buffer, separated on polyacrylamide gels 
and transferred to PVDF membranes. Membranes were blocked in TBST containing 5% 
bovine serum albumin and immunoblotted overnight at 4°C with primary antibodies 
diluted 1:1000 in blocking buffer. Blots were then washed in TBST and incubated for 1 
hour at RT with secondary HRP-conjugated antibodies (GE Healthcare) diluted 1:5000 in 
5% skim milk in TBST. After repeating the washes, signal was detected with enhanced 
chemiluminescence reagent.
Statistics
Data are depicted as dot-plots, dot-plots with mean, mean + standard deviation (SD),  or 
mean + standard error of mean (SEM), as indicated per figure. Analysis of significance 
was performed using a two-tailed paired or unpaired t test as indicated per experiment 
when comparing two groups. One-way ANOVA with Bonferroni’s multiple comparison test 
was used if more than two groups were compared. All data were analyzed with GraphPad 
Prism 5. Number of samples is depicted per experiment in figure legends. p-Values equal 
to or lower than 0.05 were considered to be statistically significant. 
Results
Genetic ablation of Mertk results in enhanced arthritis severity, both 
clinically and histologically
Naïve Mertk-/- mice did not develop arthritis spontaneously in their knee joints and these 
knee joints were indistinguishable from WT knee joints (Figure 1A). KRN STA was induced 
and 7 days later, more severe joint inflammation both clinically (Figure 1B) as well as 
histologically (Figure 1A and 1C) in Mertk-/- as compared to WT mice was observed. In 
addition, knee joints of Mertk-/- demonstrated more cartilage proteoglycan depletion, and 
cartilage and bone erosion than wild type mice (Figure 1A and 1C). 
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Figure 1 | Effect of genetic ablation of Mertk on naïve and arthritic knee joints with KRN STA
(A) Naïve (n=6 mice) or arthritic (KRN STA) WT and Mertk-/- mice (n=9-15 mice) were euthanized 
at day 7. Shown are representative pictures of histological knee joint sections stained with 
safranin O and fast green. (B) Macroscopic score of knee joints of arthritic mice as determined 
by swelling and blood vessel formation (n=18-30 knee joints). (C) Histological knee joint 
sections of arthritic mice were scored for the arthritis parameters depicted. Three semi-serial 
sections per joint were scored in a random and blinded manner with an arbitrary score from 
0-3 (n=10-18 knee joints). P = patella, F = femur, S = synovium. For (B-C) data are represented as 
mean + SEM. * = p<0.05, ** = p<0.01 with unpaired t test.
 
Adenoviral overexpression of Pros1 reduces inflammatory and 
destructive mediators and arthritis pathology
Mertk deficiency showed an endogenous protective role of MER during arthritis. Therefore, 
next, we tested whether MER activation by PROS1 could further enhance this protection. 
Murine bone marrow–derived macrophages (BMMs) were transduced with an adenovirus 
overexpressing Luciferase (Ad Luc) or Pros1 (Ad Pros1) 48 hours prior to activation of TLR4 
and TLR2. BMMs expressed prominent levels of MER and adenoviral overexpression 
of Pros1 resulted in enhanced expression of Pros1 (Supplementary Figure 1A-B). Pros1 
overexpression almost completely abolished the LPS- and P3C-induced gene and protein 
expression of IL-1β and TNF-α (Figure 2A). In addition, CCL2 protein, but not mRNA levels, 
were significantly reduced by Ad Pros1 (Figure 2A). Moreover, Adam17 expression and 
soluble MER levels were significantly reduced by Ad Pros1 (Supplementary Figure 1C-D). 
This confirmed the anti-inflammatory capacity of Ad Pros1. Next, the effect of adenoviral 
4
CHAPTER 4
88
overexpression of Pros1 in knee joints of mice with KRN STA was examined. In line with the in 
vitro results of Pros1 overexpression, reduced expression of Il1b, Tnf and Ccl2 was detected 
in synovium of mice treated with Ad Pros1 compared to Ad Luc (Figure 2B). Histology 
taken at day 14 of KRN STA showed a significant reduction of proteoglycan depletion and 
cartilage erosion in the knee joints of Pros1-overexpressing mice (Figure 2C-D). In addition, 
both bone erosion and the amount of cells infiltrating into the synovium were reduced 
in mice overexpressing Pros1 (Figure 2C-D). Consistent with the reduction of cartilage 
erosion, overexpression of Pros1 resulted in significantly diminished expression levels of 
multiple matrix metalloproteinases (MMPs) in the synovium (Supplementary Figure 2A). In 
contrast to the in vitro data, Ad Pros1 did not affect synovial Adam17 expression nor the 
serum concentration of soluble MER (Supplementary Figure 2B-C). 
Figure 2 | Outcome on inflammation and arthritis pathology following adenovirally over-
expressing Pros1 in KRN STA
(A) BMMs were transduced with Ad Luc or Ad Pros1 and stimulated with LPS or P3C for 6 hours 
(top) or 24 hours (bottom). Messenger RNA was extracted and gene expression was determined 
(top). Supernatants were analyzed (bottom). Data are representative for 2 independent 
experiments (n=3 per experiment). (B) KRN STA was induced in mice intra-articularly injected 
with Ad Luc or Ad Pros1 (n=9 mice). Knee synovial biopsies were obtained, mRNA was 
extracted and gene expression was determined (n=6 knee synovial biopsies). (C) Shown are 
representative pictures of knee joint sections stained with safranin O and fast green. (D) 
Histological knee joint sections were scored for the arthritis parameters depicted. Three semi-
serial sections per joint were scored in a random and blinded manner with an arbitrary score 
from 0-3 (n=12 knee joints). P = patella, F = femur, S = synovium, JC = joint cavity. For (A) data 
are presented as dot-plots with mean. For (B and D) data are represented as mean + SEM. * = 
p<0.05, ** = p<0.01, *** = p<0.001 with unpaired t test. See also Supplementary Figure 1 and 2.
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Figure 3 | Production of pro-inflammatory cytokines by three-dimensional synovial micro-
masses after anti-MER or PROS1 treatment
(A) Micromasses were examined for their protein expression of MER and CD68 (macrophage 
marker). Shown are representative pictures and IgG controls. (B) Micromasses were treated 
with IgG or anti-MER for 24 hours. Supernatants were examined for the presence of TNF-α and 
IL-1β (n=4). (C) Micromasses were pre-incubated with 50 nM Pros1 for 24 hours and stimulated 
with LPS (100 ng/mL), P3C (100 ng/mL) or TNF-α (10 ng/mL) for 6 hours. Messenger RNA was 
extracted and gene expression was determined (n=3). (D) Micromasses were pre-incubated 
with 50 nM Pros1 for 24 hours and stimulated with LPS (100 ng/mL), P3C (100 ng/mL) or TNF-α 
(10 ng/mL) for 24 hours. Supernatants were analyzed (n=3). All data are representative for 2 
independent experiments. For (B-D) data are presented as dot-plots with mean. * = p<0.05, ** = 
p<0.01, *** = p<0.001 with unpaired t test. See also Supplementary Figure 3.
MER-PROS1 targeting modifies the inflammatory cytokine production 
by human three-dimensional synovial micromasses 
Next, we tested whether MER also mediated an anti-inflammatory response in three- 
dimensional synovial micromasses consisting out of RAFLS and primary macrophages, 
a standardized model for the human synovium mimicking the synovial hyperplasia and 
inflammatory responses observed in RA synovium [chapter 6 and published in 32,33]. After 7 
days, a lining was formed and immunohistochemistry demonstrated MER+ cells dispersed 
throughout the micromass that had the same morphology as CD68+ macrophages 
(Figure 3A). Without any further stimulation, blocking MER by the addition of MER-specific 
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antibodies significantly enhanced the secretion of TNF-α and IL-1β by human synovial 
micromasses (Figure 3B). Conversely, addition of PROS1 significantly reduced the gene 
expression and protein secretion of TNF-α and IL-1β upon stimulation with several TLR 
ligands or TNF-α (Figure 3C-D). None of the conditions influenced the expression of 
ADAM17 or the shedding of MER (Supplementary Figure 3). This showed that MER exerted 
an anti-inflammatory effect under naïve conditions that could be further enhanced by the 
addition of PROS1.  
 
Figure 4 | Effect of MER-specific antibody treatment on clinical severity and pathology of CIA
(A) Mice with CIA were intravenously injected with IgG or anti-MER (n=11-12 mice). Two mice 
were euthanized 1 hour after injection. Lung, liver and spleen were isolated and samples were 
immunoprecipitated (IP) for MER and immunoblotted for MER or phosphorylation (pY) (n=1). 
(B) Macroscopic score of knee joints as determined by swelling and blood vessel formation 
(n=20-22 knee joints). (C) Shown are representative pictures of histological knee joint sections 
stained with safranin O and fast green of each group. (D) Histological knee joint sections were 
scored for the arthritis parameters depicted. Three semi-serial sections per joint were scored 
in a random and blinded manner with an arbitrary score from 0-3 (n=20-22 knee joints). P = 
patella, F = femur, S = synovium, JC = joint cavity. For (B and D) data are presented as mean + 
SEM. * = p<0.05, ** = p<0.01 with unpaired t test. See also Supplementary Figure 4.
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MER-specific antibodies aggravate arthritis pathology
Treatment of RA patients with PROS1 will not be the first choice because the majority of 
PROS1 complexes with C4b-binding protein making it inactive and it only has a half-life 
of approximately two days34-37. Moreover, free PROS1 contains potent anti-coagulation 
activity38. A more efficient and safer approach would be the use of MER-specific 
antibodies that were previously described to activate MER kinase activity21,31. We tested 
this approach in the CIA model. Anti-MER or IgG was administered intravenously at day 
22 of CIA and this led to MER phosphorylation in lung and to a lesser extent liver one hour 
thereafter (Figure 4A). Unexpectedly, anti-MER treatment markedly increased arthritis 
severity, determined by macroscopic knee swelling and blood vessel formation at day 30 
of CIA (Figure 4B). Moreover, histology of knee joints showed that the anti-MER treatment 
resulted in a trend towards more infiltrating cells in the synovial lining (infiltrate) and 
significant higher amount of cells in the joint cavity (exudate). Furthermore, higher 
cartilage depletion, and cartilage and bone erosion were observed after administration 
of anti-MER (Figure 4C-D). To determine the effect of anti-MER on the local expression of 
cytokines and MMPs, gene expression analysis of synovium was performed. Consistent 
with the increased bone destruction, enhanced expression of Il17a was observed in 
synovium of mice that received anti-MER. A trend of enhanced expression of Il6 and 
Cxcl1 in synovium and IL-6 and KC protein levels in sera was observed after anti-MER 
treatment (Supplementary Figure 4A-B). Moreover, anti-MER significantly enhanced 
Mmp9 and Mmp13 expression in the synovium, consistent with increased cartilage 
erosion (Supplementary Figure 4C). The enhanced synovial Socs3 expression could be an 
indication that the MER-specific antibodies evoked a local anti-inflammatory response 
(Supplementary Figure 4D), but if so, it appeared to be overruled during arthritis. Anti-MER 
did not induce shedding of soluble MER in the serum, nor did it alter Adam17 expression 
(Supplementary Figure 4-E-F). 
MER mediates efferocytosis in the arthritic knee joint
Administration of MER-specific antibodies in mice with CIA enhanced the joint inflammation 
and more apoptotic cells were present as detected by immunohistochemical staining of 
cleaved Caspas-3 (Figure 5A), a marker for apoptotic cells7. Quantitative image analysis 
showed that the cleaved Caspase-3 positive area within the inflamed area was increased 
by anti-MER treatment (Figure 5B). This suggests that the MER-specific antibodies could 
have negatively influenced efferocytosis during arthritis in the knee joint. In agreement 
with this, anti-MER reduced the efferocytosis of apoptotic cells by J774A.1 macrophages 
in a dose-dependent manner (Supplementary Figure 5A). To confirm the role of MER in 
efferocytosis during arthritis, knee joint sections from previous in vivo experiments 
were stained for cleaved Caspase-3 and quantified. In line with the results of the anti-
MER experiments, more apoptotic cells in the knee joints of Mertk-/- mice with KRN STA 
were detected (Figure 5C). Systemic adenoviral overexpression of the MER ligand PROS1 
showed less apoptotic cells in the KNR STA model (Figure 5D) and CIA model (Figure 5E), 
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indicating efferocytosis was enhanced by Pros1 overexpression. Altogether, these results 
show that MER is involved in efferocytosis in the arthritic knee joint and that MER-specific 
antibodies inhibited this process. 
 
Figure 5 | Evaluating the outcome on efferocytosis after treatment with MER-specific 
antibodies, Mertk gene ablation or Pros1 overexpression
(A) Immunohistochemical staining for cleaved Caspase-3 in knee joints of CIA mice injected 
with IgG or anti-MER. Shown are representative pictures of knee joint sections with similar 
microscopic scores of inflammation, in 2 different magnifications. (B) Pictures of knee joint 
sections shown in (A) were quantified and the cleaved Caspase-3 positive area was corrected 
by the total inflamed area (n=10-12 knee joints). (C) Quantification of immunohistochemical 
staining for cleaved Caspase-3 in knee joints of WT or Mertk-/- mice with KRN STA mice (n=10-
18 knee joints). (D) Quantification of immunohistochemical staining for cleaved Caspase-3 in 
knee joints of CIA mice intravenously injected with Ad Luc or Ad Pros1 (n=18 knee joints). (E) 
Quantification of immunohistochemical staining for cleaved Caspase-3 in knee joints of KRN 
STA mice intra-articularly injected with Ad Luc or Ad Pros1 (n=12 knee joints). P = patella, F = 
femur, S = synovium. For (B-E) data are presented as mean + SEM. * = p<0.05, ** = p<0.01, *** = 
p<0.001 with unpaired t test. See also Supplementary Figure 5.
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Figure 6 | Assessment of secondary necrosis after treatment with MER-specific antibodies, 
Mertk gene ablation or Pros1 overexpression
(A) J774A.1 cells were incubated with IgG or anti-MER and co-cultured with bone marrow 
neutrophils for 24 hours. Cells were stained with F4/80 (green) and DAPI (blue). Representative 
pictures are shown for each group. White arrows indicate an engulfed cell (IgG group) or an 
apoptotic cell (anti-MER group). (B) J774A.1 cells were incubated with IgG or anti-MER and co-
cultured with bone marrow neutrophils for 48 hours. Supernatants were examined for the 
presence of IL-16C (n=6 individual experiments). (C) Supernatants of (B) were analyzed for the 
presence of TNF-α (n=6 individual experiments). (D) Serum samples from CIA mice systemically 
treated with IgG or anti-MER were analyzed for IL-16C (n=10-11 mice). (E) Serum samples from WT 
or Mertk-/- mice with KRN STA were analyzed for IL-16C (n=9-15 mice). (F) Serum samples from mice 
with CIA intravenously injected with Ad Luc or Ad Pros1 were analyzed for IL-16C (n=7-8 mice). For 
(B-C) data are presented as dot-plots. * = p<0.05, ** = p<0.01 with paired t test. For (D-F) data are 
presented as mean + SEM. * = p<0.05 with unpaired t test. See also Supplementary Figure 5.
 
 
MER-mediated efferocytosis limits the secondary necrosis of 
apoptotic cells in the arthritic joint
Effective clearance of apoptotic cells by efferocytosis is essential for tissue homeostasis. If 
this process is impaired, apoptotic cells go into a process of secondary necrosis39,40. When 
neutrophils go into secondary necrosis, the intracellular inactive pre-IL-16 is cleaved in a 
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Caspase-3-dependent manner to the biologically active IL-16C and released40. To show 
that blocking MER-mediated efferocytosis leads to secondary necrosis, neutrophils were 
co-cultured with macrophages in the presence of anti-MER or IgG. Anti-MER prevented the 
uptake of apoptotic neutrophils (Figure 6A) and culture supernatants showed increased 
IL-16C (Figure 6B) and TNF-α levels (Figure 6C). The IL-16C most likely originated from 
neutrophils, as IL-16C was not detectable in this assay in the absence of neutrophils. In 
these conditions, TNF-α protein levels and Adam17 expression were unaltered. However, 
anti-MER did abolish all soluble MER in the supernatant (Supplementary Figure 5B-D). 
Anti-MER administration led to a significant increase of systemic IL-16C protein levels at 
day 30 of CIA (Figure 6D), suggesting that prevention of efferocytosis by blocking MER 
led to secondary necrosis of neutrophils in the arthritic joint. In addition, systemic IL-
16C levels were significantly higher in Mertk-deficient mice (Figure 6E). Conversely, 
systemic levels of IL-16C were significantly reduced in CIA mice treated with Ad Pros1 
compared to Ad Luc (Figure 6E). This showed that MER plays a protective role during 
arthritis by mediating efferocytosis and that this nullifies the protective effect of agonistic 
MER-specific antibodies in arthritis. Blocking of efferocytosis by anti-MER led to a pro-
inflammatory cascade initiated by the secondary necrosis of apoptotic neutrophils.
Discussion
Our study shows that MER plays a protective role during experimental arthritis in the 
macrophage-dependent KRN STA model41, the T and B cell-dependent CIA model42,43, and 
in a three-dimensional model of the human synovium. We found that activating MER by 
PROS1 is indeed anti-inflammatory and also ameliorates arthritis. However, this could 
not be mimicked by agonistic MER-specific antibodies which also possess the bivalent 
function of blocking MER-mediated efferocytosis.
Mice with a deficiency of Mertk showed aggravated diseases and treatment with Pros1 by 
viral overexpression ameliorated the disease in the KRN STA model. The latter confirmed 
our previously published observation of the protective effect of Pros1 overexpression 
in the CIA model16. MER activation via PROS1 delivers a negative feedback signal via 
the induction of SOCS3 that dampens inflammatory cytokine response10-14,16,17. Indeed, 
we found increased synovial expression of this gene in the CIA model after Pros1 
overexpression16. This could explain the arthritis protective effect of MER activation in 
the mouse models and anti-inflammatory effect of MER activation in the human synovial 
micromass model. It is also in line with more severe arthritis observed in Mertk-deficient 
mice and higher cytokine release by human synovial micromasses in the presence of 
blocking MER-specific antibodies. Whether this is all due to SOCS3 induction or through 
inducing specialized proresolving mediators21, remains to be determined.
Based on our results that the endogenous protective role of MER during arthritis could be 
further enhanced by exogenously delivered PROS1 or viral overexpression, we envision 
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that MER targeting would be a therapeutic option to treat RA patients. However, PROS1 
will not be the first choice because this protein has a half-life of only two days and its 
availability is reduced due to complex formation with C4b-binding protein34-37. Local viral 
delivery of the Pros1 gene could be an option, but safety is still an issue and an unlikely 
strategy to treat all affected joints in the RA patient. For that, treatment of RA patients 
with an agonistic MER-specific antibody would be safer and possibly also more efficient. 
This was tested in the CIA model and unexpectedly, we found that this specific anti-
MER antibody treatment deteriorated the disease due to accumulation of apoptotic 
cells in the joint that go into secondary necrosis and release their proinflammatory 
content thereby fueling joint inflammation. Although we cannot exclude that anti-MER 
suboptimally activates the MER receptor, we can conclude that anti-MER interferes with 
MER-mediated efferocytosis and appears to have a bivalent function: activation of the 
receptor but also blocking of MER-mediated efferocytosis. It does not appear that the 
inhibition of efferocytosis is due to shedding of the MER receptor. In all in vivo studies, 
serum levels of soluble MER and Adam17 expression were unaltered. In vitro, anti-MER and 
adenoviral Pros1 completely abolished the shedding of MER. The complete absence of 
soluble MER by MER activation could be due to the internalization of the receptor upon 
activation, a common method deployed by receptor tyrosine kinases44.
The importance of MER in efferocytosis is demonstrated by the fact that adult Mertk-/- mice 
exhibit apoptotic cell accumulation in multiple tissues12,45,46. During arthritis, neutrophils 
migrate in high numbers into the joint cavity47. Neutrophils are short-lived cells and die by 
apoptosis48. Apoptotic cells which are not taken up by phagocytes undergo secondary 
necrosis39,40,49. We showed that neutrophils (which do not express Mertk) went into 
secondary necrosis when co-cultured with anti-MER-treated macrophages, as shown by 
increased levels of IL-16C. IL-16C is processed from its inactive pre-form in a Caspase-3-
dependent manner to the biologically active IL-16C, in neutrophils40. Additionally, serum of 
anti-MER-treated mice and Mertk-/- mice contained higher levels of IL-16C during arthritis. 
Conversely, protective effects were observed when Pros1 was virally overexpressed as IL-
16C serum levels were reduced in these mice. IL-16C is a pro-inflammatory cytokine that 
induces amongst others IL-650. We found that the IL-16C levels correlated significantly 
with the synovial gene expression of Il6 (R2=0.8349; p=0.0002) in the CIA model. Enhanced 
levels of IL-16 are observed in RA patients, associated with joint destruction and 
inflammation, making it tempting to speculate secondary necrosis plays an aggravating 
role during RA51,52. Noteworthy, IL-16 is an extraordinarily effective parameter to measure 
clinical responses during early treatment53.
Little has been described about the TAM receptors and their ligands in human synovium. 
One study showed that human RA fibroblast-like synoviocytes respond to GAS6, likely via 
TYRO3 and AXL54. Another study showed the presence of AXL in human synovial lining 
cells and also the presence of GAS6 in synovium and synovial fluid55. We showed that 
targeting the MER-PROS1 axis in a human three-dimensional model of the synovium is 
beneficial both at homeostasis and in an inflammatory environment. 
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PROS1 protein therapy and PROS1 gene therapy are not the first choice for treatment of 
RA patients whereas the use of antibodies, such as anti-TNF-α, is the first line biological 
after methotrexate. However, our study showed that activating the MER receptor using 
an antibody strategy may have a counterproductive effect of blocking MER-mediated 
efferocytosis, leading to necrotic cell death that stimulates inflammation. In summary, 
our data show that MER-mediated efferocytosis plays a crucial role in the arthritis process 
suggesting that preserving or stimulating this pathway is a therapeutic option in RA.  
Acknowledgements
We thank Greg Lemke for the Mertk-/- mice and for helpful discussions, Paqui González 
Través and Anna Zagórska for help with the KRN STA experiments in Mertk-/- mice and 
immunoprecipitation and immunoblotting, Joe Hash for mouse colony management, 
Sakiran Partowidjojo for setting up the efferocytosis assay, Birgitte Walgreen and 
Monique Helsen for histological processing, the Microscopic Imaging Centre of the 
Radboudumc for using their facilities, Carla Rothlin for valuable consultations, and 
members of the Experimental Rheumatology department for useful discussions. This 
study was supported by a fellowship from the Deutsche Forschungsgemeinschaft (BE 
5437/1-1+2) and the Dutch Arthritis Foundation (RF15-2-403). There are no conflicts of 
interest to report. 
CHAPTER 4
98
References
1 Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis 
and rheumatism. 2008;58(1):15-25.
2 van den Berg WB, Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: 
evidence of a dominant role for interleukin-I. Baillieres Best Pract Res Clin Rheumatol. 
1999;13(4):577-97.
3 McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England journal of 
medicine. 2011;365(23):2205-19.
4 Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological 
agents. Journal of Crohn’s & colitis. 2013;7(4):257-62.
5 van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in 
steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology. 
1997;113(2):383-9.
6 van Roon J, Wijngaarden S, Lafeber FP, Damen C, van de Winkel J, Bijlsma JW. Interleukin 10 
treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression 
on monocytes and responsiveness to immune complex stimulation. The Journal of 
rheumatology. 2003;30(4):648-51.
7 Lew ED, Oh J, Burrola PG, Lax I, Zagorska A, Traves PG, et al. Differential TAM receptor-ligand-
phospholipid interactions delimit differential TAM bioactivities. eLife. 2014;3.
8 Gonzalez NA, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, et al. Apoptotic cells 
promote their own clearance and immune tolerance through activation of the nuclear 
receptor LXR. Immunity. 2009;31(2):245-58.
9 Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. TAM receptor signaling in immune 
homeostasis. Annual review of immunology. 2015;33:355-91.
10 Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic 
inhibitors of the innate immune response. Cell. 2007;131(6):1124-36.
11 Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8(5):327-36.
12 Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. Current opinion in 
immunology. 2010;22(6):740-6.
13 Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013;5(11):a009076.
14 Deng T, Zhang Y, Chen Q, Yan K, Han D. Toll-like receptor-mediated inhibition of Gas6 and 
ProS expression facilitates inflammatory cytokine production in mouse macrophages. 
Immunology. 2012;135(1):40-50.
15 Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC. TNF-alpha, IL-6, and IL-1 expression is 
inhibited by GAS6 in monocytes/macrophages. Journal of leukocyte biology. 2010;87(5):869-75.
16 van den Brand BT, Abdollahi-Roodsaz S, Vermeij EA, Bennink MB, Arntz OJ, Rothlin CV, et al. 
Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced 
arthritis. Arthritis and rheumatism. 2013;65(3):671-80.
17 Veenbergen S, Bennink MB, de Hooge AS, Arntz OJ, Smeets RL, van den Berg WB, et al. 
Splenic suppressor of cytokine signaling 3 transgene expression affects T cell responses 
and prevents development of collagen-induced arthritis. Arthritis and rheumatism. 
2008;58(12):3742-52.
MER
99
4
18 Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine 
kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen 
species, protein kinase Cdelta, and p38 mitogen-activated protein kinase (MAPK). The 
Journal of biological chemistry. 2011;286(38):33335-44.
19 Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, et al. A soluble form 
of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and 
platelet aggregation. Blood. 2007;109(3):1026-33.
20 Ballantine L, Midgley A, Harris D, Richards E, Burgess S, Beresford MW. Increased soluble 
phagocytic receptors sMer, sTyro3 and sAxl and reduced phagocytosis in juvenile-onset 
systemic lupus erythematosus. Pediatr Rheumatol Online J. 2015;13:10.
21 Cai B, Thorp EB, Doran AC, Subramanian M, Sansbury BE, Lin CS, et al. MerTK cleavage limits 
proresolving mediator biosynthesis and exacerbates tissue inflammation. Proceedings of 
the National Academy of Sciences of the United States of America. 2016;113(23):6526-31.
22 Bellan M, Pirisi M, Sainaghi PP. The Gas6/TAM System and Multiple Sclerosis. Int J Mol Sci. 
2016;17(11).
23 Cai B, Thorp EB, Doran AC, Sansbury BE, Daemen MJ, Dorweiler B, et al. MerTK receptor 
cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J Clin 
Invest. 2017;127(2):564-8.
24 Xu L, Hu F, Zhu H, Liu X, Shi L, Li Y, et al. Soluble TAM receptor tyrosine kinases in rheumatoid 
arthritis: correlation with disease activity and bone destruction. Clin Exp Immunol. 
2018;192(1):95-103.
25 Zizzo G, Guerrieri J, Dittman LM, Merrill JT, Cohen PL. Circulating levels of soluble MER in 
lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and 
disease activity. Arthritis research & therapy. 2013;15(6):R212.
26 Wu J, Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Gottsater A, et al. Increased plasma 
levels of the soluble Mer tyrosine kinase receptor in systemic lupus erythematosus relate to 
disease activity and nephritis. Arthritis research & therapy. 2011;13(2):R62.
27 Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, Casagranda F, et al. Tyro-3 family receptors are 
essential regulators of mammalian spermatogenesis. Nature. 1999;398(6729):723-8.
28 Carr AJ, Vugler A, Lawrence J, Chen LL, Ahmado A, Chen FK, et al. Molecular characterization 
and functional analysis of phagocytosis by human embryonic stem cell-derived RPE cells 
using a novel human retinal assay. Mol Vis. 2009;15:283-95.
29 Miksa M, Komura H, Wu R, Shah KG, Wang P. A novel method to determine the engulfment of 
apoptotic cells by macrophages using pHrodo succinimidyl ester. Journal of immunological 
methods. 2009;342(1-2):71-7.
30 Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova 
FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents 
joint inflammation and bone erosion by decreasing RANKL and interleukin-1. The American 
journal of pathology. 2005;167(1):141-9.
31 Zagorska A, Traves PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor 
tyrosine kinase function. Nat Immunol. 2014;15(10):920-8.
32 Kiener HP, Watts GF, Cui Y, Wright J, Thornhill TS, Skold M, et al. Synovial fibroblasts self-
direct multicellular lining architecture and synthetic function in three-dimensional organ 
culture. Arthritis and rheumatism. 2010;62(3):742-52.
CHAPTER 4
100
33 Broeren MG, de Vries M, Bennink MB, Arntz OJ, van Lent PL, van der Kraan PM, et al. 
Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy 
in a three-dimensional micromass model of the human synovial membrane. Arthritis 
research & therapy. 2016;18:186.
34 Dahlback B, Stenflo J. High molecular weight complex in human plasma between vitamin 
K-dependent protein S and complement component C4b-binding protein. Proceedings of 
the National Academy of Sciences of the United States of America. 1981;78(4):2512-6.
35 Hillarp A, Dahlback B. Novel subunit in C4b-binding protein required for protein S binding. 
The Journal of biological chemistry. 1988;263(25):12759-64.
36 Dahlback B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-
binding protein. The Journal of biological chemistry. 1986;261(26):12022-7.
37 Dahlback B. Protein S and C4b-binding protein: components involved in the regulation of the 
protein C anticoagulant system. Thromb Haemost. 1991;66(1):49-61.
38 Griffin JH, Gruber A, Fernandez JA. Reevaluation of total, free, and bound protein S and 
C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood. 
1992;79(12):3203-11.
39 Silva MT. Secondary necrosis: the natural outcome of the complete apoptotic program. 
FEBS letters. 2010;584(22):4491-9.
40 Roth S, Agthe M, Eickhoff S, Möller S, Karsten CM, Borregaard N, et al. Secondary necrotic 
neutrophils release interleukin-16C and macrophage migration inhibitory factor from stores 
in the cytosol. Cell Death Differentiation Association. 2015.
41 Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H. A crucial role for 
macrophages in the pathology of K/B x N serum-induced arthritis. European journal of 
immunology. 2005;35(10):3064-73.
42 Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II 
collagen-induced arthritis (CIA). Clin Exp Immunol. 1998;111(3):521-6.
43 Corthay A, Johansson A, Vestberg M, Holmdahl R. Collagen-induced arthritis development 
requires alpha beta T cells but not gamma delta T cells: studies with T cell-deficient (TCR 
mutant) mice. Int Immunol. 1999;11(7):1065-73.
44 Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 
2010;141(7):1117-34.
45 Fourgeaud L, Traves PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, et al. TAM receptors 
regulate multiple features of microglial physiology. Nature. 2016;532(7598):240-4.
46 Burstyn-Cohen T, Lew ED, Traves PG, Burrola PG, Hash JC, Lemke G. Genetic dissection of 
TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. Neuron. 
2012;76(6):1123-32.
47 Weissmann G, Korchak H. Rheumatoid arthritis. The role of neutrophil activation. 
Inflammation. 1984;8 Suppl:S3-14.
48 van Lent PL, Licht R, Dijkman H, Holthuysen AE, Berden JH, van den Berg WB. Uptake of 
apoptotic leukocytes by synovial lining macrophages inhibits immune complex-mediated 
arthritis. Journal of leukocyte biology. 2001;70(5):708-14.
49 Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol. 2008;3:99-126.
MER
101
4
50 Mathy NL, Bannert N, Norley SG, Kurth R. Cutting edge: CD4 is not required for the functional 
activity of IL-16. Journal of immunology. 2000;164(9):4429-32.
51 Lard LR, Roep BO, Toes RE, Huizinga TW. Enhanced concentrations of interleukin 16 are 
associated with joint destruction in patients with rheumatoid arthritis. The Journal of 
rheumatology. 2004;31(1):35-9.
52 Kaufmann J, Franke S, Kientsch-Engel R, Oelzner P, Hein G, Stein G. Correlation of circulating 
interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. 
Rheumatology. 2001;40(4):474-5.
53 Murota A, Suzuki K, Kassai Y, Miyazaki T, Morita R, Kondo Y, et al. Serum proteomic analysis 
identifies interleukin 16 as a biomarker for clinical response during early treatment of 
rheumatoid arthritis. Cytokine. 2016;78:87-93.
54 Ruiz-Heiland G, Zhao Y, Derer A, Braun T, Engelke K, Neumann E, et al. Deletion of the 
receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. 
Annals of the rheumatic diseases. 2014;73(4):771-9.
55 O’Donnell K, Harkes IC, Dougherty L, Wicks IP. Expression of receptor tyrosine kinase Axl and 
its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. 
The American journal of pathology. 1999;154(4):1171-80.
CHAPTER 4
102
Supplementary materials and methods
Supplementary Table 1 | List of oligonucleotide primer sequences 
Species Oligo description Sequence (5’ → 3’)
Human GAPDH_FW ATCTTCTTTTGCGTCGCCAG
Human GAPDH_RV TTCCCCATGGTGTCTGAGC
Human IL1B_FW TGGGTAATTTTTGGGATCTACACTCT
Human IL1B_RV AATCTGTACCTGTCCTGCGTGTT
Human TNF_FW TCTTCTCGAACCCCGAGTGA
Human TNF_RV CCTCTGATGGCACCACCAG
Human ADAM17_FW TCACGTTTGCAGTCTCCAAA
Human ADAM17_RV CACTCGATGAACAAGCTCTTC
Human PROS1_FW CCCTGGAGGTTACACTTGCT
Human PROS1_RV ACTGCTCCGCCAAGTAAAGT
Mouse Gapdh_FW GGCAAATTCAACGGCACA
Mouse Gapdh_RV GTTAGTGGGGTCTCGCTCCTG
Mouse Il1b_FW GGACAGAATATCAACCAACAAGTGATA
Mouse Il1b_RV GTGTGCCGTCTTTCATTACACAG
Mouse Tnf_FW CAGACCCTCACACTCAGATCATCT
Mouse Tnf_RV CCTCCACTTGGTGGTTTGCTA
Mouse Ccl2_FW TTGGCTCAGCCAGATGCA
Mouse Ccl2_RV CCTACTCATTGGGATCATCTTGCT
Mouse Ccl3_FW TTGGCTCAGCCAGATGCA
Mouse Ccl3_RV CCTACTCATTGGGATCATCTTGCT
Mouse Mmp3_FW TGAAGCCACCAACATCAGGA
Mouse Mmp3_RV TGGAGCTGATGCATAAGCCC
Mouse Mmp13_FW AGACCTTGTGTTTGCAGAGCACTAC
Mouse Mmp13_RV CTTCAGGATTCCCGCAAGAG
Mouse Mmp14_FW GCCTGCATCCATCAAACT
Mouse Mmp14_RV CAGTGCTTATCTCCTTTGAAGAAG
Mouse Il17a_FW CAGGACGCGCAAACATGA
Mouse Il17a_RV GCAACAGCATCAGAGACACAGAT
Mouse Il6_FW CAAGTCGGAGGCTTAATTACACATG
Mouse Il6_RV ATTGCCATTGCACAACTCTTTTCT
Mouse Cxcl1_FW TGGCTGGGATTCACCTCAA
Mouse Cxcl1_RV GAGTGTGGCTATGACTTCGGTTT
Mouse Mmp9_FW GGAACTCACACGACATCTTCCA
Mouse Mmp9_RV GAAACTCACACGCCAGAAGAATTT
Mouse Socs1_FW CCGTGGGTCGCGAGAAC
Mouse Socs1_RV AAGGAACTCAGGTAGTCACGGAGTA
Mouse Socs3_FW TAGACTTCACGGCTGCCAAC
Mouse Socs3_RV CGGGGAGCTAGTCCCGAA
Mouse Pros1_FW GCACAGTGCCCTTTGCCT
Mouse Pros1_RV CAAATACCACAATATCCTGAGACGTT
Mouse Adam17_FW ATCGTTGGGTCTGTTCTGGTT
Mouse Adam17_RV ATCTCAATGTTACTGTGATGAAACA
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Supplementary figures
 
 
Supplementary Figure 1 | Expression of MER, soluble MER, Pros1 and Adam17 by BMMs
(A) BMMs were analyzed with flow cytometry for the membrane protein expression of MER. Red 
= unstained, blue = stained for MER. (B-C) BMMs were transduced with Ad Luc or Ad Pros1 and 
stimulated with LPS (100 ng/mL) or P3C (100 ng/mL) for 6 hours. Messenger RNA was extracted 
and gene expression was determined (n=3 per experiment). (D) BMMs were transduced with 
Ad Luc or Ad Pros1 and stimulated with LPS (100 ng/mL) or P3C (100 ng/mL) for 24 hours. 
Supernatants were analyzed (n=3 per experiment). For (B) data are presented as dot-plots with 
mean. For (C-D) data are presented as mean + SEM. * = p<0.01, *** = p<0.001 with unpaired t 
test comparing Ad Luc to Ad Pros1 conditions. All data are representative for 2 independent 
experiments. ND = not detected. See also Figure 2.
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Supplementary Figure 2 | Effect of local adenoviral Pros1 overexpression on metallo-
proteinase expression, Adam17 expression and soluble MER levels in KRN STA
KRN STA was induced in mice overexpressing luciferase (Ad Luc) or Pros1 (Ad Pros1) in their knee 
joints and mice were euthanized at day 14. (A-B) Knee synovial biopsies were obtained, mRNA 
was extracted and gene expression was determined (n=6 knee synovial biopsies). (C) Serum 
samples from the same mice were analyzed for soluble MER (n=12 mice). Data are represented 
as mean + SEM. ** = p<0.01, *** = p<0.001 with unpaired t test. See also Figure 2.
Supplementary Figure 3 | Expression of Pros1, Adam17 and soluble MER levels by three-
dimensional synovial micromasses after anti-MER or PROS1 treatment
(A and C) Micromasses were treated with IgG or anti-MER for 24 hours, mRNA was extracted 
and gene expression was determined (n=4).  (B) Micromasses were treated with IgG or anti-
MER for 24 hours. Supernatants were examined for the presence of soluble MER (n=4). (D-
E) Micromasses were pre-incubated with 50 nM Pros1 for 24 hours and stimulated with LPS 
(100 ng/mL), P3C (100 ng/mL) or TNF-α (10 ng/mL) for 6 hours. Messenger RNA was extracted 
and gene expression was determined (n=3). (F) Micromasses were pre-incubated with 50 nM 
Pros1 for 24 hours and stimulated with LPS (100 ng/mL), P3C (100 ng/mL) or TNF-α (10 ng/mL) 
for 24 hours. Supernatants were analyzed (n=3). All data are representative for 2 independent 
experiments. For (A-C) data are presented as dot-plots with mean. For (D-F) data are presented 
as mean + SEM. See also Figure 3.
MER
105
4
Supplementary Figure 4 | Local and systemic effects of anti-MER on inflammation and 
destruction in CIA
Knee synovial biopsies were obtained at day 30 from mice with CIA intravenously injected with 
10 µg IgG or anti-MER. Messenger RNA was extracted and gene expression was determined for 
(A) cytokines and chemokines, (C) metalloproteinases (D) SOCS genes and (E) Adam17 (n=10 
knee synovial biopsies). (B and F) Serum samples from the same mice were analyzed for IL-6 
and KC or soluble MER (n=10-11 mice). All data are presented as mean + SEM. * = p<0.05, ** = 
p<0.01 with unpaired t test. See also Figure 4.
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Supplementary Figure 5 | Effect of anti-MER on efferocytosis
(A) J774A.1 cells were incubated with IgG or anti-MER and co-cultured with pHrodo-labeled 
apoptotic cells. Efferocytosis was analyzed by fluorescence microscopy (n=6). (B) J774A.1 cells 
were incubated with IgG or anti-MER, mRNA was extracted and gene expression was determined 
(n=3-4). (C) J774A.1 cells were incubated with IgG or anti-MER. Supernatants were examined 
for the presence of soluble MER (n=4). (D) J774A.1 cells were incubated with IgG or anti-MER. 
Supernatants were examined for the presence of soluble MER (n=4).  For (A) data are presented 
as mean + SD. For (B-D) data are presented as dot-plots with mean. For (A) ** = p<0.01 with one-
way ANOVA with Bonferroni post test. ND = not detected. See also Figure 5 and 6.
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Abstract
Introduction
We have previously shown that the TAM receptor MER plays a protective role in models of 
rheumatoid arthritis (RA). In both humans and mice, MER can be proteolytically cleaved 
resulting in the soluble form of this receptor. Soluble MER is regarded to be a decoy 
receptor for the TAM receptor ligands Growth Arrest-Specific 6 (GAS6) and Protein S. Two 
studies showed conflicting data on the systemic levels of soluble MER in RA patients. In 
this study, we measured the systemic levels of soluble MER in a mouse model of RA and 
the local soluble MER levels in RA, as the latter might be more relevant for the arthritic 
process. 
Materials and methods
KRN serum transfer arthritis was induced in wild-type (WT) mice. Ankle joints were 
examined immunohistochemically for MER. Serum levels of soluble MER were measured 
by ELISA. Human synovial biopsies of RA and osteoarthritis (OA) patients were examined 
for MER and the wash-outs for soluble MER and GAS6. Human RA synovial fluid was 
examined for soluble MER, GAS6 and inflammatory cytokines. 
Results
During full-blown arthritis, serum soluble MER levels were increased in WT mice whereas 
the amount of MER+ synovial cells was unaltered. In human RA synovium, numerous 
MER+ macrophages were present in the lining and sublining but not around the blood 
vessels. We found enhanced soluble MER in RA synovial tissue wash-outs as compared 
to OA controls, and this correlated positively with GAS6. Moreover, in synovial fluid of 
RA patients, soluble MER and GAS6 also positively correlated whereas soluble MER and 
GAS6 negatively correlated with interleukin (IL)-6. No correlation was found with soluble 
MER and Tumor Necrosis Factor α or IL-1β. 
Conclusion
Soluble MER levels are enhanced in experimental arthritis and locally in rheumatoid 
arthritis, but whether this has a modulating effect on joint inflammation remains to be 
determined. 
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Introduction
Rheumatoid arthritis (RA) is an auto-immune disease marked by chronic and unrestrained 
inflammation in synovial joints. In the arthritic joint, the synovium is infiltrated by, amongst 
others, blood monocytes that fuel the number of synovial macrophages1. Synovial 
macrophages are the main producers of the pathogenic cytokine Tumour Necrosis 
Factor α (TNF-α), the target of anti-TNF which is the gold standard treatment for RA2. 
These macrophages, together with the proliferation of the tissue-resident fibroblasts, 
lead to pannus tissue formation at the articular cartilage and bone interface. Overall, this 
eventually results in damage and loss of the articular cartilage matrix and bone tissue3,4. 
One family of tyrosine kinases expressed by macrophages are the TAM receptors. The 
TAM receptors – TYRO3, AXL and MER (gene name Mertk) – play a critical role in natural 
anti-inflammatory feedback mechanisms. The two principal TAM receptor protein 
ligands are Growth Arrest-Specific 6 (GAS6) and Protein S (PROS1). GAS6 is a ligand for 
all three receptors whereas PROS1 can only activate TYRO3 and MER but not AXL5. GAS6 
is a more potent ligand than PROS1 to induce MER activation5. These ligands act as a 
bridging molecule between one of the TAM receptors and phosphatidylserine (PS) that is 
expressed as an ‘eat-me signal’ on the surface of apoptotic cells5. PROS1/GAS6 binding 
to PS effectively opsonizes apoptotic cells for TAM receptor-mediated efferocytosis6,7. 
Additionally, others have shown the TAM receptors and their ligands negatively regulate 
inflammation, and we have shown this in experimental models of RA8-15. 
The TAM receptors can be proteolytically cleaved, leading to shedding of their soluble 
ectodomain and consequently a soluble form of the receptors. Much attention has 
been given to soluble MER. In the murine system, MER is cleaved by A Disintegrin and 
Metalloprotease Domain (ADAM) 1716. The formation of soluble MER can be induced by 
inflammatory stimuli such as phorbol 12-myristate 13-acetate (PMA) or lipopolysaccharide 
(LPS)16-19. Soluble MER, or the MER-Fc fusion protein mimicking soluble MER, acts as 
a decoy receptor for GAS6- or PROS1-mediated activation of MER17,20-23. Conversely, 
inhibiting the release of soluble MER, either by chemically inhibiting ADAM17 activity, or 
by genetically modifying MER in such a manner that the receptor becomes cleavage-
resistant, enhances activation of MER16,19,24-27. 
One study showed that soluble MER levels are enhanced in plasma of RA patients28. 
However, these levels did not correlate to disease activity28. Recently, a study showed the 
controversial finding that the soluble MER levels in plasma are reduced in RA29. Moreover, 
nothing is known about the soluble MER levels in experimental arthritis. This prompted 
us to investigate the levels of soluble MER in experimental arthritis and locally in RA, and 
whether this correlated to inflammatory cytokines. In addition, one of the ligands of MER, 
GAS6, is reduced in serum of RA patients30. However, to date, nothing has been described 
about the GAS6 levels locally in rheumatoid arthritis. Therefore, we studied the levels of 
soluble MER and GAS6 and in murine experimental arthritis and human RA. 
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Materials and methods
Murine
Mice
Wild-type (WT) mice were bred and housed at the Salk Institute for Biological Studies 
and fed a standard diet with freely available food and water. Arthritis was induced 
by two intraperitoneal injections, at day 0 and 2, of 150 µL arthritic K/BxN serum. Mice 
were sacrificed at day 7 of arthritis. In vivo studies were executed in The United States 
of America and were conducted according to guidelines established by the Salk 
Institutional Animal Care and Use Committee.
Murine soluble MER Enzyme-Linked Immuno Sorbent Assay (ELISA) 
Murine soluble MER in serum was examined using the mouse MER DuoSet ELISA (DY591; 
R&D systems) and the DuoSet Ancillary Reagent kit 2 (DY008; R&D systems) according to 
manufacturer’s instructions. Serum was diluted 1:5.
Immunohistochemical analysis of MER on murine ankle joints
Whole ankle joints were dissected, fixed in 4% phosphate-buffered formalin, decalcified 
with 5% formic acid and embedded in paraffin. Tissue sections (7 μm) were deparaffinized 
and rehydrated. Endogenous peroxidase was blocked by 3% hydrogen peroxide in 
methanol. Antigen-retrieval was performed in citrate buffer (pH 6) heated to 37ºC for 2 
hours and subsequent trypsin treatment at 37°C for 7 minutes. Sections were blocked 
by 10% rabbit serum in phosphate-buffered saline (PBS) for 20 minutes at room 
temperature (RT). Sections were incubated with rat anti-mouse MER (2.5 µg/mL; 14-
5751; eBioscience) or rat IgG1 (2.5 µg/mL; 559072; BD Pharmingen) overnight at 4°C. 
Subsequently, sections were incubated with biotinylated rabbit anti-rat IgG (1:200; BA-
4001; Vector Laboratories) for 30 minutes at RT. Antibodies were diluted in 2% rabbit 
serum in PBS. A biotin-streptavidin horseradish peroxidase detection system was used 
according to manufacturer’s protocol (PK6101; Vector Laboratories). Bound complexes 
were visualized with diaminobenzidine (DAB) (Merck). Sections were counterstained with 
hematoxylin. Two sections per ankle joint were stained. Sections were randomized and 
blinded and pictures were taken with the Leica DMR microscope (Leica Microsystems) 
at 100x magnification. Quantification of the staining was performed using the LAS V4.3 
software (Leica Microsystems). The synovial lining was selected and the area of MER+ 
cells was expressed as percentage of the total area of the synovial lining. The average of 
each ankle joint is depicted.
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Human
Patient material
Synovial biopsies from rheumatoid arthritis (RA) patients and osteoarthritis (OA) 
patients were obtained during joint replacement surgery from the Orthopaedics 
department (Radboud University Medical Center, Nijmegen, the Netherlands) and the 
Sint Maartenskliniek, Nijmegen, the Netherlands. The presence of a synovial lining was 
determined on 7 µm cryosections stained with hematoxylin and eosin staining to confirm 
the synovial origin of the tissue (not shown). Three mm synovial biopsy punches were 
either fixed in formalin for immunohistochemistry, stored in Tissue-Tek (Sakura) for 
histological analysis or cultured. Synovial fluid from RA patients was obtained during 
consultations at the polyclinic to alleviate pressure and pain of the joint. All material was 
considered surplus material. Procedures were performed in accordance to the code of 
conduct for responsible use of human tissue in medical research (https://www.federa.
org/code-goed-gebruik). 
Immunohistochemistry on human synovium
Protein expression was evaluated on 7 μm tissue sections. Sections were deparaffinized 
and rehydrated. Antigen retrieval was performed in Tris-ethylenediaminetetraacetic 
acid (EDTA) buffer (pH 9) heated to 60°C. Endogenous peroxidase was blocked by 3% 
hydrogen peroxide in methanol. Sections were blocked by 10% normal goat serum, 1% 
bovine serum albumin (BSA) in PBS for 20 minutes at RT before incubation with rabbit anti-
human MER (0.2 µg/mL; ab52968; Abcam) overnight at 4°C. Subsequently, sections were 
incubated with biotinylated goat anti-rabbit IgG (1:400; PK-6101; Vector Laboratories) 
for 30 minutes at RT. A biotin-streptavidin horseradish peroxidase detection system 
was used according to manufacturer’s protocol (PK6101; Vector Laboratories). Bound 
complexes were visualized with DAB by incubation for 10 minutes at RT (Merck). Next, 
sections were incubated with mouse anti-human CD68 (4 µg/mL; M0814; DAKO), mouse 
anti-human CD3 (0.7 µg/mL; M7254; DAKO) or mouse anti-human CD20 (2 µg/mL; 120M-
84; Cell Marque) for 60 minutes at RT. All antibodies were diluted in 1% BSA in PBS. The 
Powervision AP detection system was used. Bound complexes were visualized with Fast 
Blue by incubation for 20 minutes at 37C°. In addition to the double stainings, single 
stainings were also taken along where one of the two primary antibodies was not added 
during the incubation. For the staining of OA synovium, sections were counterstained 
with hematoxylin.  
Short-term culture supernatants of human synovium
Three mm synovial biopsy punches were cultured in Roswell Park Memorial Institute 
(RPMI) medium (Gibco) supplemented with 10% heat-inactivated foetal calf serum (FCS), 
1 mM pyruvate and penicillin/streptomycin (P/S). Samples were kept at 37°C with 5% 
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CO2. After 24 hours, supernatants were collected, spun down at 300g for 5 minutes and 
stored in -20°C until further analysis. Three to eight synovial biopsies were taken from 
synovium of one patient, and the average of their supernatants is depicted in the figures. 
Human synovial fluid
Synovial fluid was spun down at 1,700g for 10 minutes at 4°C, supernatants were 
aliquoted and stored in -20°C. All synovial fluid samples were thawed and treated with 
hyaluronidase at the same time. Synovial fluid was treated with 75 U/mL of hyaluronidase 
(H3506; Sigma-Aldrich) for 15 minutes at 37°C and subsequently spun down at 1.000g for 
10 minutes at 4°C. Samples were aliquoted and stored in -20°C until further analysis. 
Human soluble MER and GAS6 ELISAs
Human soluble MER levels in supernatants and synovial fluid were examined using the 
total human MER DuoSet ELISA (DYC891; R&D systems). Supernatant was diluted 1:2 
and synovial fluid was diluted 1:5. Human GAS6 in supernatants and synovial fluid was 
examined using the GAS6 DuoSet ELISA (DY885B; R&D systems). Supernatant was 
diluted 1:5 and synovial fluid was diluted 1:25. Both ELISAs were performed according 
to manufacturer’s instructions using the DuoSet Ancillary Reagent kit 2 (DY008; R&D 
systems). Samples were diluted in the same buffer as the samples for the standard curve. 
Multiplex ELISA
Cytokines in synovial fluid were measured on a Bio-Plex 200 system using a magnetic 
bead-based multiplex immunoassay. Data analysis was performed with Bio-Plex Manager 
software (all Bio-Rad). Synovial fluid was diluted 1:4. 
Statistical analysis
Data were analyzed with GraphPad Prism software (version 5.03). Analysis of significance 
was performed using a Mann Whitney test. For correlations, the Pearson’s correlation 
coefficient was calculated. p-Values lower than 0.05 were considered to be significantly 
different.
Results
Systemic soluble MER levels are enhanced in experimental arthritis
We first examined the soluble MER levels in the serum of WT mice before the onset of 
inflammatory arthritis and at day 7 of KRN STA, a stage of arthritis with full-blown 
inflammation15,31. Soluble MER levels were significantly enhanced at day 7 of inflammatory 
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arthritis (Figure 1A). Next, we aimed to show that the systemic levels of soluble MER could 
be derived from the synovium. Immunohistochemical staining for MER in ankle joints of 
mice showed that the synovial lining in the ankle joints was MER+. However, there was 
no difference between day 0 and day 7 in the amount of MER+ cells in the synovial lining 
(Figure 1B-C). 
 
 
Figure 1 | Analysis of mouse serum and ankle joint synovium before and after onset of 
experimental arthritis 
Wild-type mice in a naïve state (day 0) or with KRN serum transfer arthritis (day 7). (A) Serum 
levels of soluble MER at day 0 and day 7. Data are presented as mean + S.E.M. n=11-13 mice per 
group. *=p<0.05 with Mann Whitney test. (B) Percentage of immunohistochemically detected 
MER+ cells in the synovial lining of ankle joints. Data are presented as mean + S.E.M. n=6 mice 
day 0, n=15 mice at day 7. Data were tested with Mann Whitney test. (C) Representative pictures 
of immunohistochemical staining at day 0 and day 7 for MER or IgG control in 200x magnification. 
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Human RA synovial tissue contains MER+ macrophages and releases 
higher levels of soluble MER and GAS6
Next, we examined synovial biopsies of RA patients for the presence of MER, and on which 
cell types it is expressed. As shown in Figure 2A, the lining and sublining of RA synovium 
contained numerous MER+ cells which co-localized with the macrophage marker CD68 
whereas MER did not co-localize with the T cell and B cell markers CD3 and CD20, 
respectively. MER+ macrophages were not found around the blood vessels. To examine 
whether RA synovial tissue secretes more soluble MER, we cultured synovial biopsies 
of RA or OA patients and examined the levels of soluble MER. Soluble MER levels were 
significantly enhanced in supernatants derived from RA synovial tissue, compared to OA 
controls (Figure 2C). Notably, this did not appear to be due the fact OA synovial tissue did 
not express abundant levels of MER (Figure 2B). Interestingly, although serum GAS6 levels 
are reduced in RA patients30, GAS6 secretion by RA synovium was also significantly higher 
compared to OA synovium (Figure 2D). Moreover, soluble MER and GAS6 significantly 
positively correlated (Figure 2E). 
Figure 2 | Analysis of human synovial biopsies and short-term culture supernatants of human 
synovium
(A) Synovial biopsies of rheumatoid arthritis patients were processed for immunohistochemical 
staining. Shown are single stainings (upper two panels) and double stainings (bottom two 
panels). Pictures were taken at 100x magnification (upper three panels) or 200x magnification 
(bottom panel). Cell surface markers of interest were CD68 (blue) – MER (brown), CD3 (blue) 
– MER (brown), or CD20 (blue)  –  MER (brown). (B) A synovial biopsy of an osteoarthritis 
patients was processed for immunohistochemical staining of MER (brown), counterstained 
with hematoxylin. Picture was taken at 100x magnification. (C) Three mm synovial biopsies 
of rheumatoid arthritis and osteoarthritis patients were cultured for 24 hours. Supernatants 
were examined for soluble MER. Data are presented dot-plots with mean. Each dot presents 
the average of 3-8 cultured synovial biopsies per patient.  n=17 osteoarthritis patients, n=15 
rheumatoid arthritis patients. **=p<0.01 with Mann Whitney test. (D) Three mm synovial 
biopsies of rheumatoid arthritis and osteoarthritis patients were cultured for 24 hours. 
Supernatants were examined for GAS6. Data are presented dot-plots with mean. Each dot 
presents the average of 3-8 cultured synovial biopsies per patient.  n=11 osteoarthritis 
patients, n=12 rheumatoid arthritis patients. **=p<0.01 with Mann Whitney test. (E) Three mm 
synovial biopsies of rheumatoid arthritis and osteoarthritis patients were cultured for 24 hours. 
Supernatants were examined for soluble MER and GAS6. Data are presented as a correlation. 
Each dot presents the average of 3-8 cultured synovial biopsies per patient.  n=11 osteoarthritis 
patients, n=12 rheumatoid arthritis patients. **=p<0.01 with Pearson r’s correlation analysis. 
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In RA synovial fluid, the levels of soluble MER positively correlate with 
GAS6 and negatively correlate with IL-6
The positive correlation of soluble MER with GAS6 observed in wash-outs of synovial 
tissue was also observed in RA synovial fluid (Figure 3A). We, and others, have shown that 
MER plays a crucial role in an anti-inflammatory effect8-15. Therefore, we examined whether 
soluble MER correlated with enhanced inflammation in RA synovial fluid. Surprisingly, IL-6 
significantly negatively correlated with soluble MER and GAS6 (Figure 3B-C). IL-1β and 
TNF-α did not correlate to soluble MER levels (Figure 3D-E). 
 
Figure 3 | Analysis of human RA synovial fluid
Synovial fluid of rheumatoid arthritis patients was examined for the presence of proteins. 
Correlations are depicted for (A) soluble MER – GAS6, (B) soluble MER – IL-6, (C) GAS6 – IL-6, 
(D) soluble MER – TNF-α, and (E) soluble MER – IL-1β. Each dot presents the protein level of one 
patient. n=9. *=p<0.01, ***=p<0.0001 with Pearson r’s correlation analysis.
Discussion
 In this study, we show that the systemic soluble MER levels are significantly higher in mice 
with experimental arthritis compared to mice without arthritis. However, we find that the 
amount of MER+ cells during full-blown inflammatory arthritis is similar to baseline levels. 
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If soluble MER in serum is derived from the ankle joint synovium, this could be explained 
by the recovery of membrane-bound MER after proteolytic cleavage by an increased 
Mertk expression, as has been described in the retinal pigment epithelium of the eye20. 
Whether the increased levels of soluble MER in the serum are derived from the synovium 
remains to be determined. Measuring ADAM17 expression and activity, the enzyme 
responsible for proteolytically cleaving MER16, or by direct inhibition of ADAM17 by intra-
articular injection of the ADAM17 inhibitor TAPI-O32, in the murine ankle synovium could 
show that the enhanced systemic soluble MER levels are derived from the synovium. 
However, this inhibitor might also influence the disease process, as ADAM17 inhibition 
reduces the clinical scores of collage-induced arthritis33, thereby complicating the 
interpretation of the results. Moreover, measuring wash-out of ankle synovium could 
indicate whether locally during arthritis, soluble MER levels are enhanced. Importantly, 
whether soluble MER truly plays a role in the disease process necessitates further 
investigation. This could be done by the synovial overexpression of a MER mutant that 
cannot be cleaved16, or overexpression of the natural MER, in Mertk-/- mice to see whether 
this mutant can reduce arthritis pathology.
Serum levels of soluble MER are enhanced in RA patients compared to healthy controls28. 
Another study showed the opposite29. We find that soluble MER levels are significantly 
enhanced, derived from RA synovium, compared to OA synovium. Although it has not 
been established that ADAM17 or other sheddases are responsible for the cleavage of 
MER in humans, this finding is in line with the fact that ADAM17 is expressed at significant 
lower levels in OA synovial tissue34. In contrast, the fact that soluble MER and TNF-α, 
the latter being proteolytically cleaved by ADAM1735, do not significantly correlate in the 
synovial fluid suggest that ADAM17 may not be the enzyme (solely) responsible for the 
cleavage of MER in humans. 
It is generally accepted that OA and RA are low grade and high grade inflammatory, 
respectively36. Therefore, we cannot exclude that the higher concentration of soluble 
MER in the wash-outs of RA synovium is merely a reflection of the number of macrophages 
present in the synovial biopsies. Moreover, gender and age should be matched between 
RA and OA patients in order to exclude the influence of these factors to the levels of 
soluble MER. In addition, the time point should be taken along, as MER cleavage can be 
regulated by the circadian rhythm, at least in case of the eye20. 
Interestingly, although we find prominent enhanced soluble MER levels in inflammatory 
experimental arthritis and in wash-out of human RA synovium, membrane-bound MER on 
synovial macrophages was also still present. Moreover, prominent levels of GAS6 were 
also secreted by RA synovium. GAS6 can potently reduce IL-68. Possibly, there was still 
effective signalling by GAS6 in the synovium, as IL-6 levels negatively correlated with 
GAS6. It is possible that GAS6-mediated suppression of inflammation is counteracted 
by soluble MER. Visa versa, it is also possible that enhanced levels of GAS6 could be a 
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compensatory mechanism for the elevated levels of soluble MER. A positive correlation 
between soluble MER and GAS6 could also be explained by the interaction of these 
proteins, as soluble MER has been described to be a decoy receptor for GAS617,20-23. 
Similar interactions have been described in the synovial fluid for soluble AXL and GAS637.
We could not find any evidence that soluble MER is positively associated with 
inflammatory cytokines in RA. The role of soluble MER, in addition to MER activation, 
has also been extensively described for efferocytosis16-23. Whether soluble MER results 
in reduced efferocytosis in arthritis remains to be elucidated. Moreover, the effect of 
soluble MER on T cell activation should be investigated. Activated T cells produce PROS1, 
which can reduce the activation status of dendritic cells, thereby in turn constraining the 
activation of T cells38. This mechanism controls the local immune response. Possibly, T 
cells are hyperactivated due to the lack of inhibition, caused by the binding of PROS1 to 
soluble MER. This could also explain the weak role of activated T cells in OA.
In conclusion, the data we collected show that soluble MER levels are enhanced in 
experimental arthritis and locally in rheumatoid arthritis, and the latter levels positively 
correlate to GAS6 but not to inflammatory cytokines. Whether this has an effect on joint 
inflammation remains to be determined. 
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Abstract
Therapeutic agents that are used by patients with rheumatic and musculoskeletal 
diseases were originally developed and tested in animal models, and although 
retrospective studies show a limited predictive value, it could be explained by the fact 
that there are no good in vitro alternatives. In this study, we developed a 3-dimensional 
synovial membrane model made of either human primary synovial cell suspensions or 
a mix of primary fibroblast-like synoviocytes and CD14+ mononuclear cells. We analyzed 
the composition of the mature micromasses by immunohistochemical staining and 
flow cytometry and show that the outer surface forms a lining layer consisting out of 
fibroblast-like and macrophage-like cells, reflecting the in vivo naïve synovial membrane. 
To recreate the affected synovial membrane in rheumatoid arthritis (RA), the micromasses 
were exposed to the pro-inflammatory cytokine Tumor Necrosis Factor Alpha (TNF-α). 
This led to increased pro-inflammatory cytokine expression and production and to 
hyperplasia of the membrane. To recreate the synovial membrane in osteoarthritis (OA), 
the micromasses were exposed to Transforming Growth Factor Beta (TGF-β). This led to 
fibrosis-like changes of the membrane, including increased Alpha Smooth Muscle Actin 
and increased expression of fibrosis-related genes PLOD2 and COL1A1. Interestingly, 
the macrophages in the micromass showed phenotypic plasticity as prolonged TNF-α 
or TGF-β stimulation strongly reduced the occurrence of Cluster of Differentiation 
163-positive M2-like macrophages. We showed the plasticity of the micromasses as a 
synovial model for studying RA and OA pathology and propose that the synovial lining 
micromass system can be a good alternative for testing drugs.
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Introduction
Rheumatoid arthritis (RA) and osteoarthritis (OA) are the most common rheumatic 
diseases. The global incidence of RA is estimated to be 0.5%-1%1 and an estimated 12.1% 
of the adult population has clinical symptoms of OA2. RA and OA are both viewed as multi-
factorial diseases involving multiple risk factors3,4 but their exact etiology is unknown. 
Both diseases cannot be cured at present, but disease-modifying drugs (DMARDs) are 
available for RA and non‐steroidal anti‐inflammatory drugs (NSAIDs) are commonly 
prescribed for OA.
During the abovementioned rheumatic diseases, many processes occur in the synovium. 
Already in the early phase of RA, hyperplasia of the synovial lining occurs and immune 
cells infiltrate the sublining5,6. The cells in the synovium can produce several pro-
inflammatory cytokines and matrix-degrading enzymes. At the interface of the synovium, 
cartilage and bone, pannus tissue is formed that contributes to bone destruction. An 
important mediator of these processes is Tumor Necrosis Factor Alpha (TNFα)7. Specific 
inhibitors of TNF-α are the most widely used biological therapies and can successfully 
inhibit the progress of RA in the majority of patients8.
Synovial pathology is also described for OA. Although OA has traditionally been described 
as a wear-and-tear disease of the articular cartilage, synovitis is observed in up to 50% 
of the OA patients and might contribute to the disease process9. A second factor that 
contributes to the synovial thickening in OA is tissue fibrosis10. Synovial fibrosis is also 
associated with joint pain and stiffness11. Although the pathogenesis of OA is poorly 
understood, the cytokine most critically associated with processes occurring in OA 
is Transforming Growth Factor Beta (TGF-β)12. TGF-β is pivotal for the development and 
maintenance of the articular cartilage, but excessive signaling can have detrimental 
results. For example, adenoviral overexpression of TGF-β in mice resulted in osteophyte 
formation13. Moreover, TGF-β stimulates the differentiation of myofibroblasts and the 
expression of collagen type 1 that contribute to synovial fibrosis14, 15. 
Many experiments have been performed in animal models of RA and OA to study the initial 
stages of inflammation, hyperplasia and fibrosis in the synovium. However, the predictive 
value of animal models for the screening of potential drugs in RA is variable and for OA, many 
therapies have been successful in treating experimental OA, but no treatment has been 
sufficiently effective in clinical trials16,17. In addition, the translation of these findings to the 
human synovium is difficult because there is a lack of relevant human in vitro 3-dimensional 
models to simulate synovial pathology, including hyperplasia and synovial fibrosis.
Translational arthritis research with human cells is often performed in monolayer culture 
with in vitro expanded synovial fibroblasts. Although monolayer culture with fibroblasts 
is easy to perform, the absence of extracellular matrix and other cell types results in 
alterations of cell functioning and a rapid loss of phenotype18. One way to maintain the 
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cell composition and matrix interactions of the cells is by using synovial explants instead 
of cultured monolayer cells. Although synovial explants better represent the original 
joint environment for the cells, important disease processes including hyperplasia 
and cartilage damage may have already taken place and can thus not be studied using 
explants. Moreover, there is considerable variability between biopsies from a single joint, 
resulting from a variation in lining thickness19, sublining composition and an unequal 
distribution of synoviocyte types in the synovial membrane20,21.
To circumvent these challenges and provide a relevant model for the synovial membrane 
in which cells can interact with cellular matrix, Kiener and co-workers have developed a 
3-dimensional (3D) micromass model based on a mixture of fibroblast-like synoviocytes 
(FLS) and Matrigel solution. When kept on ice, the Matrigel was liquid and could be mixed 
with cells to obtain a homogenous solution. Single drops were pipetted in a culture well 
and became solid at 37 °C. Within weeks, the FLS formed a lining layer on the Matrigel-
medium surface that was reminiscent of a synovial membrane22. Reticulin fibers on 
the surface of the micromasses were arranged in an orientation similar to basement 
membrane structures in synovial biopsies. The FLS in the micromass lining produced 
lubricin and showed hyperplasia after 3 weeks stimulation with TNF-α23. The lining 
formation was not observed when using dermal fibroblasts.
We have recently applied the synovial micromass using the complete cell suspension after 
biopsy digestion for micromass formation24. This was performed without further isolation 
and purification of the synovial fibroblasts to better mimic their cellular composition and 
interactions as present in the starting material. In this study, we further characterized the 
synovial micromasses to study the fate of the different cell types. After lining formation, 
the micromass mainly consisted of synovial fibroblasts and macrophages. We therefore 
used micromasses produced from primary FLS and macrophages throughout the rest of 
the study. TNF-α and TGF-β exposure of the synovial micromasses was used to mimic 
the inflammatory conditions present in RA and OA. This showed that short-term exposure 
to TNFα already leads to proinflammatory gene expression and long-term exposure 
to hyperplasia. Long-term exposure to TGF-β resulted in fibrosis-like changes of the 
micromass lining. In conclusion, these results provide a detailed analysis of the synovial 
micromasses and show the suitability as a synovial membrane model for translational 
research in RA and OA. The micromasses may replace animal experiments in which 
advanced synovial pathology can be studied. An unpublished survey done by us under 
20 leading research groups in the arthritis field revealed that 40% is of the opinion that 
in vitro models may replace animal experimentation entirely and 60% finds it a useful 
addition.
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Materials and methods
Patient material
Synovial biopsies from 5 RA patients were obtained during joint replacement surgery from 
the Orthopedics department of the Sint Maartenskliniek, Nijmegen, the Netherlands. This 
material was considered surgery surplus material. Patients gave written informed consent 
for the use of their material for research. The patient material was pseudonymized. There 
was no need for the approval by an ethical committee. Procedures were performed in 
accordance to the code of conduct for responsible use of human tissue in medical 
research (https://www.federa.org/code-goed-gebruik). The presence of a synovial 
lining was determined on 7 µm cryosections stained with hematoxylin and eosin staining 
(H&E) to confirm the synovial origin of the tissue (not shown). All patients adhered to the 
American College of Rheumatology (ACR) criteria and were end-stage RA.
Human CD14+ cells
Peripheral blood mononuclear cells (PBMCs) were obtained from 3 healthy donors by 
density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Chicago, IL, 
USA). Cluster of Differentiation (CD) 14+ cells were isolated from the PBMC fraction using 
the MagniSort Human CD14 Positive Selection Kit (Invitrogen, Carlsbad, CA, USA) (purity 
>90%) according to the manufacturer’s protocol.
Micromass production
Micromasses were produced from both complete synovial cell suspensions from RA 
synovium as described previously24 and from a combination of primary RA fibroblast-
like synoviocytes (FLS) after several passages and CD14+ monocytes. In short, for 
micromasses from complete cell suspensions, the biopsies were digested using 
Liberase (Roche, Basel, Switzerland) for 1h at 37 °C and the cells were filtered through a 
70 µm cell strainer (Corning, NY, USA). Red blood cells (RBCs) were lysed for 2 min at RT 
in 4 ml RBC lysis buffer (155 nM NH4Cl, 12 mM KHCO3, 0.1 mM EDTA, pH 7.3). The cells were 
mixed on ice with liquid Matrigel and 25 µl droplets containing ~5x105 cells were pipetted 
on a poly-(2-hydroxyethyl methacrylate) (poly-HEMA) (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) coated 24-wells plate (Greiner Bio-one, Alphen a/d Rijn, the Netherlands). 
Alternatively, micromasses were produced from 2x105 FLS combined with 106 CD14+ 
mononuclear cells. FLS were obtained after biopsy digestion and RBC lysis by culturing 
the adhering cell fraction and passing the cells at least once. After 30 min gelation at 
37 °C, 500 µl Roswell Park Memorial Institute (RPMI) medium (Gibco, Thermofisher 
Scientific, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal calf serum 
(FCS) (v/v) (Gibco, Thermofisher Scientific), 1 mM pyruvate (Thermofisher Scientific) and 
1% penicillin/streptomycin (P/S) (v/v) (Westburg, Leusden, the Netherlands) was added. 
The micromasses were cultured for the time and conditions as indicated in the separate 
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Figures. In general, medium was replaced twice weekly and micromasses were cultured 
at 37 °C and 5% CO2.
Flow cytometry
Micromasses were kept on ice for 2h and the cells were washed to remove the liquid 
Matrigel. Unspecific binding of antibodies by Fc receptors was blocked by incubation with 
hFc block (1:100 for 20 minutes at 4 °C) (564220 BD Biosciences, San Jose, CA, USA). For 
all cell suspensions, CD90 was stained using mouse anti-human CD90-APC (1:20 for 30 
minutes at 4 °C); CD68 was stained using mouse anti-human CD68-PE (1:20 for 60 minutes 
at 4 °C); CD14 was stained using mouse anti-human CD14-APC (1:20 for 60 minutes at 4 
°C). The samples were measured on the CyAn ADP analyzer (Beckman Coulter, Woerden, 
the Netherlands) using the 488 nm laser at the FL7 and FL8 channels for Alexa Fluor 568/
PE and APC respectively. Gates were determined using Fluorescence minus one (FMO). 
The gating strategy and unstained controls are shown in Supplementary Figure 1. A 
comprehensive overview of all antibodies used in this study is shown in Table 1.
Immunohistochemistry
Micromasses were fixed in 2% paraformaldehyde in phosphate-buffered saline 
(PBS)/1 mM CaCl2 for 2h, dehydrated and embedded in paraffin. 7 µm sections were 
deparaffinized, rehydrated and stained with hematoxylin and eosin (H&E) or processed 
for immunohistochemistry (IHC). For IHC, endogenous peroxidase activity was block 
with 3% H2O2 (Merck Millipore, Amsterdam, the Netherlands) in methanol and antigen 
retrieval was performed in 10 mM citrate buffer pH 6.0 at 60 °C. Subsequently, sections 
were stained with primary antibodies: mouse anti-human 11-Fibrau (1:100 for 60 minutes 
at room temperature (RT)), mouse anti-human CD68 (1:100 for 60 minutes at RT), mouse 
anti-human CD163 (1:25 for 60 minutes at RT), rabbit anti-human Alpha Smooth Muscle 
Actin (α-SMA) (1:400 overnight at 4 °C), or rabbit anti-human Ki67 (1:100 for 60 minutes 
at RT). Isotype control antibodies were used at the same concentrations as the primary 
antibodies. Subsequently, the primary antibodies for CD68 were stained with HRP-
conjugated rabbit-anti-mouse IgA/G/M (1:200 for 60 minutes at RT), antibodies for 
11-Fibrau and CD163 were stained with biotinylated anti-mouse IgG H+L (1:100 for 30 
minutes at RT and antibodies for α-SMA and Ki67 were stained with biotinylated anti-
rabbit (1:400 for 30 minutes at RT). For 11-Fibrau, CD163 and α-SMA, a biotin-streptavidin 
detection system was used according to manufacturer’s protocol (Vector Laboratories). 
Peroxidase was developed with diaminobenzidine and counterstained with hematoxylin 
for 60 seconds. Representative pictures of all control IgGs are shown in Supplementary 
Figure 3. A comprehensive overview of all antibodies used in this study is shown in Table 1.
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Table 1 | List of antibodies
Antibody Isotype Conjugate Monoclonal/
polyclonal
Stock
concentration
Dilution Appli-
cation
Company Catalog
number
CD14 Mouse 
IgG2a, κ
APC Monoclonal 
[M5E2]
200 µg/ml 1:20 FC Biolegend 301808
CD68 Mouse 
IgG2b, κ
PE Monoclonal 
[Y1/82A]
100 µg/ml 1:20 FC eBioscience 12-0689
CD90 Mouse 
IgG1, κ
APC Monoclonal 
[5E10]
50 µg/ml 1:20 FC eBioscience 17-0909
11-Fibrau Mouse 
IgG2a
N/A Monoclonal 
[D7-FIB]
1 mg/ml 1:100 IHC AbD Serotec MCA1399G
α-SMA Rabbit IgG N/A Polyclonal 0.2 mg/ml 1:400 IHC Abcam ab5694
CD3 Mouse 
IgG1, κ
N/A Monoclonal 
[F7.2.38]
Undetermined 1:50 IHC DAKO M7254
CD20 Mouse 
IgG2a, κ
N/A Monoclonal 
[L26]
18 µg/ml 1:100 IHC Cell Marque 120M-84
CD31 Rabbit IgG N/A Unspecified 100 µg/ml 1:50 IHC Genetex GTX48364
CD68 Mouse 
IgG1, κ
N/A Monoclonal 
[KP1]
410 µg/ml 1:100 IHC DAKO M0814
CD163 Mouse IgG1 N/A Monoclonal 
[10D6]
Undetermined 1:25 IHC Thermo 
Fischer
MA5-11458
Ki67 Rabbit IgG N/A Monoclonal 
[SP6]
Undetermined 1:100 IHC Thermo 
Fischer 
RM-9106
Mouse 
IgG1, κ 
N/A N/A N/A 100 µg/ml * IHC DAKO X0931
Mouse 
IgG2a, κ 
N/A N/A N/A 100 µg/ml * IHC DAKO X0943
Rabbit
IgG 
N/A N/A N/A 15 mg/ml * IHC DAKO X0936
An-
ti-mouse 
IgA/G/M
N/A HRP N/A 1.3 mg/ml 1:200 IHC DAKO P0260
An-
ti-mouse 
IgG
N/A Biotinylat-
ed
N/A 0.5 mg/ml 1:200 IHC Vector Labo-
ratories
BA-2001
Anti-rabbit 
IgG
N/A Biotinylat-
ed
N/A 1.5 mg/ml 1:400 IHC Vector Labo-
ratories
PK 6101
APC = allophycocyanin
FC = flow cytometry
HRP = horseradish peroxidase
IHC = immunohistochemistry
N/A = not applicable
PE = phycoerythrin
* similar concentration (not dilution) to primary antibody directed to antigen of interest
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Image analysis
Microscopic images for histology were taken using the VS120 slide scanner (Olympus, 
Leiderdorp, the Netherlands) using Panoramic Viewer (3DHISTECH, Budapest, Hungary) 
and for quantification, pictures were taken using the Leica DMR light microscope after 
randomization and blinding of the samples. For hyperplasia, Ki67 and fibrosis analysis, 3 
sections were analyzed per micromass and per section up to 5 pictures were taken from 
the micromass lining after H&E staining, Ki67 staining or α-SMA staining respectively. For 
CD163 analysis, pictures from the complete micromass matrix were taken. Images were 
analyzed using the Leica Application Suite (LAS) software. 
Gene expression analysis
The micromasses were dissolved in 500 µl Tri reagent (Sigma-Aldrich) and total RNA was 
isolated according to the manufacturer’s protocol. qPCR was performed as previously 
described25. Primer sequences are listed in Table 2. Values are depicted as threshold 
cycle, corrected for GAPDH expression.
Table 2 | Primer sequences
Multiplex ELISA
Cytokines and chemokines in supernatants were measured on a Bio-Plex 200 system 
using a magnetic bead-based multiplex immunoassay. Data analysis was performed with 
Bio-Plex Manager software (both Bio-Rad). 
Statistical analysis
The results are displayed as box plot (median) with whiskers: min to max. Statistical 
analysis was performed by Mann-Whitney U test using Graphpad Prism software v5.03. 
p-values below 0.05 were regarded as significant.
Gene Forward primer sequence Reverse primer sequence
ACTA2 CTGACCCTGAAGTACCCGATA GAGTGGTGCCAGATCTTTTCC
COL1A1 AGATCGAGAACATCCGGAG AGTACTCTCCACTCTTCCAG
GAPDH ATCTTCTTTTGCGTCGCCAG TTCCCCATGGTGTCTGAGC
IL1B TGGGTAATTTTTGGGATCTACACTCT AATCTGTACCTGTCCTGCGTGTT
IL6 AGCCCACCGGGAACGA GGACCGAAGGCGCTTGT
IL8 AGAAGTTTTTGAAGAGGGCTGAGA CAGACCCACACAATACATGAAGTG
PLOD2 AAGACTCCCCTACTCCGGAAA AGCAGTGGATAATAGCCTTCCAA
SERPINE1 GTCTGCTGTGCACCATCCCCCATC TTGTCATCAATCTTGAATCCCATA
TNF TCTTCTCGAACCCCGAGTGA CCTCTGATGGCACCACCAG
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Results
Analysis of micromass composition and formation
The composition of the cell suspension after digestion of a synovial biopsy was 
determined using cell surface markers. In the cell suspension prior to micromass 
formation, we observed cells positive for fibroblast marker CD90 (67.6%), monocyte/
macrophage marker CD68 (23.1%) and monocyte marker CD14 (CD14low 22.9% 
and CD14high 4.58%) (Figure 1A, Supplementary Figure 1). This cell composition was 
comparable in repeat experiments. No T cells (CD3), B cells (CD20) or dendritic cells 
(CD11c) were observed in this cell suspension (data not shown). Almost all CD68-positive 
cells also stained positive for CD14. The CD68-positive cells were CD14low.
We next analyzed the composition of the mature micromass from the synovial cell 
suspension after formation of the lining at day 7. The composition of the micromass was 
comparable to the cultured cell suspension at day 0 (Figure 1A, Supplementary Figure 
1). We observed adequate amounts of cells positive for CD90 (62.0%) and CD68 (30.8%). 
The CD68-positive cells showed only low expression of CD14, reminiscent of the culture 
effects observed with culture of the cell suspension. These results show that the mixed 
cell population is maintained during micromass culture. The CD14high fraction dropped to 
3.38% and the CD14low fraction was not detected after 7 days culture. The distinct CD68+/
CD14low cells lost most CD14 expression after 7 days.
The kinetics of lining formation and cell migration in the synovial micromasses were 
assessed at different time points. Immediately after micromass formation, the cells 
had not regained their original morphology and all cells were round-shaped (Figure 1B). 
The first time point at which a distinct lining was visible, was after 7 days. In multiple 
experiments we observed lining formation between day 7 and day 14. The synovial lining 
remained visible until the end of the experiment at day 35. Immediately after formation of 
the micromasses, CD68-positive cells appeared randomly distributed over the complete 
micromass. During the first week of micromass culture, a gradual increase in the relative 
amount of CD68-positive cells was observed and after 7 days most CD68-positive cells 
appeared as large cells. Throughout the 35 days of analyzed culture time, many 11-Fibrau-
positive fibroblasts were present at all time points. The analyzed biopsy also contained 
CD31-positive endothelial cells and foci of B cells (CD20-positive) and T cells (CD3-
positive), which incorporated at low frequency in the micromasses. However, these cells 
had disappeared by day 7 (Supplementary Figure 2).
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Figure 1 | Flow cytometry and histological analysis of synovial cell suspension and 
micromasses
(A) A RA synovial biopsy was digested using Liberase. Cells were cultured for <24 hours (Figure 
1A, day 0) or mixed with Matrigel and cultured for 7 days, after which the Matrigel was re-liquified 
on ice (Figure 1A, day 7). The cell suspensions were subsequently stained for fibroblasts 
(CD90), macrophages (CD68) and monocytes (CD14). Similar profiles were obtained in at least 
3 experiments with unique donors. FS = forward scatter, SS = side scatter. The gating strategy 
and unstained controls are shown in Supplementary Figure 1. (B) At different time points (day 0, 
4, 5, 7, 14 and 35) micromasses were fixed and embedded in paraffin. 7 µm sections were stained 
with H&E, anti-CD68 or antibodies against fibroblast marker 11-Fibrau. Pictures were taken at 
200x magnification. Negative control IgG stainings are shown in Supplementary Figure 3.
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Figure 2 | Composition of micromasses constructed from primary RA FLS and CD14+ PBMCs
(A) H&E staining of day 7 micromasses at 50x and 200x magnification. (B) CD68 staining of 
macrophages in the micromass. Black arrows indicate CD68-positive cells and grey arrows 
indicate CD68-negative cells. (C) 11-Fibrau staining of FLS in the micromass. Black arrows 
indicate 11-Fibrau-positive cells and grey arrows indicate 11-Fibrau-negative cells. Negative 
control IgG stainings are shown in Supplementary Figure 3.
 
Based on the observation that the synovial fibroblasts and macrophages were the two 
cell types that we could identify in the lining of micromasses composed of synovial cell 
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suspensions and because these cells represent the two types of synoviocytes found in 
the synovial lining, we switched in subsequent experiments to micromasses produced 
from cultured primary RA FLS and primary CD14+ cells purified from peripheral blood of 
healthy donors. This approach has previously been explored by Kiener et al. As expected, 
these micromasses produced a lining in 7 days (Figure 2A), which contained both 
11-Fibrau-positive FLS and CD68+ macrophages (Figure 2B,C).
Figure 3 | Gene expression after short-term micromass exposure to inflammatory stimuli
Micromasses were generated from primary RA FLS and CD14+ PBMCs and stimulated for 3 
weeks with 10 ng/ml recombinant human TNF-α or TGF-β, which was replaced 2 times per week. 
Control micromasses received culture medium without stimulation. (A) The gene expression of 
pro-inflammatory cytokines IL1B, IL6, IL8 and TNF was measured by qPCR. Gene expression 
values were corrected for GAPDH expression and are depicted as ΔCt. (B) Cytokine secretion 
was measured in the culture supernatant using a multiplex ELISA. n=5/6 per group. Data points 
are combined from 2 independent experiments. Expression levels were compared to medium 
condition by Mann-Whitney U test. * =p<0.05, ** =p<0.01, *** =p<0.001.
 
Long-term exposure of synovial micromasses to inflammatory stimuli 
leads to inflammatory gene expression and cytokine production
We established the inflammatory response of micromasses to 3 week stimulation with 
recombinant human TNF-α (Abcam, Cambridge, UK) and TGF-β (Biolegend, San Diego, 
CA, USA). On gene expression level, we observed a significant increase in expression of 
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IL6 and IL8 with both stimuli (Figure 3A). TNF and IL1B expression were not significantly 
increased. On protein level, IL-6 levels in the micromass supernatants were increased 
after stimulation with both TNF-α and TGF-β (Figure 3B). IL-8 was only increased after 
stimulation with TNF-α and TGF-β stimulation could induce the release of TNF-α from the 
micromasses. These results show that the micromasses are sensitive to inflammatory 
triggers.
Long-term TNFα exposure of synovial micromasses leads to 
hyperplasia of the micromass lining and an altered macrophage 
phenotype
In addition to pro-inflammatory effects, we observed striking differences in the cells 
residing in the micromass matrix after long-term stimulation with TNF-α. When the 
micromasses were not treated with TNF-α, some cells positive for CD68 throughout the 
complete micromass showed a hypertrophic phenotype (Figure 4A). After stimulation 
with TNF-α, there was a strong reduction in this phenotype and instead, cells showed 
a spindle-like morphology. The large round cells were positively stained for CD163, a 
membrane marker associated with type 2 macrophages (Figure 4B)26. The appearance of 
these cells throughout the complete micromass could be abolished by both TNF-α and 
TGF-β stimulation (Figure 4E).
An additional important feature of arthritis is synovial hyperplasia, which was also 
assessed after 3 weeks of repeated stimulation. Without TNF-α stimulation, the lining 
thickness was on average 1 cell layer (Figure 4C). After long-term stimulation with TNF-α, 
the lining thickness increased. The hyperplasia was assessed by quantifying the amount 
of hematoxylin staining and by the proliferation marker Ki67 in the lining in >9 images per 
micromass. The cellularity and proliferation of the lining was significantly increased after 
TNF-α stimulation (Figure 4D, F, G) whereas this was unaltered by TGF-β stimulation.
TGF-β can induce fibrosis-like changes in the micromass lining
The effects of 3 week stimulation on micromass fibrosis-associated processes were first 
assessed on gene expression level. TGF-β signaling marker SERPINE1 was significantly 
induced by recombinant TGF-β, indicating that active TGF-β signaling was induced in 
the micromasses (Figure 5A). This resulted in an increased expression of PLOD2, Alpha 
Smooth Muscle Actin (ACTA2) and collagen type 1 (COL1A1), which are all associated with 
fibrosis27. Histological staining of α-SMA showed that fibrotic-like changes had occurred 
in the micromass lining, which was significantly increased after stimulation with TGF-β 
(Figure 5B,C). Moreover, TGF-β induced a stellate-cell morphology of α-SMA-positive 
cells, characteristic for myofibroblasts (Figure 5B)28.
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Figure 4 | Micromass lining hyperplasia and macrophage phenotype after long-term stimulation
Micromasses were generated from primary RA FLS and CD14+ PBMCs and stimulated for 
3 weeks with 10 ng/ml recombinant human TNF-α or TGF-β, which was replaced 2 times per 
week. Control micromasses received culture medium without stimulation. Micromasses 
were stained for (A) CD68, (B) CD163 (C) with H&E and (D) Ki67. Black arrows indicate cells 
positive for the marker of interest. Grey arrow indicate a hyperplasic lining. (E) Quantification 
of CD163-positive cells throughout the entire micromass. Values were corrected for the total 
surface area of the images analyzed and are depicted as fold change compared to the average 
of the unstimulated controls. (F) Quantification of H&E staining for lining hyperplasia. (G) 
Quantification of Ki67 staining for proliferation of the micromass lining. n= 5/6 per group and 
the average score of >3 images per 3 sections of every micromass was calculated. Statistical 
analysis was performed by Mann-Whitney U test comparing to medium condition. * =p<0.05, ** 
=p<0.01. Negative control IgG stainings are shown in Supplementary Figure 3.
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Figure 5 | Fibrosis-like changes after long-term stimulation of micromasses
Micromasses were generated from primary RA FLS and CD14+ PBMCs and stimulated for 
3 weeks with 10 ng/ml recombinant human TNF-α or TGF-β, which was replaced 2 times per 
week. Control micromasses received culture medium without stimulation. (A) qPCR analysis 
of downstream TGF-β signaling genes and fibrosis-related genes. Gene expression values 
were corrected for GAPDH expression and are depicted as ΔCt. (B) Staining of Alpha Smooth 
Muscle Actin (α-SMA) in the micromasses. Magnification 200x. (C) Digital quantification of 
α-SMA-positive lining surface. Values are depicted as a fold change compared to unstimulated 
micromasses. n=5/6 per group. Statistical analysis was performed by Mann-Whitney U test 
comparing to medium condition. * =p<0.05, ** =p<0.01. Negative control IgG stainings are 
shown in Supplementary Figure 3.
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Discussion
In this study, we further characterized the 3D synovial micromass model produced from 
primary human biopsies for application in both RA and OA research as an alternative 
to animal experiments. The model was first explored by Kiener and co-workers, based 
on primary synovial fibroblasts (FLS) culture. The experiments were focused on cell-
cell and cell-matrix interactions during the formation of the lining and the involvement 
of Cadherin-1122,29. We adapted a procedure that was briefly explored in these studies 
to produce micromasses with both FLS and CD14+ PBMCs, which resulted in a lining 
that included 11-Fibrau-positive fibroblasts and CD68-positive macrophages23. These 
2 cell types were the predominant lining cell types in the micromasses produced from 
the complete synovial cell suspension and correspond with the cell types observed in 
the intimal layer of the synovium, the type B synoviocyte (FLS) and type A synoviocyte 
(macrophage-like synoviocyte), respectively30. The survival of the macrophage-like cells 
has previously been shown to be dependent on the presence of synovial fibroblasts23. The 
inclusion of these cells in the micromass model is important, because the macrophages 
produce large amounts of TNF-α and TGF-β and can activate latent TGF-β31,32. Moreover, 
macrophages are pivotal for bone erosion, cartilage damage and ectopic bone formation 
in RA and OA33-35.
For the micromasses that were generated from primary CD14+ PBMCs and primary 
FLS, FLS were first cultured in vitro. It has been observed that directly after digestion 
of the synovium, the adherent fraction also contains adherent synovial macrophages 
and the FLS have a disease phenotype, which includes the spontaneous production of 
pro-inflammatory cytokines36. However, after prolonged culture the disease imprint is 
gradually lost18, 37, 38, making the FLS more suitable for the micromass model in which part 
of the disease is mimicked by stimulation with TNF-α or TGF-β. The micromass model 
is therefore not dependent on the original disease phenotype of the fibroblasts. This is 
in agreement with the observation that without stimulation with exogenous TNF-α, no 
spontaneous hyperplasia was observed.
The survival of FLS and macrophage-like cells was observed both by immuno-
histochemistry and flow cytometry. Several results imply changes in the macrophage 
population. During micromass culture, the amount of CD68+ cells expressing 
CD14 decreased at day 7 compared to day 0. This can be the result of macrophage 
differentiation, which is associated with a decrease in CD14 expression39. During the 
3 week micromass culture, we observed large CD68+ and CD163+ cells. These cells 
represented an M2-like anti-inflammatory macrophage phenotype26,40. The appearance 
of these cells was abolished by stimulation with TNF-α, which is known to polarize the 
macrophages to a pro-inflammatory M1-like phenotype41. We also observed a significant 
down-regulation of CD163 by TGF-β, which has also been described previously42. Although 
additional markers are required for more accurate and reliable identification of specific 
cell types and cell subsets, the results clearly indicate a plasticity in the macrophage-like 
cell population in the synovial micromass.
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Interestingly, we found that when kept on ice, the Matrigel liquidized and could be washed 
away from the cells. The resulting cell suspension could be analyzed by flow cytometry 
without the requirement of enzymatic digestion, which further enhances the applicability 
of the micromass model.
We evaluated the long-term effects of TNF-α exposure on micromasses. In addition to 
the well-known role of TNF-α in RA, the TNF-α produced by the osteoarthritic synovium 
is strongly associated with systemic low-grade inflammation and production of matrix-
degrading enzymes by multiple cells in the joint34,43. The observation that systemic 
TNF-α levels are increased prior to the most pronounced cartilage damage supports the 
hypothesis that inflammation in OA is a cause rather than a consequence. We observed 
that the pro-inflammatory effects of TNF-α can be studied in the micromasses. In 
addition, synovial hyperplasia is observed in the synovium of both RA and OA patients44. 
We could re-create this pathogenic process by stimulating the micromasses for 3 weeks 
with TNF-α, which is a major advantage compared to studies using synovial biopsies, in 
which hyperplasia has already occurred45.
Although both pro- and anti-inflammatory functions of TGF-β have been described for 
arthritic diseases, we observed a strong increase in expression of IL-6 and TNF-α after 
stimulation with TGF-β. IL-8 mRNA was significantly increased by TGF-β, but not IL-8 
protein levels. The effects of TGF-β on IL-6 and IL-8 have been described before in PBMCs 
and synovial fibroblasts46,47. Interestingly, TGF-β stimulation resulted in increased TNF-α 
secretion, but not on mRNA level. Previous experiments with TGF-β and synovial cell 
cultures did not result in increased TNF-α production, which indicates that our finding 
of increased TNF-α might be an indirect effect48. The most pronounced effect of long-
term TGF-β stimulation was the strong increase of an α-SMA-positive lining, which was 
not observed after stimulation with TNF-α. The increased α-SMA was not caused by 
hyperplasia, which did not occur after TGF-β stimulation. 
The joint is considered a complex organ and joint diseases like RA and OA are thought 
to involve several cell types and tissues, including the synovium, but also the articular 
cartilage and (subchondral) bone49. These tissues are also dependent on the extracellular 
matrix for proper interactions and several in vitro studies have aimed at recreating 3D 
matrix mixed with specific cells. For example, chondrocytes can be co-suspended 
with gelatin microspheres in an alginate solution to obtain an articular cartilage-like 
structure50. This can be cultured in combination with FLS and in vitro differentiated 
macrophages to mimic OA cartilage pathology51. In addition, FLS have been cultured 
in several scaffolds to generate 3D structures. In one study, FLS were combined with 
endothelial cells in a methylcellulose sphere which was subsequently incorporated in 
a collagen gel52. This method was used to study angiogenesis into a collagen scaffold. 
These studies highlight the added value of 3D models for joint tissues and the micromass 
adds a model to study the synovial membrane.
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We propose that the synovial micromass model can be a solution for experiments that 
require a synovial membrane in which disease processes have not yet occurred, since 
the availability of healthy synovial tissue is very limited. The production of micromasses 
will result in a uniform composition of the starting material, which can also be easily 
manipulated in sense of composition. In future applications, the micromasses may be 
co-cultured with different cell types or scaffolds, or in co-culture with cartilage explants 
to study effects on cartilage degeneration. Although no 3D models are available yet that 
include all cell types and tissues involved, the micromass model can be a good alternative 
for animal experiments in RA and OA, both for fundamental research, target validation 
and pre-clinical treatment testing. To our knowledge, this is the first human 3D culture 
model to study the interplay between macrophages and fibroblast-like synoviocytes in 
hyperplasia and synovial fibrosis-like pathology by stimulation with TNF-α and TGF-β, 
respectively.
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Supplementary figures
Supplementary Figure 1 | Gating strategy and unstained controls for flow cytometry
A RA synovial biopsy was digested using Liberase. Cells were cultured for <24 hours or mixed 
with Matrigel and cultured for 7 days, after which the Matrigel was re-liquified on ice. Shown are 
unstained controls. Similar profiles were obtained in at least 3 experiments with unique donors. 
FS = forward scatter, SS = side scatter. Data of stained samples are shown in Figure 1. 
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Supplementary Figure 2 | Cell type composition during micromass formation
RA synovial biopsies were divided into several pieces. One piece (synovium) was processed 
and sections were stained for macrophage marker CD68, B cell marker CD20, T cell marker CD3 
and endothelial cell marker CD31. The remaining pieces were digested and used for micromass 
formation of complete cell suspensions. At day 0, day 3, day 5 and day 7 micromasses were 
fixed and embedded in paraffin. 7 μm sections were stained for cell markers. Pictures were 
taken at 200x magnification and black scale bars represent 100 μm. IgG: isotype IgG negative 
control.
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6Supplementary Figure 3 | Histological analysis of synovial micromasses
Micromasses were generated from primary RA FLS and CD14+ PBMCs and were fixed and 
embedded in paraffin. 7 µm sections were stained with anti-CD68, antibodies against fibroblast 
marker 11-Fibrau, anti-CD163, anti-α-SMA, and anti-Ki67, or their IgG controls. Shown are 
representative pictures of isotype IgG negative controls. Pictures were taken at 200x 
magnification. Stainings are shown in Figure 1, 2, 4 and 5.
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General discussion
Rheumatoid arthritis (RA) is an auto-immune disease of the synovial joints, hallmarked by 
chronic inflammation and progressive connective tissue destruction. Despite numerous 
biologicals, a significant number of patients fail to respond to current therapies or 
develop severe side effects. Therefore, the identification of new therapeutic targets 
remains necessary. Activation of the natural negative feedback mechanism mediated by 
the TYRO3 – AXL – MER (TAM) receptors could be an interesting therapeutic approach to 
treat RA, as they mediate the resolution of inflammation. Activation of the TAM receptors 
results in an inhibition of a wide array of inflammatory cytokines and chemokines1-6. 
Moreover, they are involved in the clearance of cellular apoptotic debris (efferocytosis7-10). 
The TAM receptor system acts between innate and adaptive immunity in vivo: the TAM 
receptors dampen the activation of antigen-presenting cells (APCs), thereby restraining 
the activation of T cells, and activated T cells in return produce one of the TAM receptor 
ligands to limit the extent of APC activation11,12. Only a few studies have investigated the 
role of the TAM regulatory system in arthritis so far. In this thesis, the role of the TAM 
receptor family in experimental models of RA was described. 
First, we set out to analyze arthritis development in the disease-prone ankle joints in mice 
lacking all three TAM receptors (Tyro3/Axl/Mertk triple knock-out or TAM TKO) to determine 
the extent and sequence of pathological changes, in Chapter 2. These mice have previously 
been described to spontaneously develop arthritis at an age of 26 weeks11. None of the 
mice examined showed macro- or microscopic signs of arthritis including swollen paws, 
connective tissue destruction or synovial inflammation. However, inflammation of the bone 
marrow, also called bone marrow edema (BME) was observed. Although this infiltrate was 
not present at the age of 14 weeks, it was present at later ages and was characterized by 
a mixture of myeloid and lymphocyte cells at the age of 34 weeks which had persisted to 
the age of 52 weeks. The presence of these cells in BME has previously been described in 
experimental models of RA and in RA13-19. The cause of BME in TAM TKO mice and the cause 
of the discrepancy between this observation and the published manuscript almost two 
decades ago remains to be determined. However, we cannot exclude that TAM TKO mice 
develop any signs of arthritis at ages over 52 weeks. It is tempting to speculate that the 
absence of spontaneous arthritis development we observed compared to the publication 
of Lu and Lemke11, is a result of an interaction between genetic and environmental factors. 
Phenotypic differences in mice with similar genotypes, although from a different breeding 
generation, have been described before20. Moreover, long-term breeding of mouse lines 
results in marked changes in intestinal microbiota composition and microbiota can 
account for genotype-specific phenotypes21.
After finding that TAM TKO did not (any longer) spontaneously developed arthritis at an 
adult age, the aim was to unravel the relative contribution of AXL and MER in experimental 
arthritis and RA (Chapter 3-5). The deleterious role of TYRO3 on synovial hyperplasia and 
bone damage has previously been described in experimental arthritis22. We hypothesized 
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that both AXL and MER play a protective role in experimental arthritis. In Chapter 3, the role 
of AXL in arthritis was investigated. During KRN serum transfer arthritis (STA), ankle joints 
of Axl-/- mice showed exacerbated arthritis pathology whereas no effect of Axl deletion 
was observed on gonarthritis pathology. These data coincided with the observation that 
ankle synovial cells of mice prominently expressed AXL, in contrast to the knee where the 
majority of the synovial cells did not express AXL. However, this is in contrast with the fact 
that AXL is expressed during inflammatory conditions, and not during homeostasis10,23. The 
spatial differences were not limited to AXL expression. We found that F4/80+ macrophages 
in the synovial lining of the ankle joint were cluster of differentiation (CD) 206+, a marker of 
M2-like macrophages24, whereas only few cells were CD206+ in the knee synovial lining. 
Human M2-like macrophages also expressed high AXL levels. Moreover, inhibition of AXL 
in human M2-like macrophages resulted in enhanced interleukin (IL) 1β secretion upon 
Toll-like receptor (TLR) ligation. Next, we sought which factor could cause the spatial 
difference in AXL expression. In naïve murine and arthritic human synovium, TGFB1 and 
AXL expression correlated. Transforming Growth Factor Beta (TGF-β) stimulation of either 
human M2-like macrophages or human synovial micromasses (this model is described 
in Chapter 6), consisting of fibroblasts and macrophages, induced AXL expression. In 
addition, viral overexpression of active Tgfb1 induced AXL gene and protein expression in 
murine knee joints, a tissue largely devoid of AXL in a naïve state. The overexpression also 
resulted in the presence of F4/80+ macrophages and a moderate amount of CD206+ cells 
in the knee joint. These data suggest that the local differences in the expression of the 
anti-inflammatory receptor AXL could be due to TGF-β. The difference in TGF-β between 
ankle and knee joint could potentially have an underlying biomechanical cause. Loading 
articular cartilage leads to the activation of TGF-β which in turn induces TGF-β in a positive 
feedback loop25. The articular cartilage in the ankle joint experiences the highest contact 
force of all the major joints26-28. Therefore, the enhanced force experienced in the ankle, 
compared to the knee, could explain the increased levels of TGF-β we observed in the 
ankle compared to the knee joint synovium.
In Chapter 4, the contribution of the MER tyrosine kinase to gonarthritis was investigated. 
As we found prominent differences between the ankle and knee joint in Chapter 3, we 
aimed to focus on both joints in Chapter 4. However, Mertk gene ablation did not result 
in altered full-blown arthritis in experimental models of RA in the ankle joint (data not 
shown). Possibly, in the ankle joint, the presence of AXL could make the function of 
MER redundant. Mertk-/- mice showed exacerbated gonarthritis pathology during KRN 
STA whereas adenoviral Pros1 overexpression diminished knee joint pathology in this 
experimental model of arthritis. Moreover, Pros1 overexpression in in vitro differentiated 
macrophages resulted in a reduction of several inflammatory cytokines and chemokines. 
Human synovial micromasses challenged with MER-specific antibodies enhanced the 
secretion of inflammatory cytokines whereas stimulating these micromasses with 
the MER ligand Protein S (PROS1) reduced the secretion of these cytokines. PROS1 is 
also an anti-coagulation factor29. Therefore, a safer approach would be to use of MER-
specific antibodies that were previously described to activate MER kinase activity10,30. 
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However, this treatment resulted in a marked increase of gonarthritis severity and 
enhanced inflammation in the collagen-induced arthritis (CIA) model. We showed 
that this counterintuitive effect of anti-MER was related to inhibition of MER-mediated 
efferocytosis. This led to an increased amount of apoptotic cells in the knee joint, and 
subsequent secondary necrosis of these cells. These effects were also observed in 
Mertk-/- mice, whereas the opposite outcome was observed with Pros1 overexpression. 
These data suggest that MER plays a protective role in experimental gonarthritis via 
efferocytosis. 
PROS1 is present in relatively high levels in the circulation29.  However, both viral 
overexpression of Pros1 in vivo, or addition of PROS1 in vitro still potently reduced 
inflammatory cytokines and chemokines. Recent literature suggests that one of the TAM 
receptors and one of the TAM receptor ligands is not enough for proper TAM receptor 
signaling. AXL is constitutively occupied by Growth Arrest Specific 6 (GAS6) in vivo without 
full-blown activation of the receptor10. The Gla domain in the ligands is not necessary 
for binding to the TAM receptors and Gla domain-less GAS6 can bind as efficiently as 
full GAS6 to AXL31,32. However, the Gla domain is required for proper activation of TAM 
receptor signaling10,32-34. It appears that for TAM receptor activation, the γ-carboxylated 
Gla domain of the TAM receptor ligands must bind to the phospholipid phosphatidylserine 
(PS)35. PS is expressed, amongst others, on apoptotic cells32. The presence of multiple PS 
molecules on one apoptotic cell drives the clustering of the TAM receptors which results 
in full-blown signaling34. 
The differences we find between AXL and MER are in line with other literature. First of 
all, the function of each of the three TAM receptors appears to be tissue-specific8. For 
example, efferocytosis in the thymus and retina solely depends on MER, but not TYRO3 or 
AXL. We showed that AXL plays a significant role in a murine model of arthritis in the ankle 
joint but not the in knee joint, whereas the opposite was observed for MER. Secondly, 
AXL and MER can have different functions in the same tissue. In an experimental model 
of immune-mediated nephritis, Mertk-/- mice developed more severe disease whereas 
Axl-/- mice had reduced disease characteristics23. Although we find that mice genetically 
ablated for AXL or MER both had less severe clinical and histological characteristics of 
arthritis, the mechanism for this protective effect appeared to be different. An increased 
amount of apoptotic cells in the knee joint during experimental arthritis in Mertk-/- mice 
was observed. In contrast, the ankle joint synovium of Axl-/- mice did not contain more 
apoptotic cells during experimental arthritis (data not shown). We suggested that the 
deleterious effect of genetically ablating AXL could be mediated by enhanced maturation 
of IL-1β. However, whether this mechanism was responsible for the enhanced arthritis 
severity in Axl-/- mice remains to be investigated.  
Having found that MER appears to play a regulatory role in experimental arthritis, we 
turned from the murine to the human situation in Chapter 5. The lining and the sublining 
of RA synovium contained an abundant number of MER+ CD68+ macrophages. In contrast, 
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both CD3+ T cells and CD20+ B cells did not express MER. All three TAM receptors can 
be cleaved, resulting in soluble receptors of TYRO3, AXL and MER. In mice, the enzyme 
involved in the cleavage of MER is A Disintegrin and Metalloprotease Domain (ADAM) 
17, also called Tumor Necrosis Factor-α Converting Enzyme (TACE)36. We analyzed the 
release of MER and measured higher soluble MER levels in conditioned-medium of RA 
synovial tissue explants as compared to OA synovial explants. Soluble MER levels in 
RA synovial conditioned-medium positively correlated with secreted GAS6 levels. In 
synovial fluid of RA patients, soluble MER and GAS6 also positively correlated. However, 
both soluble MER and GAS6 negatively correlated with IL-6. Cleavage of the ectodomain 
of MER has been shown to result in the inactivation of the receptor and neutralization of 
the TAM receptor ligands30,36-45. This shows that the TAM receptor family is also regulating 
itself.  The results of this chapter were unexpected as GAS6-mediated suppression of 
inflammation would be counteracted by soluble MER. Possibly, MER is increased in the 
synovium and compensates for the enhanced shedding. Alternatively, the regulatory role 
of MER is redundant and taken over by AXL. Still, as we only measured a limited number of 
synovial fluid samples, our data has to be interpreted with caution and must be confirmed 
in a larger patient cohort. 
After finding the effects of AXL and MER on experimental arthritis in Chapter 3 and 
Chapter 4, and the presence of soluble MER in RA synovial fluid in Chapter 5, we further 
developed an in vitro model of the human synovium to be able to confirm our results and 
study the effect of TAM receptor targeting (in the future) in Chapter 6. A human three-
dimensional synovial membrane model made of primary fibroblast-like synoviocytes 
and CD14+ mononuclear cells was characterized which was initially described by Kiener 
and colleagues46. The outer surface of these mature micromasses formed a lining layer 
consisting out of fibroblast-like and macrophage-like cells, reflecting the in vivo naïve 
synovial membrane. To recreate the affected synovial membrane in RA, the micromasses 
were exposed to TNF-α, a pathological cytokine in RA47. This led to increased pro-
inflammatory cytokine gene and protein expression. Moreover, long-term exposure 
to TNF-α resulted in modulation of the macrophage phenotype. These cells lost their 
expression of CD163, another M2-like macrophage marker24, and showed a more spindle-
like morphology. Long-term exposure to TNF-α also led to hyperplasia of the lining layer 
of the micromasses, characteristic for human RA synovium48, 49. In contrast, TGF-β did 
not induce hyperplasia of the lining layer in these micromasses. These data show that 
the human model mimics several characteristics of RA synovium in vitro. Therefore, it 
could be a suitable human model to study the pathology of RA in vitro and test whether 
activation of the TAM receptor feedback system reduces the inflammatory process and 
hyperplasia, as well as to study the role of the soluble receptors on these processes. 
In conclusion, we have shown in this thesis the protective role of the TAM receptors, in 
particular AXL and MER, in models for rheumatoid arthritis, the shedding of MER in the 
arthritic joint in addition to further developing and characterizing a three-dimensional 
model of the human synovium.
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Future perspectives
The distinct anatomical locations of affected joints are clinically significant signs of 
RA50. However, the foundation for such selective positional manifestation of RA is a 
largely unsolved scientific knowledge gap. Recent studies have highlighted that synovial 
fibroblasts display a distinct joint-specific signature51,52. However, synovial macrophages 
have not been studied in a similar fashion so far. We have shown that in mice, synovial 
macrophages display a joint-specific phenotype. Not only do they express different 
macrophage markers, they also express different levels of the TAM receptor AXL. It will be 
interesting to investigate whether, before the development of RA, synovial macrophages 
express different levels of the TAM receptors, and whether this sensitizes or protects 
these joints for synovial inflammation. The effect of synovial inflammation during RA on the 
expression of AXL and MER also remains to be determined, and whether this regulation 
is also distinct for different synovial joints. All this information is crucial to understand 
which TAM receptor to target during arthritis when different joints are involved.
Although differences in the systemic levels of soluble TAM receptors between healthy 
controls and RA patients have been described53,54, the effect of these differences for the 
pathological processes in RA remains to be determined. Moreover, not only the systemic 
but also the synovial levels of these soluble receptors need to be studied in more detail. 
As we found joint-specific differences in involvement of AXL and MER in experimental 
arthritis, the plasma levels of soluble TAM receptors might not be indicative for the local 
role of this modulatory system in anatomically distinct joints in RA patients. 
In this thesis, we focused on the anti-inflammatory and efferocytotic functions of the 
TAM receptors. In particular, the anti-inflammatory role of the TAM receptors has been 
attributed to the induction of Suppressor of Cytokine Signaling (SOCS) 1 and 31,55. We 
never found any direct evidence that these proteins were induced by TAM receptor 
signaling. Moreover, activation of the TAM receptor MER can induce the production of a 
family of anti-inflammatory lipids called specialized proresolving mediators (SPMs)30,56. 
In contrast, TAM receptor signaling can also induce survival and proliferation of cells57,58. 
It will be a quest to see how all these functions of the TAM receptor family come together 
in one cell, such as the fibroblast or the macrophage, and which of these functions 
appear to be particularly important in the inflamed synovium of RA patients. We have 
already shown that inducing MER activation using antibodies had an aggravating effect 
on arthritis by blocking efferocytosis. This indicates that multiple functions need to be 
in place to mediate the resolution of inflammation by the TAM receptor family. Multiple 
strategies could be exploited to successfully target the TAM receptors, including 
inhibiting shedding of the receptors by small molecule inhibitors, administration of the 
ligands, administration of antibodies that activate the receptors but also express the Gla 
domain, or inducing the expression of the TAM receptors by certain compounds.
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Currently, RA patients can be treated with a variety of medicines including analgesics, 
glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying 
anti-rheumatic drugs (DMARDs). Interestingly, glucocorticoids can induce the expression 
of MER, possibly via the activation of the transcription factors Glucocorticoid Receptor 
(GR), Liver X Receptor (LXR) or Peroxisome Proliferator-Activated Receptor (PPAR) δ59-
65. In contract, NSAIDS have been shown the induce the degradation of AX66. It will be 
fascinating to look into whether the anti-inflammatory effects of any of the medication 
presently used to treat RA patients can be (partially) attributed to the TAM receptor family, 
or whether the medication has an adverse effect on this system. 
The role of the TAM receptors has been described in the progression of a myriad of 
infectious diseases (reviewed in67). Three studies that we would like to point out are 
focused on the TAM receptor ligand GAS6 in the oral cavity. GAS6 plays a critical role in 
maintaining oral homeostasis68,69. In line with this, Porphyromonas gingivalis infection leads 
to reduced levels of GAS6 and a higher type I interferon response driving periodontitis, a 
risk factor for the development of RA70,71. More research is needed to unravel whether not 
only the aggravation of RA is influenced by the TAM receptor family, but also whether the 
development is influenced by this regulatory system. 
To conclude, the results described in this thesis provide a valid base for future 
fundamental and clinical research to target the TAM receptor family, which has the 
potential to have a significant impact on health care for RA patients. 
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Reumatoïde artritis (RA) is een auto-immuunziekte van de synoviale gewrichten, 
gekenmerkt door chronische ontsteking en progressieve afbraak van bindweefsel. 
Ondanks talrijke biologische geneesmiddelen reageert een aanzienlijk aantal patiënten 
niet op de huidige therapieën of ontwikkelen ze ernstige bijwerkingen. Daarom blijft 
de ontwikkeling van nieuwe therapieën noodzakelijk. Activering van het natuurlijke 
negatieve feedbackmechanisme door de TYRO3 - AXL - MER (TAM) receptoren zou een 
interessante therapeutische benadering kunnen zijn om RA te behandelen, omdat zij de 
resolutie van ontsteking bemiddelen. Activatie van de TAM receptoren resulteert in de 
remming van een breed scala aan inflammatoire cytokinen en chemokinen. Bovendien 
zijn ze betrokken bij de opruiming van cellulair apoptotische restanten (efferocytose). 
De TAM receptoren werken in vivo tussen aangeboren en adaptieve immuniteit: de TAM 
receptoren dempen de activering van antigeen-presenterende cellen (APCs), waardoor 
de activering van T cellen wordt beperkt, en geactiveerde T cellen produceren in ruil 
daarvoor een van de TAM receptor liganden om de mate van APC activering te beperken. 
In slechts enkele onderzoeken is de rol van het TAM regulatiesysteem bij artritis 
onderzocht. In dit proefschrift werd de rol van de TAM receptor familie in experimentele 
modellen van RA beschreven.
Allereerst wilden we de ontwikkeling van artritis in de ziektegevoelige enkelgewrichten 
analyseren bij muizen zonder de TAM receptoren (Tyro3/Axl/Mertk drievoudige knock-
out of TAM DKO) om de omvang en volgorde van pathologische veranderingen te 
bepalen, in Hoofdstuk 2. Over deze muizen is eerder geschreven dat ze spontaan artritis 
ontwikkelen op een leeftijd van 26 weken. Geen van de onderzochte muizen vertoonde 
macro- of microscopische tekenen van artritis waaronder gezwollen poten, afbraak van 
bindweefsel of synoviale ontsteking. Er werd echter wel een ontsteking van het beenmerg 
waargenomen, ook wel beenmergoedeem (BMO) genoemd. Hoewel dit infiltraat niet 
aanwezig was bij muizen van 14 weken oud, was het op latere leeftijden wel aanwezig 
en werd het gekenmerkt door zowel myeloïde als lymfoïde cellen. De aanwezigheid van 
deze cellen in BMO is eerder beschreven in experimentele modellen van RA en in RA. De 
oorzaak van BMO bij TAM DKO muizen en de oorzaak van de discrepantie tussen deze 
waarneming en het gepubliceerde manuscript bijna twee decennia geleden moet nog 
worden bepaald. We kunnen echter niet uitsluiten dat TAM DKO muizen tekenen van 
artritis na een leeftijd van 52 weken ontwikkelen. Het is verleidelijk om te speculeren dat 
de afwezigheid van ontwikkeling van spontane artritis die we waarnamen in vergelijking 
met de publicatie van Lu en Lemke, het resultaat is van een interactie tussen genetische 
en omgevingsfactoren. Fenotypische verschillen bij muizen met vergelijkbare genotypen, 
hoewel van een andere fokgeneratie, zijn eerder beschreven. Bovendien resulteert 
het fokken van muizenlijnen op de lange termijn in opmerkelijke veranderingen in de 
samenstelling van de microbiota van de darmen en microbiota kunnen verantwoordelijk 
zijn voor genotype-specifieke fenotypen.
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Na te hebben vastgesteld dat TAM DKO muizen op volwassen leeftijd niet (langer) 
spontaan artritis ontwikkelen, was het doel de relatieve bijdrage van AXL en MER in 
experimentele artritis en RA te ontrafelen (Hoofdstuk 3-5). De schadelijke rol van TYRO3 
op synoviale hyperplasie en botschade is eerder beschreven bij experimentele artritis. 
We veronderstelden dat zowel AXL als MER een beschermende rol zouden hebben bij 
experimentele artritis. In Hoofdstuk 3 werd de rol van AXL tijdens artritis onderzocht. 
Tijdens KRN serum transfer artritis (STA) vertoonden enkelgewrichten van Axl-/- muizen 
verergerde artritis pathologie, terwijl geen effect van de deletie van Axl op gonartritis 
pathologie werd waargenomen. Deze gegevens kwamen overeen met de waarneming 
dat synoviale cellen in de enkel van muizen AXL tot expressie brachten, in tegenstelling 
tot de knie, waar het grootste deel van de synoviale cellen AXL niet tot expressie 
brachten. Dit is echter in strijd met het feit dat AXL tot expressie wordt gebracht tijdens 
ontsteking en niet tijdens homeostase. De verschillen tussen de twee gewrichten 
waren niet beperkt tot de expressie van AXL. We vonden dat F4/80+ macrofagen in 
het synovium van het enkelgewricht cluster van differentiatie (CD) 206+ waren, een 
marker voor M2-achtige macrofagen, terwijl slechts enkele cellen CD206+ waren in 
het synovium van de knie. Humane M2-achtige macrofagen brachten ook AXL hoog tot 
expressie. Bovendien resulteerde remming van AXL in humane M2-achtige macrofagen 
in verhoogde interleukine (IL) 1β secretie na Toll-like receptor (TLR) ligatie. Vervolgens 
hebben we gezocht welke factor het verschil tussen de gewrichten in AXL expressie zou 
kunnen veroorzaken. In naïef synovium van de muis en artritisch synovium van de mens 
correleerden de expressie van TGFB1 en AXL. Transforming Growth Factor Beta (TGF-β) 
stimulatie van ofwel humane M2-achtige macrofagen of humane synoviale micromassa’s 
(dit model wordt beschreven in Hoofdstuk 6), bestaande uit fibroblasten en macrofagen, 
induceerde AXL expressie. Bovendien zorgde virale overexpressie van actieve Tgfb1 voor 
gen- en eiwitexpressie van AXL in muizen kniegewrichten, een weefsel dat nauwelijks 
AXL tot expressie brengt in een naïeve situatie. De overexpressie resulteerde ook in de 
aanwezigheid van F4/80+ macrofagen en een matige hoeveelheid CD206+ cellen in het 
kniegewricht. Deze data suggereren dat de lokale verschillen in de expressie van de anti-
inflammatoire receptor AXL te verklaren zouden kunnen zijn door TGF-β. Het verschil in 
TGF-β tussen enkel en kniegewricht kan mogelijk een onderliggende biomechanische 
oorzaak hebben. Het belasten van gewrichtskraakbeen leidt tot de activatie van TGF-β 
die op zijn beurt TGF-β induceert in een positieve feedbacklus. Het gewrichtskraakbeen 
in het enkelgewricht ervaart de hoogste contactkracht van alle belangrijke gewrichten. 
Daarom zou de verhoogde kracht die wordt ervaren in de enkel, vergeleken met de knie, 
de verhoogde niveaus van TGF-β kunnen verklaren die we in de enkel waarnamen in 
vergelijking met het synovium van het kniegewricht.
In Hoofdstuk 4 werd de bijdrage van de MER tyrosine kinase in gonartritis onderzocht. 
Omdat we in Hoofdstuk 3 opvallende verschillen tussen het enkel- en kniegewricht 
aantroffen, wilden we ons in Hoofdstuk 4 concentreren op beide gewrichten. De 
verwijdering van Mertk resulteerde echter niet in een verandering van volledig 
ontwikkelde artritis in experimentele RA in het enkelgewricht (data niet weergegeven). 
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Het is mogelijk dat de aanwezigheid van AXL de functie van MER overbodig zou maken 
in het enkelgewricht. Mertk-/- muizen vertoonden echter wel verergerde gonartritis 
pathologie tijdens KRN STA, terwijl adenovirale Pros1 overexpressie de pathologie van het 
kniegewricht verminderde in dit experimentele model van artritis. Bovendien resulteerde 
overexpressie van Pros1 in in vitro gedifferentieerde macrofagen in een reductie van 
verschillende inflammatoire cytokinen en chemokinen. Humane synoviale micromassa’s 
gestimuleerd met MER-specifieke antilichamen versterkten de uitscheiding van 
inflammatoire cytokinen, terwijl het stimuleren van deze micromassa’s met het MER 
ligand Protein S (PROS1) de uitscheiding van deze cytokinen verminderde. PROS1 is ook 
een anti-coagulatiefactor. Daarom zou een veiligere benadering zijn om MER-specifieke 
antilichamen te gebruiken die eerder werden beschreven om MER kinase activiteit 
te activeren. Deze behandeling resulteerde echter in een duidelijke toename van de 
ernst van gonartritis en verhoogde de ontsteking in het collageen-geïnduceerde artritis 
(CIA) model. We toonden aan dat dit contra-intuïtieve effect van anti-MER gerelateerd 
was aan de remming van MER-gemedieerde efferocytose. Dit leidde tot een verhoogde 
hoeveelheid apoptotische cellen in het kniegewricht en daaropvolgende secundaire 
necrose van deze cellen. Deze effecten werden ook waargenomen bij Mertk-/- muizen, 
terwijl het tegenovergestelde resultaat werd waargenomen met overexpressie van Pros1. 
Deze gegevens suggereren dat MER een beschermende rol speelt in experimentele 
gonartritis via efferocytose.
PROS1 is aanwezig in een relatief hoge concentratie in de circulatie. Echter, zowel 
virale overexpressie van Pros1 in vivo, of toevoeging van PROS1 in vitro verminderde 
verschillende inflammatoire cytokinen en chemokinen. Recente literatuur suggereert 
dat een van de TAM receptoren en een van de TAM receptor liganden niet voldoende is 
voor volledige TAM receptor signalering. AXL wordt constant bezet door Growth Arrest 
Specific 6 (GAS6) in vivo zonder volledige activering van de receptor. Het Gla-domein in 
de liganden is niet noodzakelijk voor binding aan de TAM receptoren en Gla-domein-loze 
GAS6 kan net zo efficiënt binden als de volledige vorm van GAS6 aan AXL. Het Gla-domein 
is echter vereist voor de volledige activering van TAM receptor signalering. Het lijkt erop 
dat voor de activering van de TAM receptor het γ-gecarboxyleerde Gla-domein van de TAM 
receptor liganden moet binden aan het fosfolipide fosfatidylserine (FS). FS komt onder 
meer tot expressie op apoptotische cellen. De aanwezigheid van meerdere FS moleculen 
op één apoptotische cel stimuleert de clustering van de TAM receptoren wat resulteert in 
complete signaaloverdracht.
De verschillen die we vinden tussen AXL en MER komen gedeeltelijk overeen met de 
literatuur. Allereerst lijkt de functie van elk van de drie TAM receptoren weefselspecifiek. 
Bijvoorbeeld, efferocytose in de thymus en het netvlies hangt alleen af van MER, maar 
niet van TYRO3 of AXL. We hebben aangetoond dat AXL een belangrijke rol speelt 
in een muizenmodel van artritis in het enkelgewricht, maar niet in het kniegewricht, 
terwijl het tegenovergestelde werd waargenomen voor MER. Ten tweede kunnen AXL 
en MER verschillende functies in hetzelfde weefsel hebben. In een experimenteel 
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model van nefritis ontwikkelden Mertk-/- muizen een ernstigere vorm van de ziekte, 
terwijl Axl-/- muizen verminderde ziektekenmerken hadden. Hoewel we vinden dat 
muizen die genetisch gemanipuleerd zijn waardoor ze geen AXL of MER meer hebben, 
minder ernstige klinische en histologische kenmerken van artritis hadden, leek het 
mechanisme voor dit beschermende effect anders te zijn. Een toegenomen hoeveelheid 
apoptotische cellen in het kniegewricht tijdens experimentele artritis in Mertk-/- muizen 
werd waargenomen. Daarentegen bevatte het synovium van het enkelgewricht van Axl-/- 
muizen niet meer apoptotische cellen tijdens experimentele artritis (data niet getoond). 
We veronderstelden dat het schadelijke effect van genetisch verwijdering van AXL 
veroorzaakt zou kunnen worden door verhoogde maturatie van IL-1β. Of dit mechanisme 
de oorzaak was voor de ernst van artritis in Axl-/- muizen moet echter nog worden 
onderzocht.
Nadat geconstateerd werd dat MER een regulerende rol lijkt te spelen bij experimentele 
artritis, schakelden we in Hoofdstuk 5 over van de muis naar de humane situatie. De 
voeringlaag en sublininglaag van RA synovium bevatten een groot aantal MER+ CD68+ 
macrofagen. Daarentegen brachten zowel CD3+ T cellen als CD20+ B cellen geen MER tot 
expressie. Alledrie de TAM receptoren kunnen worden gesplitst van het celmembraan, 
wat resulteert in een oplosbare vorm van de TAM receptoren. Bij muizen wordt het enzym 
dat betrokken is bij de splitsing van MER A Disintegrin and Metalloprotease Domain 
(ADAM) 17, ook wel Tumor Necrosis Factor-α Converting Enzyme (TACE), genoemd. 
We analyseerden de splitsing van MER en maten hogere oplosbare MER niveaus in 
geconditioneerd medium van RA synoviale weefsel explantaten in vergelijking met 
OA synoviale explantaten. Oplosbare MER niveaus in RA synoviaal geconditioneerd 
medium correleerden positief met uitgescheiden GAS6 niveaus. In synoviale vloeistof 
van RA patiënten correleerden oplosbare MER en GAS6 ook positief. Zowel oplosbare 
MER als GAS6 correleerden echter negatief met IL-6. Er is aangetoond dat splitsing van 
het ectodomein van MER resulteert in de inactivering van de receptor en neutralisatie 
van de TAM receptor liganden. Dit toont aan dat de TAM receptor familie zichzelf 
ook reguleert. De resultaten van dit hoofdstuk waren onverwacht, aangezien GAS6-
gemedieerde suppressie van ontsteking zou worden tegengegaan door oplosbare MER. 
Mogelijk wordt MER expressie verhoogd in het synovium om te compenseren voor de 
verhoogde uitscheiding. Als alternatief is de regulerende rol van MER overbodig en wordt 
deze overgenomen door AXL. Omdat we echter slechts een beperkt aantal monsters 
van synoviale vloeistof hebben gemeten, moeten onze gegevens voorzichtig worden 
geïnterpreteerd en moeten ze worden bevestigd in een groter patiënten cohort.
Na het vinden van de effecten van AXL en MER in experimentele artritis in Hoofdstuk 3 
en Hoofdstuk 4, en de aanwezigheid van oplosbare MER in RA synoviale vloeistof in 
Hoofdstuk 5, hebben we een in vitro model van het humane synovium verder ontwikkeld 
om onze resultaten te kunnen bevestigen en het effect van de activatie van de TAM 
receptoren te bestuderen (in de toekomst) in Hoofdstuk 6. Een humaan driedimensionaal 
model van het synoviaal membraan gemaakt van primaire fibroblast-achtige synoviocyten 
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en CD14+ mononucleaire cellen werd gekarakteriseerd; dit model werd aanvankelijk 
beschreven door Kiener en collega’s. Het oppervlak van deze gerijpte micromassa’s 
vormde een voeringlaag die bestond uit fibroblast-achtige en macrofaag-achtige cellen, 
die het in vivo naïeve synoviale membraan reflecteren. Om het aangetaste synoviale 
membraan in RA na te bootsen, werden de micromassa’s blootgesteld aan TNF-α, een 
pathologische cytokine in RA. Dit leidde tot een verhoogde pro-inflammatoire cytokine 
expressie op zowel gen- als eiwitniveau. Bovendien resulteerde langdurige blootstelling 
aan TNF-α in modulatie van het fenotype van macrofagen. Deze cellen verloren hun 
expressie van CD163, een andere M2-achtige macrofaag marker, en vertoonden een 
meer staaf-achtige morfologie. Langdurige blootstelling aan TNF-α leidde ook tot 
hyperplasie van de voeringlaag van de micromassa, kenmerkend voor humaan RA 
synovium. Daarentegen induceerde TGF-β geen hyperplasie van de voeringlaag in deze 
micromassa’s. Deze gegevens tonen aan dat het humane model verschillende kenmerken 
van RA synovium in vitro nabootst. Daarom zou het een geschikt humaan model kunnen 
zijn om de pathologie van RA in vitro te bestuderen en te onderzoeken of activering van 
het TAM receptorsysteem de ontstekingsreactie en hyperplasie vermindert, evenals de 
rol van de oplosbare receptoren op deze processen te bestuderen.
Samenvattend, in dit proefschrift hebben we de beschermende rol van de TAM 
receptoren aangetoond, in het bijzonder AXL en MER, in modellen voor reumatoïde 
artritis, het afwerpen van MER in het artritisch gewricht naast het verder ontwikkelen en 
karakteriseren van een driedimensionaal model van het humane synovium.
 

173
8
Curriculum vitae
Claire Elisabeth Joyce Waterborg werd op 31 augustus 1989 geboren te Venlo. Na het 
behalen van haar tweetalig vwo diploma aan het College Den Hulster in Venlo in 2008, 
is zij Biomedische Wetenschappen gaan studeren aan de Universiteit Leiden. Tijdens 
haar bachelor liep zij stage op de afdeling Reumatologie onder begeleiding van Inge 
Klein-Wieringa en Dr. Andreea Ioan-Facsinay op de afdeling van Prof. Dr. R.E.M. Toes. 
In 2011 begon zij aan haar master Molecular Mechanisms of Disease aan de Radboud 
Universiteit Nijmegen. Hier liep zij stage op de afdeling Experimentele Reumatologie van 
het Radboudumc onder begeleiding van Ben van den Brand in de groep van Dr. Fons van 
de Loo. Daarnaast liep zij stage op het La Jolla Institute for Allergy and Immunology onder 
begeleiding van Dr. Robert Tacke in de groep van Prof. Dr. C.C. Hedrick. 
In 2013 behaalde zij haar masterdiploma cum laude waarna ze een korte periode werkte 
op het laboratorium van Prof. Dr. Ir. E.A.L. Biessen op de Universiteit Maastricht. Hierna 
begon ze in 2014 als promovenda op de afdeling Experimentele Reumatologie, opnieuw 
in de groep van Dr. Fons van de Loo. Hier deed zij ruim vier jaar onderzoek naar de rol 
van de TAM receptoren in inflammatoire artritis. De resultaten van dit onderzoek staan 
beschreven in dit proefschrift. In het kader van dit promotieonderzoek heeft Claire voor 
een periode van 2 maanden gewerkt bij The Salk Institute for Biological Studies in La 
Jolla, Californië, Verenigde Staten van Amerika onder begeleiding van Dr. Paqui G. Través 
en Dr. Anna Zagórska in de groep van Prof. Dr. G. Lemke. 
Inmiddels is Claire sinds november 2018 werkzaam bij Synthon in Nijmegen; ze begon 
daar als Drug Safety Specialist en is nu werkzaam als Clinical Research Associate. 
CURRICULUM VITAE

175
8
PUBLICATIONS
List of publications
Waterborg, C.E.J., M.G.A. Broeren, E.N. Blaney Davidson, M.I. Koenders, P. van Lent, W.B. van 
den Berg, P.M. van der Kraan, F.A.J. van de Loo (2018). “The level of synovial AXL expression 
determines the outcome of inflammatory arthritis, possibly depending on the upstream role 
of TGF-β1.” Rheumatology (Oxford). 
Waterborg, C. E. J., M. I. Koenders, P. van Lent, P. M. van der Kraan and F. A. J. van de Loo (2018). 
“Tyro3/Axl/Mertk-deficient mice develop bone marrow edema which is an early pathological 
marker in rheumatoid arthritis.” PLoS One.
Broeren, M. G. A., Waterborg, C. E. J., R. Wiegertjes, R. M. Thurlings, M. I. Koenders, P. Van Lent, P. 
M. Van der Kraan and F. A. J. Van de Loo (2018). “A three-dimensional model to study human 
synovial pathology.” ALTEX.
Waterborg, C. E. J., S. Beermann, M. G. A. Broeren, M. B. Bennink, M. I. Koenders, P. van Lent, W. B. 
van den Berg, P. M. van der Kraan and F. A. J. van de Loo (2018). “Protective Role of the MER 
Tyrosine Kinase via Efferocytosis in Rheumatoid Arthritis Models.” Front Immunol.
Tacke, R., I. Hilgendorf, H. Garner, C. Waterborg, K. Park, H. Nowyhed, R. N. Hanna, R. Wu, F. K. 
Swirski, F. Geissmann and C. C. Hedrick (2015). “The transcription factor NR4A1 is essential 
for the development of a novel macrophage subset in the thymus.” Sci Rep.
Tel, J., S. Anguille, C. E. Waterborg, E. L. Smits, C. G. Figdor and I. J. de Vries (2014). “Tumoricidal 
activity of human dendritic cells.” Trends Immunol.
van den Brand, B. T., E. A. Vermeij, C. E. Waterborg, O. J. Arntz, M. Kracht, M. B. Bennink, W. B. van 
den Berg and F. A. van de Loo (2013). “Intravenous delivery of HIV-based lentiviral vectors 
preferentially transduces F4/80+ and Ly-6C+ cells in spleen, important target cells in 
autoimmune arthritis.” PLoS One.
van den Brand, B., C. Waterborg, W. van den Berg and F. van de Loo (2013). “Is the serum amyloid A 
we use really serum amyloid A? Comment on the article by Connolly et al.” Arthritis Rheum.

177
8
PHD PORTFOLIO
PhD portfolio
Attended (inter)national symposia and congresses – oral presentations
Attended (inter)national symposia and congresses – poster presentations
 
Courses
The Art of Presenting Science
Loopbaanmanagement voor Promovendi 
Scholarships
- Radboud internationalization travel grant for the visit of the laboratory of Greg Lemke at The Salk 
Institute for Biological Studies, La Jolla CA, USA 
- Travel Grant of the Dutch Arthritis Foundation for the visit of Immunology 2016, Seattle WA, USA 
- Travel grant of the Dutch Society for Immunology (NVVI) for the visit of British (BSI) and Dutch 
Society for Immunology Joint Congress, Liverpool, United Kingdom 
- Travel Grant of the EULAR for the visit of European Workshop for Rheumatology Research (EWRR) 
2017, Athens, Greece 
- Radboud Internationalization travel grant for the visit of American College of Rheumatology (ACR) 
Annual Meeting, San Diego CA, USA
Teaching
 
- One week bachelor student supervision 
- Two months bachelor student supervision
- Six months master student supervision
- Three months master student supervision
2015 European Congress of Immunology (ECI) Vienna, Austria
2015 Najaarsdagen Nederlandse Vereniging Reumatologie (NVR) Arnhem, the Netherlands
2016 Immunology Seattle WA, USA
2016 Joint IMPL/MNL meeting of Salk Institute for Biological 
Studies
La Jolla CA, USA
2016 Young Investigator Immunology Day Nijmegen, the Netherlands
2016 Najaarsdagen Nederlandse Vereniging Reumatologie (NVR) Arnhem, the Netherlands
2018 European Workshop for Rheumatology Research (EWRR) Geneva, Switzerland
2018 Radboud RIMLS PhD Retreat Veldhoven, the Netherlands
2014 Dutch Society for Immunology (NVVI) 
50th Anniversary Congress
Kaatsheuvel, the Netherlands
2016 British (BSI) and Dutch (NVVI) Society for Immunology Joint 
Congress
Liverpool, United Kingdom
2017 European Workshop for Rheumatology Research (EWRR) Athens, Greece
2017 European Workshop for Rheumatology Research (EWRR) Athens, Greece
2017 American College of Rheumatology (ACR) Annual Meeting San Diego CA, USA
2017 Dutch Society for Immunology (NVVI) Annual Meeting Noordwijkerhout, the Netherlands

179
8
Research data management
 
Findable: 
All data described in this thesis are stored and can be found at the department of 
Experimental Rheumatology of the Radboud University Medical Center in Nijmegen, the 
Netherlands. 
Accessible: 
The data and protocols can be obtained on request from the department of Experimental 
Rheumatology of the Radboud University Medical Center in Nijmegen, the Netherlands. 
Interoperable: 
The data are documented in Dutch and English according to the FAIR principles. 
Reusable: 
The data shown in this thesis are adequately documented to be reusable for further 
research and analysis.
DATA MANAGEMENT

181
8
Dankwoord
Een wijs man zei ooit eens tegen me: als je denkt, richting het einde van je promotie, dat 
het echt nooit meer gaat lukken, weet dan, dat je er bijna bent. Hij had gelijk! Het boekje 
is af. EINDELIJK! Dit hoofdstuk zal veruit het meest gelezen worden van dit hele boekje, 
en zal ook de minste aangepaste versies hebben. Ik wil graag iedereen bedanken die 
een bijdrage heeft geleverd aan dit proefschrift, maar in het bijzonder onderstaande 
personen. Dao gaon we haer! 
Net zoals bij TAM signalering de TAM receptoren de basis zijn, zo is de 
begeleiding de basis tijdens een PhD traject.
Daarbij wil ik Fons als eerste bedanken. Na een moeizaam traject in Maastricht mocht ik 
direct bij jou aan de slag voor een jaar. Hierbij schreven wij succesvol een Reumafonds 
project, samen met Silke, en kon ik mijn PhD project zelf invullen en uiteindelijk ook 
afmaken. Ik ben je dankbaar voor alle kennis die je me hebt gegeven, en dat je mij vrij 
liet op mijn eigen project in te delen. Tijdens onze gesprekken kwam het altijd weer uit 
op onderzoek, en hebben deze gesprekken mij veel inspiratie gegeven. Soms ging het 
wat stroefjes tussen ons, maar dat maakte de TAM receptoren uiteindelijk zo’n goed 
onderwerp: het temmen van de opvlamming. Fons, dankjewel!
Marije, tijdens mijn PhD project, toen het allemaal niet zo makkelijk ging, kreeg ik van jou 
tijdens Sinterklaas een chocoladeletter, omdat ik je adoptie AIO was geworden. Ik ben 
je ontzettend dankbaar dat je altijd voor me klaarstond, zowel om kritisch te kijken naar 
mijn presentaties en manuscripten, maar ook om over persoonlijke dingetjes te praten. 
Marije, ik vond je een ontzettend gezellig kamergenootje in San Diego (lekker samen 
Chipotle eten) en ik vind het supertof dat je mijn co-promotor wil zijn; dankjewel!
Hierbij wil ik ook graag Peter van der Kraan bedanken, met name voor het feit dat ik mocht 
promoveren op jouw afdeling, maar ook voor je fijne bemiddeling, en dat ik uiteindelijk 
toch nog het nut heb in kunnen zien van TGF-β.
Bovendien wil ik ook graag het Reumafonds/ReumaNederland bedanken voor de 
financiering van het project. 
Bij de TAM signalering zijn de liganden een essentieel deel van het geheel. 
Zij zwengelen de boel aan, en zijn er altijd als je ze nodig hebt (als het goed 
is). Zoals de liganden belangrijk zijn tijdens TAM signalering, zo waren mijn 
collega’s goud waard tijdens mijn PhD traject.
Om te beginnen, Miranda, jij maakte mij direct wegwijs op het lab en mocht ik snel de plek 
van Marieke in U3 innemen waar wij samen jaren een soepel lopend U’tje van maakten. 
Ik ruimde op en zette alles recht; jij zorgde dat er geen stofje te bekennen viel. Samen 
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werkten wij aan het TLR4 project, waar ik nog met Ben aan had gewerkt. Ondanks dat die 
vervelende celdelingskleuring uiteindelijk werkte, bleek mijn drang om de waarheid te 
achterhalen over dat vervelende haarpinnetje het einde voor het project. Gelukkig was dat 
niet het einde van onze vriendschap. Ik kijk terug op een prachtige tijd in U3, waar wij samen 
lief en leed deelden, en ook nog af en toe wat onderzoek wisten uit te voeren. Samen met 
Mathijs en Esmeralda wisten wij op maandag vaak een cappuccino te scoren om even op 
te laden voor de week. Mathijs, samen publiceerden wij een van de laatste hoofdstukken 
van dit proefschrift en leerde jij mij alle ins-en-outs over de micromassa’s en ook over 
onderzoek doen in het algeheel. Ik heb veel van je geleerd over je relaxte werkwijze, en het 
nut van systematic reviews. Esmeralda, samen wisten wij al snel ons ierste vastelaovespekse 
in mekaar te dreije. Nog maar ein paar maond geleeje stonde weej te joekse op de Parade in Venlo en 
moch ik weer van dien gezelschap geneete. Ik bin dich dankbaar veur deze biezondere vrindschap, 
en de steun diesse mich hes gegaeve de aafgelaupe jaore. Weer terug naar het Nederlands: lieve 
dinner-date whatsapp genootjes, lieve Miranda en de Limbo’s, dankjewel! 
Naast mijn dinner/cappuccino groepje was ik deel van nog een ‘groepje’: de Spice Girls. 
Tijdens de promotie van Debbie kwam ik erachter dat wij zo genoemd werden. Waarom, 
dat snap ik nog steeds niet helemaal. We zijn toch maar met z’n viertjes? Enfin, lieve 
Debbie, Rebecca, en Stephanie, wat een toffe tijd hadden wij samen op het lab. Lol aan 
de koffietafel, lekker samen naar Liverpool voor een congres, etentjes om gal te spuwen 
over onderzoek doen, en griezelen deelden wij als hobby. In Liverpool smokkelden we 
Stephanie nog even het congres binnen, en weken later keken we nog gezellig een random 
film gemaakt door de Beatles. Nog altijd spreken we eens in de zoveel tijd af, en daar geniet 
ik enorm van! Dankjewel voor al jullie steun, roddelmomentjes over het lab, escape rooms, 
griezelmomenten in het levende spookhuis en alle gezelligheid! Jullie zijn geweldig!
Elly, praktisch gezien waren wij niet met elkaar verbonden (als je kijkt naar de 
werkgroepen) maar persoonlijker waren wij dat des te meer. Ik vond het heel fijn dat we 
vaak over het leven in het algemeen konden praten, en al je steun en knuffels die ik kreeg 
tijdens mijn periode op het lab. Je bent een geweldig mooi mens, en ik ben je dankbaar 
voor alle leuke momenten op het lab.
Tijdens mijn jaren op het lab was ik deel van groep 2: het enige groepje waarin een divers 
scala aan onderwerpen werd onderzocht. De maandagochtend vergaderingen waren 
altijd leerzaam. Dankjewel, (oud) leden van werkgroep 2 die ik nog niet had benoemd: 
Ben, Eline, Bartijn, Onno, Marina, Marieke, Juan, en Renske.
Silke, I would like to personally thank you as a former member of work group 2. We 
had the pleasure of working together and were TAM partners in crime. We successfully 
performed several in vivo studies (and also some unsuccessful ones), and we could never 
understand how they found all these amazing effects of TAM receptor stimulation with 
commercially available ligands. Nevertheless, we found some nice effects. I hope you can 
continue the work you like to do, and enjoy your time in Germany.
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Verder wil ik alle mede PhD studenten, postdocs, en andere collega’s bedanken voor 
de waanzinnig mooie tijd dat ik bij de lab ruima familie mocht horen. Dankjewel, Annet, 
Monique, Liduine, Birgitte, Shahla, Arjen (bunny boks), Peter van Lent (what about the 
macrophage?), Martijn (bunny boks), Rik, Wouter, Giuliana (the cells don’t look so good), 
Irene (where’s the M-CSF?), Yvonne, Yvonne, Margot, Edwin, Niels, Guus, Henk, Laurie, 
Arjan, Dennis, Wojciech, Ellen, Eva, Marijn, Daphne (samen douchemutsen verzamelen), 
Nathalie, Joyce (Limburgs mooiste), Rogier en Marianne. 
Ook wil ik graag de patiënten partners van werkgroep 2, Christa, Marrie en Peter, met 
de begeleiding van Yvette bedanken. Ik ben jullie dankbaar voor alle dingen die jullie mij 
geleerd hebben over het hebben van reuma, en de input die jullie geleverd hebben tijdens 
onze werkbesprekingen.
Daarnaast mocht ik een aantal stagiaires begeleiden tijdens mijn PhD traject. Dankjewel 
voor al jullie hulp, inzet en gezelligheid Arianne, Iris en Minke. Bovendien wil ik ook Tessa 
bedanken: jij was niet mijn stagiaire maar ik heb je wel zo leren kennen, en ook zien 
groeien naar een succesvolle PhD kandidaat. 
A special thanks goes out to Greg Lemke and his group. I am forever grateful that I was 
able to work in your wonderful laboratory at the Salk Institute. I would like to personally 
thank Paqui and Anna for taking me up in the group and for all the fun we had (spelling TAM 
with our bodies) but also for everything your taught me on TAM receptors and research in 
general. 
Een niet te onderschatten onderdeel bij de TAM receptor signalering is 
fosfatidylserine. Zonder dit schijnbaar kleine molecuul is het TAM receptor 
complex niet compleet. Vrienden en familie zijn mijn fosfatidylserine; zonder 
hen is het leven niet compleet.
Audry, leeve Audry, ein van mien vriendinkes die ik al ‘t langste kin en die mich ontzettend good 
kint. Same joekse weer door ‘t Venloosche, lekker shoppe, flink waat cappuccino’s drinke en aaf 
en toe ein Jägerbomb tösse de pilskes door. Altied bisse oprech geïnteresseerd wie ‘t met mich 
geit en vroogse zoe dök of ik mien rissultate al good op pepeer had kinne zette. Soms met ein 
traon kwaam ik beej dich naeve, dökker met ein glimlach, en same make weej d’r waat moeis van. 
Danke veur dien steun en dien vrindschap.We zeen ôs in de Gaaspiep!
Laura, Mat of Luuk, of wiesse auk heits, dich bis d’r veur mich! Van gen persoen in mien laeve heb 
ik zoevuuel kaertjes en bleumkes gekrege, vol met steun en wie gruuets desse op mich waas en bis. 
Dök deese dich verontschuldige umdesse neet persies begreeps waat ik deed, asse vonds desse 
ein ‘domme’ vraog stelsde, maar ik vond ‘t allein maar supertof desse d’r nao deejs vraoge. Same 
slaon weej ôs d’r wal daorhaer, en make weej ‘t moei. Danke veur dien steun en dien vrindschap.
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Tonnie, same rende weej de halve marathon in Venlo, en legde weej same tientalle kilomaeters 
aaf um dit te haole. Tiejes deze renperiode heb ik vuuel met dich kinne praote euver mien 
onderzeuk, en koste we alletwie joele as ein artikel de deur oet waar. Door de jaore haer zien 
weej close gewaore, en ik waardeer ôzze vrindschap enorm. Ik kin neet op twie hand telle wie dök 
desse mich verteld hesse desse trots (of toch gruuets) op mich bis. Danke veur dien steun en dien 
vrindschap. We zeen ôs in de Gaaspiep!
Daobeej wil ik auk gaer alle andere Ellefde Man leeje bedanke. Zonder de vastelaovend, en same 
joekse had ik dit trajec noeits kinne voltooie. De Ellefde Man is veur mich ‘t zalt in de pap! Meinig 
persoen weit wie ik nao de vastelaovend toe laef, en det kump mede door ôg. Heejbeej wil ik in ‘t 
speciaal Lieke, Puck, Tim, Michael, Wiel (Neal), Pieter (Noud), LvD (Luuk van Dijk), Nicole, 
Scooby (Rob), Bob, Guido, Margot, Sven, Tom, John (oet Thailand) en Job bedanke. Door ôg 
veul ik mich idder jaor rondum fibberwari zoe riék. Prosit senior, prosit corona (wae durft?)!
Suzanne en Michelle, Sjan en Mies, det eine giechelmoment beej wiskunde (meug ik nog ein 
blaedje) haet ôs toen beejein gebrache en sindsdeen ware, en zien weej nog steeds, vriendinne. 
Ik kiek met vuuel plezeer truuk op alle gezellige momente same, en wie we as vriendinne zien 
gegreuid. Danke veur ôgge steun en alle leeve knoevels. 
En auk mien leeve vrinde/my wonderful friends, die ik nog neet geneumd had maar wal wil 
bedanke veur alle moeie tieje en steun tiejes dit proces: Eline, Floor Wijnen, Floor van Rooij, 
Bart, Emmy, Janneke, Esther, Susan, Rebecca, en Anton. 
A special thanks also for Robert, Pinto en Agyiri. You three showed me how lucky I am to 
be living in the Netherlands. We had a wonderful time together in Venlo, singing, eating 
(toetjeee), dancing, playing football (mainly you guys) and watching it as well. I am proud to 
be able to call you my black sons, and I hope we will see each other again in the near future.
Verder wil ik nog bedanken voor alle fijne momenten en alle steun, mijn lieve familie en 
leeve schoënfemilie: Sjef, Margreet, Hanne, Bloeme, Ap, Joost, Femke, Lieve, Meiske, 
Louise, Jade, Jaap, Marjan, Linda, Wieteke, tante Marianne (ik zal noeits det tante weg kinne 
haole), Hans, Gerty, Richard, Moniek, Jill, Britt, Frank, Linda, Imke, Marit, oma Baolder, 
oma Voerendaal, Nienke, Lars, Xavi, Niek en Rosanne.
Jos en Marian, zoe wie geej weit, veult geej as mien twiejde elders veur mich. Ik kom zoe gaer 
beej ôg naeve, en altied vraog ge mich wie det ‘t ging met mien onderzeuk, en waart geej oprech 
geïntereseerd. Dankewal veur de steun, en auk alle gezelligheid, leeve schoëne elders! 
Pap en mam, ik weet niet waar ik zonder jullie zou zijn (letterlijk en figuurlijk). Ik ben 
dankbaar voor alle keren dat we gezellig samen hebben gegeten, een koffietje konden 
drinken, dat leuke weekend weg in Gent, en alle andere keren! Samen met Harm, Senn 
(the man) en sinds kort ook Kelly, hebben wij het heel gezellig en voel ik mij een rijk 
persoon met jullie als familie. Dankjewel! Ik hou van jullie.
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DANKWOORD
Noud, leeve sies, intelijk bin ik fffft. Ik bin dich nog ‘t meiste dankbaar veur al dien steun tiejes 
mien promotietrajec. Ik kos altied met dich praote as ‘t mich hoeëg zoot, en auk koste we same 
viere as weer ein artikel woort geaccepteerd of ik ein prissentasie moch gaeve op ein congres. 
Same hebbe weej de periode doorstaon toen ik in twie kier in San Diego zoot. Ondanks desse neet 
altied gans begreeps waor ik meij bezig waas, bisse mien groeëtste steun, al haos 9 jaor langk. 
Danke veur alles; ik hald van dich! Ik bin blie desse heej bis. 
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‘AiM for the stars’ heeft voor mij een driedubbele betekenis. Allereerst staan de A en M voor 
AXL en MER; de twee eiwitten die ik onderzocht hebben tijdens mijn PhD traject. Hierbij sta 
ik (‘i’) tussen die twee eiwitten in; ik kon (en ik kan nog steeds) niet kiezen welk eiwit nu de 
beste therapeutische target zou zijn bij reumatoïde artritis. Ten tweede staat AM ook voor 
‘ante  meridiem’, oftewel ‘voor de middag’. Ik ben een ochtendmens en ik was veruit het meest 
effectief in de vroege uurtjes op het lab. Ten derde staat de hele ondertitel ook symbool voor 
het grote doel dat ik voor ogen had toen ik begon met mijn PhD traject: ‘don’t limit yourself, 
aspire to achieve greatness, even if it seems impossible or impractical’. Ik heb geprobeerd alles eruit 
te halen wat erin zat de afgelopen vijf jaar, zowel op professioneel als persoonlijk gebied.
